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Abstract 
 
Allergic Contact Dermatitis is a skin condition that affects up to twenty percent of the North 
American and Western European population. The molecular initiating event (MIE) of this type IV 
delayed hypersensitivity is the formation of antigenic species by covalent modification of 
endogenous proteins. Cysteine residues, though not the most prevalent residues in skin proteins, 
are prone to react with small electrophilic molecules and thus play a crucial role in protein 
haptenation. The role of cysteine is also very prominent in removal of electrophiles. Glutathione 
(GSH) is the most prominent antioxidant in cells and contains a cysteine residue, providing a free 
reactive thiol for GSH conjugation of electrophiles and their subsequent removal. It is also the 
co-factor of an important set of enzymes involved in the metabolic clearance system, glutathione 
S-transferases (GST). However, it remains unclear whether the reactivity of small exogenous 
electrophiles with intracellular GSH could be a key factor in determining the epidermal 
bioavailability of sensitising chemicals.  
GST activity has been demonstrated both in skin and in most in vitro skin equivalents but so far 
studies have focussed on specific chemical clearance. The GSH cycle (synthesis, conjugation, 
recycling) has not been comprehensively studied in the HaCaT cell line, which is often used as a 
surrogate model for human skin. We showed that the model sensitisers 2,4-dinitrohalobenzenes, 
reacting with thiols via a SNAr mechanism, depleted intracellular GSH within the first hour of 
exposure in HaCaT cells, in a dose dependent manner. Synthesis of de novo GSH was investigated 
24 hours after treatment with a single non-toxic dose of 10 µM of three dinitrohalobenzenes. 
GSH concentration was found similar or slightly higher than the level measured in control cells 
for 1-chloro-2,4-dinitrobenzene (DNCB) and 1-fluoro-2,4-dinitrobenzene (DNFB) but not for 1-
bromo-2,4-dinitrobenzene (DNBB), which appeared to partially prevent GSH repletion. This data 
inferred that the repletion step was the differentiating factor between chemicals belonging to 
the same reactivity domain. The toxicity of the halogen released in the cells was most likely the 
reason for observing these differences and this might have been missed if only the clearance 
kinetics were investigated. Activation of the nuclear factor E2-related factor 2 (Nrf2) pathway 
was concomitantly observed for all compounds within two hours, and at concentrations less than 
10 µM.  
Nrf2 activation is the precursor event for the overproduction of Phase II metabolic enzymes such 
as GSTs, enzymes involved in the synthesis of GSH such as Glutamyl cysteine ligase (GCL) and 
Glutathione synthetase (GS) as well as GSH related enzymes acting against oxidative stress such 
as Glutathione Reductase (GR). HaCaT cells treated with the model aldehydes benzaldehyde and 
phenylacetaldehyde, which oxidised cysteine residues in chemico, did not suffer a significant 
depletion of GSH levels at sub-toxic concentrations. In addition, these aldehydes have been 
shown to react with amines via a Schiff base mechanism to form stable protein adducts. Our set 
of data indicated that the Schiff base mechanism was most probably favoured and that an 
oxidation of GSH (a reduction of the GSH:GSSG ratio), was effectively and rapidly controlled by 
GR activity. The volatility of aldehydes was likely to limit the bioavailability of these compounds 
intracellularly, possibly increasing the probability of haptenation with cell membrane proteins. 
Skin sensitisers are often defined by their potency (ranging from extreme to non-sensitising) 
rather than their chemical reactivity domain. We compared the clearance of two extreme 
sensitisers by the GSH pathway: DNCB and diphenylcyclopropenone (DPCP). We demonstrated 
that two chemicals able to react with thiols in chemico via different mechanisms (SNAr for DNCB 
and Michael addition for DPCP) were affecting GSH levels differently in HaCaT cells. DNCB 
induced GSH depletion at non-toxic concentrations, while exposure to DPCP decreased cell 
viability at concentrations for which GSH stock was not significantly reduced. DPCP reactivity 
with thiols has been suggested in cell membranes. Contrary to the results obtained for DPCP, 
diethyl maleate (DEM), a moderate sensitiser also reacting via Michael addition, was cleared by 
GSH at a rate similar to the rate of de novo GSH synthesis, masking the overall depletion of GSH. 
Exposure to DEM induced an overproduction of GSH after 24 hours that was more pronounced 
than the one observed for the more potent sensitiser DNCB, showing that the sensitising potency 
of chemicals could not be correlated solely to the ability to be conjugated by GSH (i.e. weak 
sensitisers would be cleared rapidly while potent sensitisers would not). 
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These experiments demonstrated that the defence mechanisms in the HaCaT cell line were 
providing a rapid response to chemical stress. To investigate the effects of chemical exposure on 
GSH lifecycle in reconstructed human epidermis (RHE), we attempted repeated cycles of 2 hour 
exposure to DNCB over a week long period. For three consecutive treatments, each exposure to 
DNCB led to GSH depletion. Replenishment to basal level was observed after a 22 hour recovery 
period. Accumulation of Nrf2 in the cytosol also occurred within the two hours of exposure to 
DNCB but returned to baseline during each recovery period. The amount of GSH conjugate 
formed (dinitrophenyl glutathione) increased after each exposure, suggesting that the metabolic 
capacity of skin may be enhanced in response to exposure to exogenous compounds. 
In conclusion, the GSH cycle is fully active in skin and participates in the clearance of some 
exogenous compounds with electrophilic properties. GSH skin metabolism can also potentially 
be enhanced after repeated exposures to small quantities of electrophiles. Future risk 
assessments for skin sensitisation potential of topically applied chemicals could integrate these 
findings to correlate more realistically to in vivo scenarios. 
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1.1 Introduction. 
 
Cellular defence mechanisms against exogenous or endogenous reactive small 
molecules rely on the conjugation of these electrophilic species to endogenous 
nucleophilic molecules such as glutathione (GSH), spontaneously or enzymatically 
mediated, resulting in readily excretable inert compounds. The irreversible nature of 
such chemical reactions does not differ significantly from the covalent binding of these 
same electrophiles to nucleophilic targets in skin proteins, resulting in the formation of 
antigens that are recognised by the immune system as foreign and in the induction of 
skin sensitisation. Additionally, some reactive molecules have the capacity to oxidise GSH 
to its disulfide form (GSSG) without conjugation, thus altering the balance of GSH:GSSG 
and contributing to danger signalling.  
Better understanding the detoxification capacity of skin, particularly the role of GSH, will 
enable scientists to fully utilise understanding of reactivity in the context of skin allergy. 
Detoxification processes in the skin, namely GSH conjugation, are a key factor in 
determining the epidermal bioavailability of potentially sensitising chemicals, which 
have penetrated into the viable skin tissue. This section presents an overview of the skin 
sensitisation process, detailing the key mechanisms and where the investigation of GSH, 
as a skin clearance process, could fit into the determination of the bioavailability of a 
chemical for antigen formation in skin. Typical in vitro skin models available for such 
investigations are also reviewed. 
 
 
1.2 The human skin structure. 
 
1.2.1 Definition. 
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The skin is the first line of defence against various external influences. Human skin is a 
complex organ, covering an average area of two square meters. It is constituted of 
several layers (stratum corneum, epidermis, dermis and hypodermis), each 
demonstrating different biological and physical properties (Fig 1.1).  
 
 
Figure 1.1: Skin structure depicting 1) the stratum corneum, 2) the epidermis, 3) the 
stratum basale, in which the dark coloration is due to the high concentration in melanin 
(skin donor of Caribbean ethnicity), 4) the dermis. (Image provided by H. Minter, SEAC, 
Unilever). 
 
 
1.2.2 Stratum corneum. 
 
The stratum corneum is not a definite layer of the skin per se, as it is the continuity of 
the epidermis. However, it is often designated as a separate layer due to its different 
physical characteristics compared to the lower layers of the epidermis. The cells 
constituting the stratum corneum are dead cells called corneocytes, tightly packed in a 
multilayer. The number of layers of the stratum corneum varies depending on the area 
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of the body where the skin is located. Relatively well protected areas such as eyelids 
and the forehead can contain as little as 9 layers, while the stratum corneum of 
hardwearing feet soles can be constituted of up to 50 layers [1]. Corneocytes are the 
ultimate result of the differentiation of keratinocytes present in the epidermis that have 
specialised to generate high quantities of keratin and lipids. The cells are packed 
together, each cell following an approximate hexagonal pattern, being linked to its 
immediate neighbour cells by glycoprotein structures called desmosomes.  The 
interstitial space between cells is filled with lipids organised in lamellae.  The stratum 
corneum is thus a relatively lipophilic environment, acting as a physical barrier against 
external compounds and regulating water permeation [2]. Its organised structure has 
been described as “bricks and mortar” by a number of scientists. 
 
1.2.3 Epidermis. 
 
The epidermis is the layer of the skin which contains the highest concentration and 
diversity of cells, mainly keratinocytes (90%) but also melanocytes (5-10%), Merkel cells 
and Langerhans cells, all with different nature and roles.  
The epidermis is organised in sub-layers of keratinocytes at different stages of 
differentiation.  Considering the state of specialisation the keratinocytes and their 
shape, distinct layers of the epidermis can be separated [3]: the stratum basale (where 
keratinocytes are still in their primary state and able to divide to keep the level of 
primary cells constant while some cells migrate to upper layers and differentiate), the 
stratum spinosum (where the keratinocytes start to shrink), the stratum granulosum 
(distinctive by the presence of granules of proteins and lipids in the keratinocytes), the 
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startum lucidum (where the cells have lost their nucleus and the granules have been 
expelled into the intercellular space) and the stratum corneum already described above. 
The deepest level of the epidermis, the stratum basale, also contains a number of other 
cells. The role of melanocytes is to produce melanin, which, once incorporated into the 
specialised keratinocytes of the upper layers, will give the skin its pigmentation. Merkel 
cells are also present in this layer of skin. Their role is not clearly defined yet, but they 
are thought to be involved in the sensory function of skin [4]. These cells have the ability 
to chemically communicate with neurone endings in the skin and in close proximity, 
form a “Merkel cell-neurite complex”. 
Finally, the representation of the immune system in the epidermis is assured by the 
presence of a type of dendritic cell called Langerhans cells. These cells, in steady state 
conditions, stay in close contact with keratinocytes and have a lifespan higher than 
other dendritic cells. However, when the cells process an antigen, they enter a 
maturation process, which trigger their migration first through the dermis and then to 
the draining lymph nodes, where they present their antigen to T-cells [5]. 
 
1.2.4 Dermis. 
 
The dermis is located directly underneath the epidermis. It exhibits the highest level of 
elasticity due to its composition, which is rich in fibres. The dermis is mainly constituted 
of fibroblasts which are fixed, mostly in the upper part of the dermis at the interface 
with the epidermis (the dermal papillae), into a collagen rich matrix containing elastin 
and reticular fibres. Due to this high concentration of collagen, the dermis has been 
seen, in a simplistic way, as a “gel phase” in which hair follicles and sweat glands are 
rooted, while blood capillaries circulate through it to reach the epidermis above [6]. 
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1.2.5 Hypodermis. 
 
The hypodermis is a  few millimetres thick subcutaneous fat layer separating the dermis 
from muscles and other body tissues [6]. Its primary functions are energy storage and 
body insulation, helping to maintain body temperature and protecting muscles against 
external physical shocks. Veins and nerves usually run through the hypodermis to reach 
the dermis above. 
 
1.3  Allergic Contact Dermatitis. 
 
Dermatologists diagnose patients that have developed an allergy either coming from 
routinely handling chemicals contained within hair dyes, detergents, paints, concrete, 
pesticides, etc [7] in the workplace or linked to the use of some of these products at 
home. This has led to a lot of scientific research to try and understand the mechanisms 
that caused these allergic reactions [8]. 
 
1.3.1 Definition. 
 
The skin condition Allergic Contact Dermatitis (ACD) is a delayed-type hypersensitivity 
response to external compounds that affect a small but significant percentage of the 
population [9].  It is characterised by a visible redness or rash on the skin after successive 
exposures. The only method to deliver a reliable medical diagnosis of ACD is to conduct 
a patch test on the patient, using the suspected allergen under controlled conditions 
[10].  Determined allergens should be avoided by patients who have been diagnosed 
[11]. 
1.3.2 Mechanistic understanding of ACD. 
 
Chapter 1 
8 
 
1.3.2.1 Pathway to skin sensitisation. 
 
Not all chemicals are harmful, but some have the ability to react with proteins within 
the skin, by permanently modifying the nucleophilic sites available on them. Such 
compounds are called haptens and the process by which they react with proteins is 
called haptenation. The protein-hapten adducts resulting from interactions of allergenic 
chemicals and skin proteins can be recognised as an antigen by the human body (Fig 
1.2). The presentation of this antigen by the Langerhans cells to the T cells of the 
immune system, in the lymph nodes, leads to the recognition of the chemical as foreign 
and induces an immune response. This first exposure to the chemical is the induction 
step of ACD. On following re-exposures, even at lower concentrations, clinical 
symptoms of ACD (redness, rash, oedema…) are likely to be observed on patients that 
have been previously sensitised (elicitation step). 
 
Figure 1.2 : Chemical pathway to skin sensitisation where 1) is haptenation (chemical 
binding to proteins) 2) antigen collection by Langerhans cell  and cell activation 3) 
migration to lymph node 4) presentation to T-cells 5) T-cells specialisation and 
proliferation 6) migration out of lymph node 7) re-exposure to chemical 8) signalling to 
T-cells 9) inflammation of skin. Figure reproduced from [12]. 
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The Organisation for Economic Co-operation and Development (OECD) has 
released a document formalising the Adverse outcome pathway (AOP) for skin 
sensitisation, i.e the full sequence of mechanistic steps involved in the process 
from the penetration and reaction of a chemical to the inflammation observed 
on skin at the organ level [13] (Fig 1.3). 
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Figure 1.3: Flow diagram of the pathways associated with skin sensitisation. Figure 
reproduced from [13]. 
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1.3.2.2 Protein haptenation. 
 
Protein haptenation has long been recognised as the key molecular initiating event 
(MIE) in the skin sensitisation AOP. Many investigations have been focused on 
understanding the mechanism of reaction involved in the process of haptenation (e.g. 
[14-16]) and the consequences of covalent modifications on proteins (e.g. [17, 18]). To 
assess the reactivity of chemicals towards nucleophiles, in vitro assays developed 
throughout the years tend to use model nucleophiles, thus limiting the level of 
complexity linked to a larger protein. 
The reactivity of the nucleophilic residues lysine, cysteine and histidine with a selection 
of skin sensitizers of various potencies has been reported [19].  Even though trying to 
predict the level of skin sensitisation induced by a chemical in humans using a single in 
vitro assay would be overly simplistic and prone to errors, this assay demonstrated a 
correlation between the potential for sensitisation of the sensitizers used and their 
ability to react with cysteine and lysine. 
Later, the use of a single small peptide derived from a native protein called Coronin1 in 
a peptide reactivity assay has been reported [20]. This peptide, containing two lysine 
and one cysteine residues (sequence Ac-NKKCDLF), was incubated with over 80 
chemicals of various sensitising potential. The major improvement on the previously 
reported methods came from the introduction of Liquid Chromatography-Mass 
Spectrometry (LC-MS) as the analytical technique used to measure the level of depletion 
of the peptide after 24 hours incubation. LC-MS not only enabled the quantification of 
peptide remaining after incubation but also the characterisation of adduct(s) formed 
between the test chemical and the peptide (if any) and the potential dimerisation of the 
peptide due to an oxidative process. 
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Which nucleophiles would be modified in a given skin protein where a selection of them 
would be available is still not clearly understood. The investigation of the reactivity of 
the potent skin sensitiser 1-chloro-2,4-dinitrobenzene (DNCB) with human serum 
albumin [21, 22] and two other model proteins present in skin, human cytokeratin K14 
and cofilin [23] illustrated the complexity of the problem lying ahead for the 
understanding of skin protein haptenation. Indeed, even though DNCB reacts with 
nucleophiles following only one chemical mechanism (aromatic substitution of the 
chlorine) the modification of different residues can be observed (Cys, Tyr, Lys, N-
terminus) and varies between proteins. Even the prioritisation of the reactivity of the 
lysine residues alone, present on the three proteins investigated, is difficult to establish, 
as the presence of neighbouring amino acids and the pH conditions at which the protein 
has been stored for commercialisation (presence of urea for cytokeratin K14) influence 
the reactivity observed. 
As a result, the use of small peptides containing only one reactive site for mechanistic 
understanding of hapten reactivity was extended to a selection of nucleophiles (lysine 
and cysteine but also histidine, tyrosine, arginine and the NH2 present on the N-terminal 
amino acid of the peptide chain)[24]. This publication also presents initial kinetic 
measurements obtained by slight modification of the assay, allowing the monitoring of 
the peptide depletion over several hours, from which a pseudo first order kinetic 
reaction assumption was used to determine the rate constant of the reaction between 
the peptide and the chemical investigated. 
 
1.4  Human skin in vitro models. 
 
Fresh ex vivo human skin is very difficult to source and the level of viability of the skin 
depends largely on the techniques used to preserve it after biopsy or surgery and the 
timing involved [25, 26]. This can lead to low levels of reproducibility of experimental 
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results. Alternative models to human skin have been developed for laboratory use. 
Some skin equivalents available to facilitate the development of in vitro experiments 
are described below. The aim of these models is not to replace the use of ex vivo skin, 
in terms of experimental results.  Reviews have highlighted that cell co-cultures in 2D 
and even 3D structures lack the complexity levels of in vivo skin and lead to different 
response in cell signalling, migration and phenotype, the cells being forced to adjust to 
the plastic structure of plates [3]. More complex models called organotypic skin 
cultures, which aim to reconstruct human skin in vitro, can even contain hair follicles or 
immune cells [27]. However, to construct such models it is necessary to have access to 
ex vivo skin to harvest each type of cell and the model development is very time and 
labour intensive. The models presented below are relatively easy to obtain and can 
serve as tools enabling mechanistic understanding of skin biology. 
 
1.4.1 Cell cultures. 
 
1.4.1.1 Normal human epidermal keratinocytes. 
 
Normal Human Epidermal Keratinocytes (NHEK) are primary epidermal cells. For 
laboratory research, they can be bought from a supplier as a cryopreserved stock, 
cultured in a keratinocyte specific medium and are usually ready for use after the second 
passage [28, 29]. These cells are particularly useful for scientists investigating the 
differentiation of keratinocytes at different levels of specification. 
 
1.4.1.2 HaCaT cell line. 
 
Chapter 1 
14 
 
The HaCaT cell line is derived from epidermal keratinocytes that have been 
spontaneously immortalized during culture. At the time, Boukamp and colleagues [30] 
were investigating culture conditions for human keratinocytes obtained from an adult 
male donor. Immortalisation was obtained when cells were cultured in a medium 
containing a low level of calcium under slightly elevated temperature (38.5 °C), hence 
the denomination of the new cell line: HaCaT (Human Adult, Low Calcium, High 
Temperature). 
This cell line is favoured by scientists as the cells can keep their integrity for many 
passages, as long as the culture conditions are maintained, and their subculture is 
relatively straightforward and well documented in the literature [31]. HaCaT cells are 
easily maintained in a basal state when cultured under low calcium concentrations and 
commence differentiation when calcium levels are increased. Once excess calcium is 
removed, HaCaT cells go back to basal level of differentiation. 
 
1.4.1.3 Skin fibroblasts. 
 
As with NHEK, skin fibroblasts are usually isolated from skin samples freshly obtained 
post-surgery and cultured in medium as primary cells. Fibroblasts are dermis cells that 
can be used as a 1D culture to complement the information obtained with keratinocytes 
studies. For example, fibroblasts can be used alongside keratinocytes and whole skin 
explants to assess skin damage linked to the use of irritants and sensitisers [32].  
 
1.4.1.4 Cell co-culture. 
 
The epidermis is a complex layer of skin, which does not include exclusively 
keratinocytes, even though these are in excess. In an attempt to produce more relevant 
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experimental results, comparable to the results obtained in vivo during a clinical study, 
co-cultures of a variety of epidermal cells were developed by various laboratories. 
A co-culture of immortalised murine melanocytes and keratinocytes has been used 
when putting in place a protocol enabling the measurement of pigmentation level of 
the melanocytes after application of chemicals enhancing or suppressing the production 
of melanin. It was observed that the trends for each chemical were more pronounced 
when a co-culture was used compared to melanocytes alone, highlighting the 
importance of considering the communication between cell types when developing in 
vitro models [33]. 
A co-culture of HaCaT and THP-1 (monocytic cell line derived from the blood of a patient 
with acute monocytic leukemia) cells has also been used to check the influence of 
keratinocytes in the process of skin sensitisation. It was shown that this in vitro assay 
helped to differentiate between haptens and pro-haptens using the expression of CD86, 
CD54 and CD40 from the THP-1 cells, while information about the metabolites formed 
from these haptens could be obtained by investigation of the metabolic activity of 
HaCaT cells [34]. 
 
1.4.2 3D skin models. 
 
Comparisons of the skin models commercially available have been carried out, where 
minor differences have been detailed [35, 36]. Overall, the described models all bear 
close resemblance to viable epidermis in terms of layers of differentiated keratinocytes, 
even though the cells can vary in shape compared to natural skin. However, the 
expression of certain markers can sometimes vary from model to model and the barrier 
function of the skin, essential when skin absorption studies are carried out, could not 
be satisfactorily reproduced. 
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1.4.2.1 Models available from Episkin®. 
 
Reconstructed Human EpidermisTM (RHE) is a skin model derived from the 3D culture of 
NHEK available from  Episkin [37]. It expresses some major differentiation markers and 
basal membrane markers, similar to the ones expressed in natural epidermis, which are 
used by the manufacturer to ensure reproducibility of batch production. This skin model 
can be delivered at different stages of maturation (after 10, 12 or 17 days of culture at 
the air liquid interface), in different sizes (0.5 cm2 or 4 cm2) or in a 24 or 96-well plate 
format. Its use for corrosion and irritation in vitro tests has been validated and is now 
recommended by the European Union Reference Laboratory for alternatives to animal 
testing (EURL-ECVAM). Another skin model, EpiskinTM, is also commercialised by the 
same company. The model is usually delivered after 13 days of keratinocyte 
differentiation. For specific skin penetration studies, the model can be cultured for 20 
days, to thicken the stratum corneum. The uses of the Episkin model are similar to those 
of RHE. 
 
1.4.2.2 Models available from MatTek Corporation®. 
 
EpiDermTM is a skin model derived from the 3D culture of NHEK available from MatTek 
[38]. Each set of skin models is shipped in 24-well plates and can be kept at 4 °C for up 
to 6 days before starting culture at the air liquid interface. The integrity of the tissue has 
been evaluated for up to three weeks, when the culture medium is changed every other 
day. On arrival, the skin culture should contain at a minimum 8 to 12 layers of 
keratinocytes at different stages of differentiation (stratum basale, spinosum and 
Chapter 1 
17 
 
granulosum) and 10 to 15 layers of corneocytes (stratum corneum).  More recently, 
MatTek has developed a model more representative of human skin, Epiderm FTTM, 
composed of an epidermis layer (keratinocytes) grown on a layer of cultured fibroblasts 
in collagen. 
 
1.4.2.3 Other commercialised models. 
 
The PhenionTM full-thickness model, commercialised by Henkel® [39]  is a similar type 
of model containing an epidermis and a dermis. It is sold as a 1.5 cm2 model and has 
been evaluated for use in skin penetration studies [40] but also its potential for use in 
skin metabolism studies [41].  
The LabskinTM model, commercialised by Innovenn UK Ltd [42], is very similar to the 
other full thickness models available, containing an epidermis and a dermis. The 
differences offered seem to come from the gel phase into which the fibroblasts are 
cultured, which is not collagen based. So far this model has primarily been used for 
microbiological assessment of cosmetics after topical application but has not been used 
to assess skin metabolism, linked to the GSH pathway or not. 
 
1.4.3 Culture and maintenance of ex vivo skin. 
 
Skin explants are usually obtained post-surgery and cultured at the air-liquid interface 
of a medium based on Dulbecco’s Modified Eagle’s Medium (DMEM). Explants viability 
has been maintained for a day for immediate DNA studies [43], seven days for the study 
of scarring processes [44] and up to two weeks for immunohistochemistry investigations 
linked to fibrosis [45]. The maintenance and use of such models is subject to stringent 
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ethics regulations and might require the research laboratory to set up a tissue bank. 
However, skin explants are now commercially available and can be purchased when 
working in conjunctions with companies that have been set up as branches from 
academic research laboratories and comply with all the required ethics regulations for 
the sourcing of their samples [46]. 
 
1.5  Skin metabolism. 
 
1.5.1 Transformation (Phase I). 
 
The general terminology used in metabolism studies to characterise the modification of 
xenobiotics by enzymes has been artificially separated into three Phases.  Phase I 
metabolism covers all the types of enzymatic reactions which result in a 
functionalisation of xenobiotics, i.e. either changing their hydrophilicity levels (for 
example the hydrolysis of an ester to an alcohol would increase water solubility) or 
increasing their reactivity towards molecules involved in phase II enzymatic reactions to 
favour their excretion. It has long been observed that some sensitising chemicals are 
not directly reactive but have a potential to be metabolically activated. This unwanted 
consequence of metabolism needs to be investigated because of the susceptibility of 
these new species to react with proteins. Chemicals presenting these properties need 
to be considered as potential skin sensitisers and have been denominated as 
prohaptens in the literature [7]. 
The transformations of xenobiotics in Phase I metabolism cover a wide range of 
reactions, from oxidative processes to reductions and hydrolysis. An excellent review of 
enzymes having a gene expression in skin is available [47]. While the expression of a 
number of cytochrome P450 mono-oxygenases (CYP) enzymes and flavin 
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monooxygenase enzymes genes was reported in skin biopsies and cell cultures, the 
detection of the proteins themselves and their activity levels were not usually reported 
and are poorly understood.  
A comparison of Phase I enzymes present in ex vivo skin and skin models highlighted the 
problems linked with the detection of enzymes in skin [48]. While the probes used in 
the assays have been successfully developed for enzymes in the liver, almost all 
measurements of CYP enzymes carried out in skin yielded results below the limit of 
detection. In contrast, cyclooxygenase activity was successfully measured above the 
limit of detection in all models, albeit with some result variability. While skin and 3D-
epidermis models showed activity around 20 pmol/min/mg, activity of immortalised cell 
lines such as HaCaT was below 1 pmol/min/mg, demonstrating that models were not 
always absolutely representative of human skin, especially considering metabolic 
capability.  A more systematic comparison of 3D skin models enzymatic activity was 
carried out and drew similar conclusions [49]. While the CYP activity was in the low 
pmol/mg protein/6 h range and sometimes close to the limit of detection of the assay 
for 3D skin models and ex vivo skin alike, esterase activity was easily measurable and 
the clearance values were of the same order of magnitude for all models. 
A review of CYP enzymes, carboxylesterases, alcohol dehydrogenases and flavin-
dependent monooxygenases, all involved in functionalisation of chemicals that could 
potentially increase their reactivity, was published [50]. This review covered the main 
skin models developed for in vitro testing including cells and 3D skin models. Another 
recent review included both Phase I and Phase II enzymes in human skin and skin models 
[51]. 
More work needs to be carried out to completely characterise human skin and the newly 
developed skin equivalents and the relevance of the results that they generate for phase 
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I metabolism, especially for CYP activity. However, due to the scarcity of viable ex vivo 
skin samples, models can be used whenever convenient, for a first assessment.  
 
 
1.5.2 Conjugation (Phase II). 
 
The conjugation reactions grouped in Phase II metabolism have as a biological purpose 
the inactivation of xenobiotics by addition of a small, hydrophilic moiety which will 
facilitate their evacuation from cells into the blood system, making them available for 
excretion by the kidneys. It is important to note that xenobiotics do not necessarily have 
to go through the Phase I reaction process to be metabolised by a Phase II enzyme. 
Indeed, most skin sensitisers are directly reactive. Phase II reactions are extensively 
reviewed by Lee and colleagues and include the following [52]:  
 Sulfation, reaction using 3’-phosphoadenosine-5’-phosphosulfate (PAPS) as a 
cofactor, the enzymes involved being members of the sulfotransferases family. 
 Acylation, mainly involving N-acetyltransferases (NATs) enzymes that use acetyl 
coenzyme A as a cofactor. 
  Glucuronidation, reaction with cofactor uridine diphosphoglucoronic acid 
(UDPGA) facilitated by UDP-glucoronosyl transferases (UGTs) 
 Methylation, reaction using S-adenosylmethionine (SAM) as a cofactor, the 
enzymes involved being members of the methyltransferase family. These are 
mostly enabling the methylation of aliphatic thiols, thiol methyltransferase 
(TMT) family, aromatic or heteroaromatic thiols, thiorupine methyltransferase 
family or catechols, catechol-O-methyltransferase (COMT) family. A few 
examples of N-methylation of amine containing drugs, such as nicotine have also 
been reported. 
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 Glutathione addition, reaction with glutathione mediated by glutathione S 
tranferases (GST). Details on GSTs present in skin will be given further below. 
As for Phase I metabolism, the activity levels of phase II enzymes in human skin and skin 
models has been evaluated [53]. Contrary to phase I metabolism enzymes, Phase II 
enzymes show higher levels of activity (in the nmol/min/mg) range in this study. This 
facilitated their quantification and at the same time, emphasised the fact that skin is a 
very active detoxifying organ.  The study demonstrated that 3D epidermal models 
showed slightly lower GSTs activity while UGTs and NATs were comparable. Higher 
Phase II metabolic activity compared to Phase I in 3D skin equivalents and ex vivo skin 
has also been reported elsewhere [49]. Very recent studies demonstrated that GSH 
conjugation, methylation, N-acetylation, sulfation and glucuronidation all took place to 
some extent in freshly excised skin (maintained in medium and used immediately) but 
the addition of cofactors to the maintenance medium did not increase the clearance 
rates of the chemical probes tested [54]. 
Previous studies already determined that the HaCaT cell line is a promising cell line for 
the investigation of phase II metabolism. The N-acetylated product of 4-amino-2-
hydroxytoluene, a common hair dye, has been reported in both ex vivo skin and a HaCaT 
cell line [55]. The activity level of NAT 1 enzyme in this cell line was also measured 
alongside non immortalised keratinocytes [28]. While CYP activity (Phase I) was again at 
the very low end of the limit of detection, NAT 1 could be measured and the levels were 
comparable to the results obtained in a NHEK cell line.  
 
1.5.3 Transportation (Phase III). 
 
Phase III metabolism is the denomination given to the processing of metabolites that 
have been generated by a conjugation reaction (phase II) and their excretion. It usually 
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consists of 1) further processing of the metabolite by modifying the molecule that has 
been conjugated to the original xenobiotic (for example a modification of the 
glutathione moiety of a glutathione-xenobiotic conjugate) and 2) the transport of the 
substrate through the cell membrane by transporters, the energy required for this being 
released by the consumption of adenosine triphosphate (ATP). These proteins are called 
ATP binding cassette (ABC) transporters and 46 ABCs have been identified in humans to 
date [56]. A brief review of the mechanisms involved in the transport of glutathione 
conjugates out of cells is given in Section 1.7.3. 
 
1.6  Glutathione. 
 
1.6.1 Definition. 
 
Glutathione or γ-L-Glutamyl-L-cysteinyl-glycine is a tripeptide which is formed by the 
conjunction of L-glutamate, L-cysteine and glycine featuring a characteristic γ-glutamyl 
bond (Fig 1.4). It was first discovered in 1888 by J. De Rey-Pailhade [57] but since then 
thousands of publications related to this molecule have been released (Table 1.1). 
 
Figure 1.4 : Chemical structure of glutathione, highlighting the characteristic γ-glutamyl 
bond with the cysteine residue (green), which differs from the conventional α-peptide 
bond. The specificity of this bond protects GSH from cleavage by general peptidases and 
requires the presence of γ-glutamyl transpeptidase (GGT) to occur. 
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glutathione 
year count year count year count 
2017 2882 1986 1286 1955 45 
2016 5829 1985 1138 1954 42 
2015 6084 1984 1156 1953 61 
2014 6093 1983 941 1952 50 
2013 6070 1982 832 1951 50 
2012 5768 1981 724 1950 28 
2011 5238 1980 694 1949 15 
2010 5038 1979 557 1948 11 
2009 4776 1978 497 1947 15 
2008 4568 1977 432 1946 8 
2007 4604 1976 469 1945 6 
2006 4503 1975 439 1943 4 
2005 4825 1974 370 1941 2 
2004 4612 1973 347 1939 4 
2003 4371 1972 312 1938 3 
2002 4101 1971 332 1937 2 
2001 3846 1970 324 1936 5 
2000 3770 1969 305 1935 6 
1999 3361 1968 280 1934 4 
1998 3274 1967 226 1933 7 
1997 3247 1966 213 1932 5 
1996 3137 1965 226 1931 3 
1995 2948 1964 264 1930 7 
1994 2666 1963 151 1929 3 
1993 2420 1962 90 1928 1 
1992 2245 1961 75 1927 4 
1991 2011 1960 56 1926 3 
1990 1774 1959 62 1925 5 
1989 1597 1958 72 1924 2 
1988 1537 1957 47 1923 1 
1987 1352 1956 54 No publications 
 
Table 1.1 : Number of references related to glutathione found in Pubmed. 
 
GSH is usually present at millimolar (mM) levels in tissues, throughout the body. In 
humans, the main generator of glutathione is the liver, while the main glutathione 
consumers are the kidneys. Unfortunately, GSH is mostly an intracellular peptide, which 
cannot enter the cell membrane without being turned back into amino acids. However, 
GSH can be taken out of cells using transporters, a process that has been described for 
hepatic cells, meaning that some GSH can be delivered throughout the body using the 
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blood system. Nevertheless, the level of GSH in plasma is usually low (in the µM 
concentrations level), which means that cells will usually synthesise their own pool of 
GSH, starting from constitutive amino acids [58]. 
 
1.6.2 Synthesis. 
 
The synthesis of glutathione is carried out in two steps, first the formation of the peptide 
bond between L-glutamate and L-cysteine and then the addition of glycine. A schematic 
of glutathione synthesis is presented in Fig 1.5. 
  
Figure 1.5: Synthesis of glutathione, where atoms colouring key is grey: carbon, blue: 
oxygen, red: hydrogen, yellow: sulphur and green: nitrogen. 
 
1.6.2.1 Linking glutamate and cysteine. 
 
The GSH cycle in the human body, from formation to usage has been extensively 
characterised [59-61]. The first step in the generation of de novo GSH is the conjugation 
of L-glutamate with L-cysteine, mediated by the enzyme glutamate-cysteine ligase 
(GCL). Some scientific publications use the denomination γ-glutamylcysteine synthetase 
to (GCS) for this enzyme [62, 63], but nowadays the term GCL is preferred.  This reaction 
is considered to be the rate limiting step of the overall synthesis. 
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1.6.2.2 Intracellular glutamate. 
 
Similarly to GSH, glutamate is not readily available to cells as it cannot pass through the 
cell membrane and needs to be “synthesised on demand”.  The rate of formation of 
glutamate was measured in erythrocytes using a mixture of 1H-13C Nuclear magnetic 
resonance (NMR) technique and Mass spectrometry (MS) technique [64]. While levels 
of de novo radiolabelled GSH were below the limit of detection for NMR analysis, MS 
data were used to prove that it was formed by consumption of radiolabelled glutamate 
produced by the alanine aminotransferase pathway (enzyme mediating the formation 
of glutamate and pyruvate from reaction between α-ketoglutarate and alanine), which 
was not considered to be the major contributor before. Other pathways for the 
formation of glutamate involve an aspartate aminotransferase pathway, similar to the 
one described above, and an enzymatic conversion of glutamine to glutamate using 
glutamine aminohydrolase. 
Glutamate can also be made available to the cell by consumption of extracellular GSH 
[65]. In short, transpeptidases present on the cell membrane can catalyze the 
tranformation of GSH back into glutamate and cysteinylglycine. The glutamate then 
forms a new peptide bond with another extracellular amino acid and the resulting 
“gamma-glutamyl amino acid” can then penetrate into the cell. This intermediate can 
then be hydrolysed back to the free amino acid and a cyclic version of glutamate, 5-
oxoproline, intracellularly. The mechanism of conversion of 5-oxoproline to glutamate 
has been described in detail [59].   
 
1.6.2.3 Sourcing cysteine. 
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Cysteine is a semi-essential amino acid that can be synthesized in the body from a 
variety of precursors such as N-acetylcysteine. It is obtained in the liver by degradation 
of proteins, L-homocysteine or L-cystine [66]. When cysteine cannot be sourced from a 
precursor in cells, cells might use extracellular GSH instead. As the liver excretes some 
GSH to the blood system to maintain a plasma level of GSH of a few µM [67], this 
extracellular GSH can then be degraded back to cysteinylglycine (as described  above for 
the sourcing of glutamate) which is then degraded further to cysteine by the action of a 
dipeptidase. 
 
1.6.2.4 Linking glutamyl-cysteine and glycine. 
 
The second step in the synthesis of GSH is the linkage of the glutamyl-cysteine peptide 
with the final amino acid required, glycine. Glycine is readily available in cells by 
enzymatic degradation of serine by serine hydroxymethyltransferase. The reaction 
between glutamyl-cysteine and glycine is enzymatically mediated by glutathione 
synthetase (GS). 
 
 1.7  Glutathione in skin metabolism. 
 
1.7.1 Reactivity. 
 
The detoxification of xenobiotics by GSH can occur either by direct binding of this 
molecule to the reactive species involved, or by conjugation reactions enzymatically 
mediated by GSTs. 
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The ability of GSH to react non-enzymatically with electrophiles has been considered as 
an advantage to investigate possibilities for the development of in vitro tests for skin 
sensitisation. In this context, GSH has mostly been used as a model peptide for 
measuring the reactivity level of chemicals with thiols, regardless of the biological 
relevance of GSH itself in skin detoxification. Strong and extreme sensitisers have been 
shown to deplete a significant amount of GSH within 15 minutes, when a 100 molar 
excess of chemical compare to GSH was used, whereas non-sensitisers did not [19].  
Direct reaction with GSH has been assessed for 24 skin sensitisers, for which a 
sensitisation potential had previously been established using the Local Lymph Node 
Assay (LLNA) [68]. The output of this assay was the concentration of reagent able to 
deplete 50 % of the reduced glutathione available, called EC50. For practical reasons, 
toxicologists tend to define a pEC50 value, which is the negative logarithm of EC50. Even 
though the results of this assay cannot be used on their own to discriminate between 
different potencies of sensitisation, it is noticeable that all skin sensitisers had a pEC50 
value higher than -0.55. Bearing in mind that a level lower than this threshold is not a 
guarantee that this chemical cannot be modified metabolically to become reactive, this 
approach can still be used as part of a first screening assessment, as a part of a selection 
of assays, to determine the potential of a chemical to be a direct sensitiser. 
It is noticeable, that sometimes, the GSH conjugates formed with certain xenobiotics do 
exhibit comparable or even enhanced levels of toxicity to the cell than the original 
compound itself. This finding was highlighted in a review publication of the different 
aspects of GSH cellular involvement, citing the reactivity of the conjugate 2-
bromoethylglutathione [69], based on the work carried out by others [70]. The 
nephrotoxicity of GSH conjugates derived from halogenated alkenes has also been 
demonstrated [71]. A mechanistic pathway was presented, explaining that toxicity was 
obtained from the degradation of glutathione S-conjugates, formed in rat liver, which 
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were transported to the kidneys where they got processed back into cysteine 
conjugates and finally bioactivated to very reactive thione (R – C = S) or thioketene  (R = 
C = S) derivatives by cysteine conjugate β-lyase.  
Increase in reactivity after reaction with GSH has also been reported. The reaction of 
the strong skin sensitiser 5-chloro-2-methylisothiazol-3-one with histidine residues of 
human serum albumin, used here as a model protein for haptenation studies, has been 
enhanced when the compound was first left to react with catalytic amount of GSH, 
yielding a chlorothioacyl intermediate, which showed a considerably increased 
reactivity towards protein nucleophiles [72]. 
 
1.7.2 Glutathione S transferases (GSTs) in skin. 
 
GSTs are one of the major superfamily of enzymes catalysing conjugation reactions and 
have been classified into subfamilies. Approximately 90 % of GSTs in humans belong to 
the α, , or π families, while τ, σ, ω, ζ and κ families are represented to a much lower 
extent [73]. An example of human GSTA1-1 in complex with GSH is presented in Fig 1.6.  
 
 
Figure 1.6: Crystal structure of human glutathione transferase (GST) A1-1 in complex 
with glutathione. Figure reproduced from Protein Data Bank [74]. 
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GSTs are dimeric structures, with each monomer containing two reactive domains [75]. 
The first domain is called the N-terminal domain and is the preferred location for the 
activation of GSH (detail of the activation next to a Tyr amino acid is presented in Fig 
1.7) to enhance its reactivity by increasing the nucleophilicity of the sulphur (GSH can 
then be represented by a GS- species bound to the enzyme). 
 
 
Figure 1.7 : Two views of the first-sphere and second-sphere electrostatic interactions 
in the active site of the M1-1 GSH transferase from rat. The first-sphere interactions 
with the sulfur of GSH include: a) the hydrogen bond with the hydroxyl group of Y6, b) 
a coordinated solvent molecule (or NH4+) and c) an interaction with the electropositive 
edge of the aromatic ring of Tyr6. The second-sphere interactions involve: d) an on-face 
hydrogen bond between the hydroxyl group of Thr13 and the π-electron cloud of Tyr6 
and e) a hydrogen bond between the main –chain amide of Leu12 and the hydroxyl 
group of Tyr6. Carbon, oxygen, nitrogen and sulfur atoms are illustrated in black, gray, 
light-gray and white respectively. Figure reproduced from [75]. 
 
The second domain contains the xenobiotic binding site and is referred to as the C-
terminal domain. This is where the electrophile is located, ready for reaction with the 
activated GSH. 
Intermediates of reaction can be observed inside the active site of the enzyme and after 
completion, the product glutathione-conjugate tends to face on the outside of the site, 
ready for release [75]. The catalysed reaction of GSH with 1,3,5-trinitrobenzene yields 
S-(p-bromobenzyl)-glutathione and the chemical intermediate of this reaction is known 
as the Meisenheimer complex (Fig 1.8). This particular complex was used to illustrate 
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the transition state happening inside hP1-1 GST during nucleophilic substitution at the 
aromatic ring of electrophiles [76]. 
 
Figure 1.8 : Representation of the Meisenheimer complex in the active site of GST hP1-
1: Stereo representation of the active site of GST hP1-1 in complex with S-(p-
bromobenzyl)-glutathione (cyan). The [2Fo-Fo] map is derived from this structure and 
contoured at 1.0σ (shown in blue). All residues from one monomer participating in the 
active site are shown, but only the residues from the H-site are labelled. The S-(p-
nitrobenzyl)-glutathione moiety, from the structure of GST mP1-1 in complex with it is 
superimposed and shown in green.  Figure reproduced from [76]. 
 
Several studies investigated the presence and enzymatic activity of GSTs in human skin. 
The three main isozymes of GST that could be found in skin all belonged to either the 
alpha-family or pi-family of GSTs [77]. Also the 10-15 % of enzyme activity that could 
not be recovered using their affinity column could be putatively assigned to isozymes of 
the theta family.  Samples were differentiated as per gender (6 females and 8 males) 
and it was reported that GST activity levels towards DNCB were higher in women than 
men by a 1.7 fold, the GST activity expressed as mU per g of wet tissue being 1320±180 
and 760 ±120 respectively. GST protein levels were also found to be higher in females 
than males. 
To confirm the presence of these isoenzymes, histological studies of skin samples were 
carried out separating the skin strata. The presence of class pi-GSTs was demonstrated 
in all skin cells, with the majority of enzymes being located in the stratum basale. Class 
mu-GSTs have also been mainly found in the stratum basale. In contrast, most of the 
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class alpha-GSTs were found in the upper layers of the epidermis. All GST classes were 
poorly represented in the dermis, where low level of staining could be observed in 
fibroblasts [78]. 
Cell cultures have been used to investigate the involvement of GST-P1 1(pi- family) in 
signalling pathways linked to detoxification, even though the total GST activity 
measured seemed to vary significantly depending on the type of cell used [79].  
 
1.7.3 Excretion of glutathione conjugates. 
 
Glutathione conjugates and GSSG are toxic for cells and therefore need to be removed 
from the intercellular space. Glutathione conjugates can be transported as they are or 
after conversion to mercapturic acid derivatives (this is achieved by a combination of 
enzymes: glutamyltranspeptidase removes the glutamyl group after which N-
acetyltransferase acetylates amine of the cysteine residue) [80]. The transport through 
the cell membrane is ATP dependent and carried out by transporters called multidrug 
resistance-associated protein (MRP). There are six isoforms of MRP in human. These 
proteins have been described as “efflux pump” systems and have been identified in 
different kind of cells and tissues.  
 It has been shown that MRP1 and MRP2 are involved in the transport of glutathione 
conjugates [81] but this role can also be carried out by MRP6 as has been highlighted in 
a Chinese hamster ovary cell line [82]. The efflux of GSSG from blood cells by MRP1 
transport has recently been demonstrated [83]. Few studies have tried to characterise 
efflux pumps in human skin, but it has been reported that MRP1 played a role in the 
absorption of drugs. The skin absorption of rhodamine 123, [3H]-vinblastine, and [3H]-
LTC4 was significantly decreased when the skin was previously treated with MRP1 
inhibitors [84]. 
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1.8  Glutathione antioxidant properties. 
 
1.8.1 Definitions. 
 
1.8.1.1 Oxidative stress 
 
Whatever the nature of the chemical modification occurring during or after absorption, 
the skin tries to detoxify foreign compounds using a battery of mechanisms, among 
which antioxidants play a major role. Depending on nature and chemical structure, 
certain external chemicals can interact with some biomolecules leading to the formation 
of radical species and/or Reactive Oxygen Species (ROS), able to cause further oxidative 
damage. Oxidative stress is a broad term used to qualify, on the one hand, the process 
involved in the formation of ROS and on the other hand, the ending result due to the 
imbalance induced in the biological system studied. 
 
1.8.1.2 Redox state 
 
Technically, the Redox state of a living cell can be defined as the sum of the variation of 
all the potentials of the redox couples present in it. Even though the potential of the cell 
would remain relatively stable, in theory, while the cell is in an undisturbed healthy state 
usually maintained by the principle of homeostasis, sudden imposed variations lead to 
an imbalance of these potentials and this is what most scientists defined as oxidative 
stress. This is why the investigation of redox state has gained importance over the years 
[85]. However, very few studies describe biological systems in the way they would 
describe an electrochemical cell [86]. This is probably due to the fact that 1) there are 
many redox couples involved in the homeostasis of cells and measuring all of them 
simultaneously is unrealistic, 2) the potentials need to be measured in an isolated 
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system such as a single cell, while the system is still viable, which is technically 
challenging. 
 
1.8.2 Role of glutathione in the cell redox state. 
 
The protective role of GSH, both by conjugation with electrophiles and reduction by 
oxidative species, has been recently reviewed [58]. Indeed, GSH has the ability to act as 
a radical scavenger by oxidation of its cysteine residue and therefore helps to maintain 
the level of ROS in cells. The oxidised cysteine can then react with another cysteine 
residue in a nearby molecule of GSH, resulting in the formation of GSSG.  This reaction 
is enzymatically controlled by Glutathione Peroxidase (GPx). In mammals, four 
isoenzymes of GPx have been identified: cytosolic GPx, plasma GPx, phospholipid 
hydroperoxide GPx and gastrointestinal GPx, whose location in the body, abundance 
and function are tissue specific [87]. 
GSSG is actually harmful to a cell, therefore to maintain a healthy level, GSSG needs to 
be excreted or regenerated back to GSH.   The reduction of GSSG into two molecules of 
GSH is an enzymatic reaction involving Glutathione Reductase (GR) and Nicotinamide 
adenine dinucleotide phosphate (NADPH) as a reducing agent (Fig 1.9). To investigate 
the role of GR in re-establishing the levels of GSH after chemical exposure, it is possible 
to inhibit this enzyme using 1,3-bis(2-chloroethyl)-N-nitrosurea (BCNU) or carmustine. 
A thorough review of the enzymes involved in the redox cycle of GSH is available [88]. 
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Figure 1.9 : The redox cycle of GSH 
 
 
The role of GSH as a protective mechanism against ROS has been investigated in the 
HaCaT cell line [89] using highly reactive quinones. Cells were exposed to various 1,4-
naphthoquinones and then analysed for total glutathione, ROS formation and DNA 
damage. The level of GSH and GSSG were determined and most of the quinones tested 
highly depleted the pool of GSH, sometimes in conjunction with formation of GSSG, 
especially when the production of ROS was enhanced in the cells.  
The effect of cadmium on the cellular antioxidant systems was similarly studied [90]. 
HaCaT cells were treated with different concentrations of Cd (3 to 100 µM) with or 
without previous treatment with a reagent capable of depleting the GSH pool available, 
L-buthionine sulfoximine (BSO). The level of total glutathione was evaluated and levels 
of activity for GPx and GR were measured. Both GSH and GSSG levels increased in cells 
treated with Cd only, but GSSG levels were not linked to modifications of enzyme 
activities. A decrease in the ratio GSH/GSSG was observed and linked to a modification 
of intracellular redox status probably due to an increased generation of ROS.  Indeed, 
when cells were pretreated with BSO, a high concentration of Cd induced DNA damage. 
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Even though GSH is mostly acting as a scavenger of ROS, its reducing capacity towards 
metal can sometimes be a disadvantage in terms of detoxification. Indeed, GSH can 
actually increase the production of ROS. When a metal ion is reduced by GSH, it can 
consequently be regenerated to its ion state by molecular oxygen, which acts in this 
context as an electron acceptor, yielding a superoxide anion [69]. 
 
1.8.3 The GSH:GSSG ratio. 
 
The variation of the ratio GSH:GSSG is accepted as a reliable way of measuring the effect 
of oxidative stress [67].  This is a direct consequence of the assessment of the variation 
in potential in the cell (expressed in mV) due to the variation in concentration of the 
compounds of the redox couple 2GSH:GSSG [86]. 
The Nersnst equation for this redox couple, at a temperature of 25 °C, is as follows: 
ΔE = ΔE° - 59.1/2 x log Q 
Where:   ΔE = voltage of the electrochemical cell studied (in mV, at a fixed pH),  ΔE°= 
voltage at standard conditions (for example at pH 7.4 and 25 °C ΔE°=-240mV for the 
2GSH/GSSG redox couple) and  Q =  (Concentration of GSH)2 / (concentration GSSG). 
Therefore, the measurement of Q is a way to estimate oxidative stress in cell. However, 
for convenience, most publications report the ratio GSH:GSSG instead of GSH2:GSSG. 
Even though the exact ratio GSH:GSSG can vary depending on the type of organelles, 
cells or tissues investigated, it is estimated that the overall ratio, in healthy cells resting 
at  homeostasis state, should be approximately 100:1 [52, 86]. 
Difficulties with assessing the levels, and hence, the ratio, of GSH and GSSG in biological 
samples such as blood, have long been linked to sample preparation.  It was suggested 
that up to 2-3 % of the glutathione present could be turned into GSSG during sample 
preparation, leading to an erroneous evaluation of the ratio [91]. This issue was 
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removed when a thiol blocking reagent was used to derivatise the reduced GSH and 
enzymes were inhibited using acidic conditions.  
 
1.9 Analytical methods to identify and measure glutathione. 
 
A number of studies have reported a variety of analytical techniques used for the 
measurement of reduced and oxidised glutathione [92-95]. Methods include 
spectrophotometric detection, fluorescence analysis, electrochemistry measurements, 
High Pressure Liquid Chromatography (HPLC) and more recently Mass Spectrometric 
(MS) methods.  
 
1.9.1 Spectrometric assays. 
 
Most spectrometric assays have been developed using at least one enzyme involved in 
the glutathione cycle. The analytical technique relies on monitoring the formation of 
adduct formed by reaction of GSH with a selected reagent. A method to measure the 
amount of GSH available in hepatic homogenates has been developed by  Brigelius and 
colleagues [96], based on the reaction of available glutathione with DNCB after the 
addition of glutathione S transferase. The formation of the resulting conjugate is 
monitored spectrophotometrically at 340-400 nm. This methodology forms the basis of 
many commercially available kits for measuring glutathione S transferase activity levels. 
Another procedure has been developed  to assess both GSH and GSSG using 5,5’-
dithiobis(2-nitrobenzoic acid) (DTNB) and glutathione reductase in the presence of 
NADPH [97]. 
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1.9.2 Fluorescence assays. 
 
Fluorescence assays are based on the detection of glutathione after its derivatisation 
with a reagent such as monobromobimane, o-phtalaldehyde [98, 99] or a naphthalene 
derivative containing selenium [100], the latter presenting the advantage of being an 
effective colorimetric agent as well. The resulting glutathione-reagent conjugate 
exhibits fluorescent properties and can be measured using a fluorescent 
spectrophotometer. These assays are especially popular as they only require simple 
sample preparation and the analytical equipment used is relatively inexpensive 
compared to mass spectrometers.   Their major drawback however, is the range of 
concentrations covered by these assays, usually optimum for samples containing 
hundreds of µM to mM levels of GSH. 
 
1.9.3 Liquid Chromatography-Mass Spectrometry. 
 
High Pressure Liquid Chromatography (HPLC) is used to physically separate a selection 
of analytes by their affinity with the solid phase of a chromatographic column. This piece 
of equipment is used in conjunction with Ultra Violet (UV) [101], fluorescence 
(described above) or chemiluminescence [102] detectors as well as mass spectrometers.  
Due to the high hydrophilicity of GSH, poor retention on conventional reverse-phase 
columns is observed. To solve this problem, as well as protect the thiol group of GSH 
from autoxidation into its disulfide, GSH is usually derivatised with a reagent such as N-
ethylmaleimide (NEM) [103, 104], Ellman’s reagent [105] or iodoacetic acid [101, 106]. 
More recently HILIC (Hydrophilic Interaction Liquid Chromatography) separation 
technology has been used for the analysis of GSH and GSSG [107].  
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Liquid Chromatography-Mass Spectrometry (LC-MS) is routinely carried out using an ESI 
(Electrospray) source operating in positive ionisation mode.  The detection of the parent 
ion (M+H)+ for both GSH and GSSG can be achieved using  most types of mass 
spectrometers. When GSH has been modified by haptenation and the mass of the final 
adduct is unknown it is possible to track back its presence by monitoring the neutral loss 
of m/z 129 (formed by the loss of pyroglutamate moiety, characteristic method for MS 
glutathione detection) in newly appearing peaks (Fig 1.10). 
 
 
Figure 1.10 : Mass spectrometric fragmentation of GSH conjugate showing the neutral 
loss m/z 129 
 
1.10  Thesis aims and objectives. 
 
1.10.1 Hypothesis. 
 
Current mechanistic understanding of the role of reactivity in skin sensitisation rests on 
the premise that a reactive chemical has the potential to sensitise via irreversible 
conjugation to protein nucleophiles in the skin and thus generate an antigen. The 
modification of cysteine residues present in proteins has been demonstrated to be an 
important reaction for a range of skin sensitisers. The aim of this report is to 
demonstrate that the reactivity of such sensitisers with a small free thiol, GSH, plays an 
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important role in the clearance mechanism of human skin, thus potentially preventing 
or at least limiting the amount of reactive compound available to react with proteins. 
The study also highlights the ability of human skin to generate de novo GSH as a defense 
mechanism against xenobiotics and thus compensate for the consumption of the thiol 
involved in the clearance process to maintain healthy levels of protective GSH in cells. 
 
1.10.2 Choice of chemicals. 
 
This investigation covered a range of chemicals, with various potential for skin 
sensitisation.   
DNCB (Fig 1.11) is a chemical intermediate with few reported commercial uses on its 
own and is mostly used for the production of various dyes [108]. It can also be used for 
synthesising 2,4- dinitrophenylhydrazine, a reagent used for the characterization of 
carbonyl compounds or dinitrophenylrhodanate, an insecticide.   
 
Figure 1.11 : 1-chloro-2,4-dinitrobenzene 3D chemical structure. Reproduced from 
PubChem [109], where the colouring of atoms is grey: carbon, white: hydrogen, blue: 
nitrogen , red: oxygen and green: chlorine. 
 
DNCB is mostly used for laboratory research purposes and a few clinical assessments 
involving topical application [110, 111]. Contact allergy to DNCB is a cell mediated 
hypersensitivity that has been used as a tool to detect patients with deficiencies in cell 
mediated immunity since the 60s. Potent contact sensitisers, such as DNCB, have been 
used by a few dermatological clinics to treat conditions such as alopecia areata and viral 
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warts, with various degree of success [112].  DNCB is also a very good substrate for GST 
[113] and is usually provided as part of commercial kits to measure GST enzymatic 
activity spectrometrically. 
1-bromo-2,4-dinitrobenzene (DNBB) (Fig 1.12a) and 1-fluoro-2,4-dinitrobenzene 
(DNFB) (Fig 1.12b) are structurally related to DNCB.  
 
Figure 1.12 : a) 1-bromo-2,4-dinitrobenzene and b) 1-fluoro-2,4-dinitrobenzene 3D 
chemical structures. Reproduced from PubChem [109] where the colouring of atoms is 
grey: carbon, white: hydrogen, blue: nitrogen , red: oxygen, orange: bromine and pink: 
fluorine. 
 
DNBB has little use on its own. However DNFB is used in the sequencing of polypeptides. 
The analysis of terminal amino acids after reaction with DNFB to sequence the 
polypeptides is based on the work of Sanger, who used it in his discovery of bovine 
insulin [114], hence DNFB is often called Sanger’s reagent. Both compounds react with 
GSH in chemico [115]. 
The synthesis of diphenylcyclopropenone (DPCP) (Fig 1.13) was reported for the first 
time in 1959 [116] and was also obtained by another research group following a 
different synthesis route in 1960 [117]. This chemical was found to be a potent sensitiser 
with cases of contact dermatitis reported in the 70s, and started to be used for clinical 
treatment of alopecia areata [112, 118].  
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Figure 1.13 : Diphenylcyclopropenone 3D chemical structure. Reproduced from 
PubChem [109] where the colouring of atoms is grey: carbon, white: hydrogen and 
red: oxygen. 
 
DPCP and its precursor of synthesis α,α’-dibromobenzylketone have been fully 
characterised for stability in solution and mechanism of sensitisation [119]. DPCP now 
tends to replace DNCB in alopecia areata treatment in the UK. It is known to react with 
GSH [19].  
Diethyl maleate (DEM) (Fig 1.14) is a chemical intermediate involved in the synthesis of 
many industrial products including polymers [120].  
 
Figure 1.14 : Diethyl maleate 3D chemical structure. Reproduced from PubChem [109] 
where the colouring of atoms is grey: carbon, white: hydrogen and red: oxygen. 
 
It has a moderate potential to be a skin sensitiser. When, DEM was applied as part of a 
battery of patch tests for patients with suspected allergy to dimethyl fumarate, 21 out 
of the 37 patients had a positive reaction [121]. DEM is known to react with GSH [19] 
and has been used to deplete stocks of GSH in tissues [122]. The level of depletion 
reported, however, is not complete and residual level of GSH is observed, with total 
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depletion only observed when both DEM and L-buthionine sulfoximine (BSO) are used 
simultaneously [123].   
Benzaldehyde (BA) (Fig 1.15a) is a colourless liquid, industrially prepared from toluene. 
 
Figure 1.15 : a) Benzaldehyde and b) phenylacetaldehyde 3D chemical structures. 
Reproduced from PubChem [109] where the colouring of atoms is grey: carbon, white: 
hydrogen and red: oxygen. 
 
 
It is widely used in the industry as a chemical intermediate to produce other more 
complex organic compounds. As BA has a pleasant almond smell it is also used directly as 
a flavouring or fragrance additive in consumers products. BA is not considered to be a skin 
sensitiser in the LLNA [124], however there are a few reports of allergy to BA [125]. Its 
volatility and quick metabolism to benzoic acid in skin make it generally safe to use [126]. 
Phenylacetaldehyde (PA) (Fig 1.15b) is a common fragrance that is structurally very similar 
to BA with the addition of one carbon between the benzoic ring and the aldehyde 
function. It is widely used in perfumed personal care products due to its pleasant hyacinth 
smell. It is considered a moderate skin sensitiser in the LLNA [124]. It did not react with 
GSH in the specific experimental conditions used in the in chemico assay used by Gerberick 
et al [19]. 
 
1.10.2 Research overview. 
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As the maintenance of metabolic activity in ex vivo skin is still variable and dependent 
on the techniques used to handle the freshly collected samples before they reach a 
tissue bank, experimental work investigating the detoxification of sensitisers was 
carried out using the HaCaT cell line and the RHE model. 
First, the study aimed to characterise the GSH cycle in the HaCaT cell line. The GSH basal 
level was determined in healthy cells. The activity of GSH related enzymes was then 
altered and the overall effect on GSH levels measured. The inhibition of GCL, essential to 
the de novo synthesis of GSH, was carried out with BSO.  To generate an imbalance in the 
ratio of GSH: GSSG in the cells the model oxidant H2O2, as well as aldehydes (BA and PA), 
were used. The detection of GSSG was attempted by blocking, or at least reducing, the 
activity of Glutathione Reductase (GR) with inhibitors such as 2-AAPA and carmustine 
(BCNU). 
The HaCaT cell line was then used to demonstrate the detoxification of model sensitisers 
of different potencies by GSH.  GSH dose response to sensitisers as well as 24h time course 
experiments were carried out with a moderate sensitiser (DEM), an extreme sensitiser 
(DPCP) and a series of dinitrohalobenzenes, which were also extreme sensitisers (DNCB, 
DNFB and DNBB). 
The metabolic clearance of these sensitisers in the HaCaT cell line, though similar in terms 
of GSH reactivity to the expected metabolic activity of GSTs in skin, might differ in terms 
of kinetics, mostly due to the ease of penetration of the compounds in monolayer 
cultures. To compensate for this phenomenon, the detoxification of DNCB was 
investigated after topical application on a 3D keratinocyte culture, the Reconstructed 
Human Epidermis (RHE) model. The first experiments aimed at establishing the suitability 
of the RHE model for DNCB clearance over 24 hours, by measuring the level of GSH and 
the formation of the GSH conjugate DNP-SG.  However, the main advantage of the RHE 
model remained the fact that the samples could potentially be maintained in culture for 
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long periods of time (at least 48 hours when cultured according to the manufacturer’s 
recommendations).  This allowed for the development of an in vitro strategy to investigate 
exposure to a chemical (in this case the model sensitiser DNCB) applied on a daily basis. 
This approach was tested for three cycles of exposure on the RHE model and could provide 
information on the biological impact (i.e variations of metabolic capacity) of daily 
exposure to cosmetic products on human skin.  
The data generated using this methodology provides information on the chemistry 
involved in the detoxification of potential sensitisers and, though not an MIE of skin 
sensitisation in itself, is to be considered along with haptenation to proteins, which could 
lead to ACD, for future risk assessment. The protective effect of Phase II metabolism, 
especially GSH clearance, is not currently quantified in skin and information about the 
bioavailability of potential skin sensitisers mostly rely on skin penetration experiments. It 
is expected that data generated in vitro using 3D skin models exposed daily to new 
chemicals can be extrapolated into a mechanistic model for assessing their skin 
sensitisation potential for the general population. 
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Chapter 2: Materials and Methods. 
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2.1  Materials. 
  
2.1.1 Skin models. 
 
The HaCaT cell line was a kind gift from Prof. N. Fusenig (University of Heidelberg, 
Germany), received at passage 30 and 34 in 1993, cryopreserved in Unilever 
laboratories. 
Reconstructed Human Epidermis (0.5 cm2 aged for 17 days) was supplied by Episkin (Lyon, 
France). 
 
2.1.2 Chemicals and reagents. 
 
2-acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylthiocarbonylamino) 
phenylthiocarbamoylsulfanyl] propionic acid (2-AAPA), ammonium bicarbonate, 
benzaldehyde (BA), carmustine (BCNU), L-buthionine sulfoximine (BSO), diethyl maleate 
(DEM), 1-bromo-2,4-dinitrobenzene (DNBB), 1-chloro-2,4-dinitrobenzene (DNCB), 1-
fluoro-2,4-dinitrobenzene (DNFB), diphenylcyclopropenone (DPCP), reduced 
glutathione (GSH), glutathione disulfide (GSSG), glutathione-[glycine 13C2,15N], 
iodoacetic acid (IAA), 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(methyl tetrazolium, MTT), phenylacetaldehyde (PA), radio immunoprecipitation assay 
(RIPA) buffer, sulfosalicylic acid, and trypsin-ethylenediamine tetraacetic acid (EDTA) 
solution (containing 0.25 % trypsin) were purchased from Sigma Aldrich (Gillingham, UK) 
and used without further purification.  
Solvents with a minimum HPLC grade purity were purchased from VWR (Lutterworth, 
UK) or Sigma Aldrich (Gillingham, UK).  
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Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose content, sodium 
bicarbonate, L-glutamine and sodium pyruvate were supplied by Life Technologies Ltd 
under the brand Gibco© (Paisley, UK). Foetal calf serum (FCS) and 
penicillin/streptomycin solution were supplied by PAA Laboratories Ltd (Yeovil, UK). 
Reagents required for Western blotting were supplied by Life Technologies Ltd under 
the brand NuPage© (Paisley, UK). Anti-Nrf2 and anti-beta actin antibodies were 
supplied by Abcam (Cambridge, UK). The secondary antibodies anti-rabbit IgG and anti-
mouse IgG were supplied by Sigma Aldrich (Gillingham, UK).  
RHE maintenance medium and RHE growth medium were supplied by Episkin (Lyon, 
France). 
Dinitrophenyl-glutathione (DNP-SG) was synthesised using a method described elsewhere  
[127] with a few modifications. Briefly, 0.3 g of GSH were dissolved into 8 mL of ultrapure 
water and 0.2 g of DNCB were dissolved into 3 mL of acetonitrile. The two solutions 
were mixed and the pH adjusted to approximately 8 using a few drops of 1 N sodium 
hydroxide. The mixture was mixed at ambient temperature for 30 minutes after which 
the supernatant was collected. This solution was dried using a Thermo Savant Explorer 
vacuum centrifuge and the resulting crystals collected. Purity was assessed by Nuclear 
Magnetic Resonance (NMR). The crystals contained 39 % DNP-SG and DNP-SG stability 
in aqueous solution was unaffected for 26 hours at ambient temperature. 
 
2.2  Methods. 
 
2.2.1 Skin models culture and maintenance. 
 
2.2.1.1 HaCaT cell line. 
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HaCaT cells were cultured as described by Boukamp and colleagues [30]. Briefly, the 
cells were maintained in cell culture medium consisting of DMEM high glucose content 
supplemented with final concentrations of 0.37 % sodium bicarbonate, 10 % heat 
inactivated FCS, 2 mM L-glutamine, 1 mM Sodium pyruvate and 100 U/mL /100 μg/mL 
penicillin/streptomycin, in an atmosphere of 5 % carbon dioxide in air at 37 °C. Cells 
were subcultured by trypsinisation at intervals of 3-4 days.  
 
2.2.1.1 RHE samples. 
 
The RHE samples were delivered in agarose-filled plates for model preservation. Upon 
receipt, the inserts were removed from the agarose bedding and immediately placed in 6-
well plates containing 2 mL maintenance or growth medium per well. The plates were then 
incubated at 37 °C in an atmosphere containing 5 % CO2 until use. The medium was 
refreshed daily as recommended by the supplier. 
Initial method development was carried out to select an appropriate medium into which 
the RHE samples could be cultured so that their ability to synthesise GSH was not 
compromised. Samples were cultured in maintenance medium for up to 48 h (maximum 
use time of the maintenance medium as recommended by the supplier), in growth medium 
for up to 7 days and in HaCaT cell medium for up to 7 days for comparison. The GSH level 
was measured periodically for each experiment using the methods described below. In all 
following experiments involving RHE samples the medium used was the RHE growth 
medium unless specified otherwise. 
 
2.2.2 Model compounds cytotoxicity evaluation. 
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2.2.2.1 MTT assay on HaCaT cells. 
 
HaCaT cells were subcultured by trypsinisation, disaggregated into a single cell 
suspension and reseeded in a 96-well plate at 2 x104 cells/100 μL HaCaT cell culture 
medium/well. Cells were then incubated overnight in an atmosphere of 5 % carbon 
dioxide in air at 37 °C.  
Stock solutions of DNCB, DNFB, DNBB, DEM, DPCP, BA and PA were prepared in 
dimethylsulfoxide (DMSO), stock solutions of BSO were prepared in sterile water. All stock 
solutions were then diluted as required in HaCaT cell culture medium so that the final 
DMSO content used in assays was 0.5 %. Concentrations are detailed in Table 2.1. 
 
Compound Concentration range  
BSO 0-450 µM 
DEM 0-600 µM 
DPCP 0-50 µM 
DNCB 0-30 µM 
DNFB 0-30 µM 
DNBB 0-30 µM 
BA 
0-20 µg/mL and 0-23 µM 
0-500 µg/mL (occluded) 
PA 0-500 µg/mL (occluded) 
Table 2.1 : Model compounds concentrations used in the MTT assay 
 
The MTT assay was carried out as described elsewhere [128] with a few modifications. 
In brief, each well was exposed to a 100 μL aliquot of reagent or solvent and the plate 
was incubated for 24 hours. Due to the volatility of BA and PA, the assay was also carried 
out under occluded conditions (96-well plate sealed with plastic adhesive film) for 2 
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hours. The plate was subsequently rinsed with PBS and treated with MTT (100 µL, 0.5 
mg/mL) for 3 hours. The MTT solution was removed and the resulting formazan crystals 
were rinsed with PBS and dissolved in isopropanol (150 µL). The absorbance in each well 
was read at 570 nm using a SpectraMax M2e microplate reader. 
Cell viability was calculated by ratio of absorbance read in cells treated with model 
compounds over absorbance of controls cells treated with HaCaT culture medium 
containing 0.5 % DMSO. The results were expressed as a percentage. Acceptable 
viability for in vitro experiments using the HaCaT cell line was fixed at a minimum of 
80%. 
 
2.2.2.2 MTT assay on RHE samples. 
 
A stock solution of DNCB was prepared in DMSO and appropriate dilutions of final 
concentrations 0.05, 0.1, 0.5, 1 and 10 mM prepared in RHE growth medium containing 
10 % DMSO. 
 RHE samples were treated with 50 L of DNCB solution (range 0.05-10 mM).  Positive 
control RHE models were treated with 50 L of 10 % DMSO in RHE growth medium. 
Samples were incubated for 24 hours.  RHE samples were incubated in 2 mL RHE growth 
medium so the DMSO content in final experiments did not exceed 0.25 %. Following 
treatment, each RHE sample was washed with PBS, transferred to a 24-well plate 
containing 0.3 mL of 1 mg/mL MTT solution in RHE growth medium per well and incubated 
for approximately 3 hours in an atmosphere of 5 % carbon dioxide in air at 37 °C.   The 
RHE samples were then carefully washed with PBS and transferred to a 12-well plate 
containing 2 mL of isopropanol per well. The plate was shaken at approximately 300 rpm 
for 10 minutes, placed into a sealable plastic bag and stored refrigerated overnight to 
extract the formazan crystals formed. Aliquots of each isopropanol extract were 
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transferred to a 96-well plate and the remaining steps of the assay carried out as described 
previously. 
2.2.3 Model sensitisers treatment of the HaCaT cell line: Dose 
responses. 
 
HaCaT cells were seeded in 6-well plates at 4 x105 cells per well and incubated overnight. 
Dilutions of DEM, DPCP, DNCB, DNFB, DNBB, BA and PA were prepared in HaCaT cell 
culture medium enriched with 0.5 % DMSO for use within the assay. Concentrations are 
detailed in Table 2.2. 
The cells were treated with 2 mL of the appropriate concentration of model sensitiser 
solution, the plates covered and incubated (37 °C, 5 % CO2) for 1 hour or 24 hours. The 
reagent solution was removed from the 6-well-plates and the cells rinsed twice with 
PBS. The cells were lysed by addition of 200 µL ultrapure water and one cycle of freeze-
thawing at -80 °C.  
The assay was modified significantly for volatile compounds BA and PA.  The 6-well 
plates were sealed with plastic adhesive film immediately after treatment and the plates 
incubated for 10 minutes.  
Compound Concentration range  
BSO 0-55 µM 
DEM 0-150 µM 
DPCP 0-30 µM 
DNCB 0-30 µM 
DNFB 0-30 µM 
DNBB 0-30 µM 
BA 0-500 µg/mL (occluded) 
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PA 0-200 µg/mL (occluded) 
 
Table 2.2 : Model compounds concentrations used in dose response experiments 
 
2.2.4 Model sensitisers treatment of the HaCaT cell line: 24 hour 
time course. 
 
HaCaT cells were seeded in 6-well plates at 4 x105 cells per well and incubated overnight. 
The cells were treated with 2 mL of 10 µM of DNCB, DNFB or DNBB, 2 M DPCP or 50 
M DEM. The plates were covered and incubated (37 °C, 5 % CO2) for up to 24 hours. 
The time points investigated were 0, 10, 20 and 30 minutes and 1, 2, 4, 6, 7 and 24 hours. 
The reagent solution was then removed from the 6-well-plates and the cells rinsed twice 
with PBS. The cells were lysed by addition of 200 µL ultrapure water and one cycle of 
freeze-thawing at -80 °C. 
 
2.2.5 Determination of Nrf2 release by Western blot. 
 
HaCaT cells were seeded in 12-well plates at 1 x105 cells per well and incubated 
overnight. The cells were then exposed to concentrations of DNCB, DNBB and DNFB 
ranging 1-15 µM for 2 hours, rinsed twice with culture medium and lysed with 80 µL of 
RIPA buffer enriched with 0.2 % protease inhibitor per well. Control experiments were 
carried out with 0.5 % DMSO in culture medium. 
Required amounts of lysates (10 µg protein for DNCB and DNFB samples, 8 µg for DNBB, 
adjusted for protein concentration) were denatured by reaction with 5 µL of NuPage 
sample reducing reagent (Life Technologies, Paisley, UK) at 85 °C for 10 minutes, loaded 
on gels (NuPage 4-12 % Bis-Tris gel) and separated by electrophoresis at 90 V for 10 
minutes followed by 170 V for 1 hour. The content of each gel was then transferred to 
a nitrocellulose blotting membrane (230 mA for 65 minutes), which was stained with 
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Ponceau S and blocked with non-fat dry milk solution (10 % in Tris-Buffered Saline) 
overnight. Membranes were treated with rabbit anti-Nrf2 primary antibody for 3 hours 
(or mouse anti-actin primary antibody for 30 minutes) and Nrf2 secondary antibody for 
1 hour. Membranes were treated with a Western Lightning plus enhanced 
chemiluminescence (ECL) reagent kit (Perkin Elmer, Coventry, UK) for film development.  
Quantification of free Nrf2 was carried out using a GS-800 calibrated densitometer and 
the Quantity One software version 4.6.1. Data were normalised to actin. 
 
2.2.6 BSO treatment of the HaCaT cell line: GSH synthesis 
inhibition. 
 
BSO was used an inhibitor of GCL, enzyme necessary for de novo GSH synthesis. HaCaT 
cells were seeded in 6-well plates at 4 x105 cells per well and incubated overnight. 
In dose response experiments, the cells were treated with 2 mL of BSO solution prepared 
in HaCaT cell culture medium (nominal range 0-50 µM).  The plates were then covered 
and incubated (37 °C, 5 % CO2) for 1 hour or 24 hours. 
 A 24 hour time course experiment was also carried out by treating the cells with a 50 µM 
BSO solution (2 mL).  The time points investigated were 0, 0.5, 1, 2, 4, 6, 7 and 24 hours. 
A control experiment was carried out with untreated cells for the same period of time. 
The level of GSH in each set of experiments was compared. 
 
2.2.7 BCNU and 2-AAPA treatment of the HaCaT cell line: GSH 
reductase inhibition. 
 
Stock solutions of BCNU were prepared in DMSO. Dilutions of BCNU were prepared in 
HaCaT cell culture medium enriched with 0.5 % DMSO (nominal range 10-200 µM). The 
cells were dosed with 2 mL of the various solutions and the plates incubated at 37 °C in 
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an atmosphere containing 5 % CO2 for 30 minutes and 1 hour respectively. From this 
experiment, the influence of BCNU on GSH levels in the HaCaT cell line was investigated. 
The maximum concentration in BCNU that could be applied to HaCaT cells without 
observing any significant depletion of GSH was the maximum investigated (200 µM, 1 
hour). In subsequent experiments, cells were treated with concentration of BCNU for 1 
hour then washed with PBS prior to further compound dosing. 
Due to the low availability of 2-AAPA, influence on the GSH/GSSG ratio was not 
investigated as a function of the dose applied. Instead, the concentration of 2-AAPA 
used to inhibit GR was based on the work published by [129]. A stock solution of 2-AAPA 
was prepared in a mixture water: DMSO (v/v 50:50) and diluted in HaCaT culture 
medium to prepare a 50 µM nominal solution. The cells were dosed with 2 mL of 50 µM 
2-AAPA and the plates incubated for 2 hours at 37 °C in an atmosphere containing 5 % 
CO2. The cells were then washed with PBS prior to further compound dosing. 
 
2.2.8 BA and PA treatment of the HaCaT cell line: GSH oxidation. 
 
HaCaT cells were plated out at 4 x105 cells per well in 6-well-plates and incubated at 37 
°C, overnight in an atmosphere containing 5 % CO2. Cells were either directly treated 
with aldehydes or pre-incubated with 2-AAPA (50 µM, 2 hours) or BCNU (200 µM, 1 
hour) to inhibit GR. BA and PA stock solutions were prepared in DMSO. Subsequent 
dilutions were made with HaCaT cell culture medium containing 0.5 % DMSO.   
For use in a 2 hour exposure time course assay, a 0.1 mg/mL BA solution and a 0.025 
mg/mL PA solution were prepared. These concentrations were chosen as they do not 
induce more than 20 % cell death over 2 hours, as determined by the MTT assay. HaCaT 
cells were treated with 2 mL of each solution, the plates sealed with adhesive plastic foil 
and the cells left in an incubator (37 °C, atmosphere containing 5 % CO2) for the period 
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of time specified (10 minutes to 2 hours).  
A dose response experiment, in which cells were treated with BA at 0.1, 0.2 and 0.5 
mg/mL concentration or PA at 0.025, 0.05, 0.1 or 0.2 mg/mL concentration, was also 
carried out.  The total exposure time was 10 minutes in occluded conditions. As 
previously described, the experiment was carried out with cells pre-treated with 2-AAPA 
and cells where the activity of GR enzymes was not compromised (no pre-treatment). 
H2O2 (HP) is known to oxidise GSH. For comparison, a dose response experiment was 
carried out for 4 hours in the HaCaT cell line (HP range 0-2.5 mM) and a 24 hour time 
course experiment was carried out with 1 mM and 2 mM HP solutions. 
 
2.2.9 GSH incubations with model compounds in chemico. 
 
All incubations were carried out in buffered conditions so that the GSH:chemical ratio 
was 1:10. The pH was either fixed at pH 7.4 to mimic physiological systems or pH 9.5 as 
the pKa of thiol in GSH is reported between 9.2 and 9.4 [130, 131]. 
A 50 mM buffer solution of potassium phosphate (monobasic/dibasic) at pH 7.4 was 
prepared in water. A 10 mM solution of ammonium bicarbonate was prepared in water. 
The pH was adjusted to pH 9.5 using ammonia.  
GSH and GSSG solutions were prepared in buffer solution at pH 7.4 or pH 9.5 for use in 
the incubations. Chemicals (DEM, DPCP, BA, PA and HP) were dissolved in acetonitrile 
and appropriately diluted so that the final concentration was approximately 10 mM. 
GSH incubations contained 1 mL of 100 µM GSH (pH 7.4 or pH 9.5) and 100 µL of each 
chemical in acetonitrile. Control incubations contained 1 mL of 100 µM GSH (pH 7.4 or 
pH 9.5) and 100 µL acetonitrile or 1 mL of 100 µM GSSG (pH 7.4 or pH 9.5) and 100 µL 
acetonitrile. Stock solutions of GSH and GSSG were analysed by LC-MS after 24 h 
refrigerated storage. 
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2.2.10 RHE samples single exposure to DNCB. 
 
2.2.10.1 Initial GSH basal level determination in RHE samples. 
 
In the first experiment, the suitability of the RHE maintenance medium (recommended by 
the supplier for model maintenance for up to 48 hours) was evaluated.  GSH level was 
measured in duplicate RHE samples on the day of arrival (t= 0 h), after brief equilibration 
in maintenance medium (t= 3 h), which is a realistic representation of the time required to 
prepare solutions to treat the models, t= 24 h, which is a usual time at which a read-out of 
the experiment is carried out (i.e. end of 24 hours MTT assay) and t= 48 h, which is the 
maximum time for which the models can be maintained in the RHE maintenance medium 
(as recommended by the supplier).  The RHE samples were washed with sterile PBS by 
removing each insert from the 6-well plates and continuously irrigating for 10-15 seconds.   
Each RHE sample was excised from the insert, placed in a heat-proof glass vial and 
homogenised in 2 mL of RIPA buffer using a Soniprep 150plus  (MSE Ltd, London, UK). The 
amplitude of sonication of the probe was fixed at 6.5. Five bursts of sonication of 1 minute 
each were carried out per sample. The lysate produced was stored at -80 °C until analysis. 
A second experiment was carried out, in which the RHE samples were cultured in HaCaT 
cell culture medium or RHE growth medium for a period of 7 days. The medium was 
refreshed daily in all 6-well plates. GSH level was measured in single replicate analysis on 
RHE samples cultured in each medium, every 24 hours. 
 
2.2.10.2 RHE samples exposure to DNCB: 24 hour experiment. 
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A stock solution of DNCB was prepared in DMSO. Solutions of 1 mM or 0.1 mM of DNCB 
were prepared in growth medium containing 1 % DMSO for the dosing of the RHE 
samples.  
Triplicate RHE samples were lysed at the start of the experiment (t= 0 h). RHE samples were 
treated with 50 µL of the 1 mM (0.1 mM) solution of DNCB. After 2 hours of exposure, all 
RHE samples were washed with PBS. PBS rinses and growth medium aliquots from each 
well were collected and stored frozen at -80 °C for further analysis. 
Triplicate RHE samples were lysed (t= 2 h) and the remaining samples placed into 2 mL of 
fresh growth medium and the plates incubated at 37 °C in an atmosphere containing 5 
% CO2. Triplicate RHE samples were lysed at t=4 h, t=6 h and t=24 h. For each RHE sample 
aliquots of growth medium and PBS rinse were collected when the lysing procedure was 
carried out. 
 
2.2.11 RHE repeated treatment with DNCB. 
 
2.2.11.1 Three cycles of treatment with DNCB: 72 hour experiment. 
 
A stock solution of DNCB was prepared in DMSO. Solutions of 0.1 mM, 0.5 mM or 1 mM 
of DNCB were prepared daily in growth medium containing 1 % DMSO for the treatment 
of the RHE samples.  
The time points investigated were t=0, 2, 24, 26, 48, 50 and 72 h.  Triplicate RHE samples 
were lysed at each time point. RHE samples were treated with 50 µL of the 1 mM (0.1 mM) 
solution of DNCB at t=0, 24 and 48 h. All RHE samples were washed with PBS at t=2, 26, 50 
and 72 h. PBS rinses and growth medium aliquots from each well were collected and stored 
frozen at -80 °C for further analysis. 
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RHE samples were incubated at 37 °C in an atmosphere containing 5 % CO2. RHE growth 
medium was refreshed at t=2, 26 and 50 h. 
The general procedure for the experiment is summarised in Fig 2.1.  
 
 
Figure 2.1: Daily exposure of RHE samples to 0.1, 0.5 or 1 mM of DNCB for 2 hours,  
followed by 22 hours of recovery time in fresh growth medium:  
experimental set-up and samples collection. 
 
2.2.11.2 Daily 1 mM treatment with DNCB: 7 day experiment. 
 
A stock solution of DNCB was prepared in DMSO. Solutions of 1 mM of DNCB were 
prepared daily in growth medium containing 1 % DMSO for the treatment of the RHE 
samples.  
RHE samples were treated daily with a 1 mM DNCB solution following the procedure 
described in section 2.211.1.One RHE sample was lysed at t=0, 2, 24, 26, 48, 50, 72, 74, 
96, 98, 120, 122, 144, 146 and 168 h. PBS rinses and growth medium samples were 
collected as previously described. 
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2.2.12 RHE lysates, PBS rinses and growth medium samples 
preparation for DNP-SG measurements. 
 
400 µL of each RHE lysate or growth medium sample were mixed with 100 µL of acetonitrile 
and the mixture filtered through a 0.2 µm nylon centrifuge filter by centrifugation (10000 
rpm, 10 min). The resulting samples were analysed. PBS rinses were analysed without any 
further sample preparation. 
 
2.2.13 Determination of Nrf2 activation by Western blot. 
 
RHE samples were submitted to three cycles of 0.5 mM DNCB treatment (72 hours 
experiment) as described in section 2.2.11.1. Triplicate samples were lysed at each time 
point in 1 mL RIPA buffer containing 1 % protease inhibitor. The samples were 
maintained on ice in the Soniprep 150plus (MSE Ltd, London, UK). The amplitude of 
sonication of the probe was fixed at 6.5 and the lysing time was 5 times 1 minute. 
8 µg of lysates were denatured by reaction with 5 µL of NuPage sample reducing reagent 
at 85 °C for 10 minutes, loaded on gels (NuPage 4-12 % Bis-Tris gel) and separated by 
electrophoresis at 90 V for 10 minutes followed by 170 V for 1 hour. The content of each 
gel was then transferred to a nitrocellulose blotting membrane (230 mA for 65 minutes), 
which was stained with Ponceau S and blocked with non-fat dry milk solution (10 % in 
TBS) overnight. Membranes were treated with rabbit anti-Nrf2 primary antibody 
overnight (or mouse anti-actin primary antibody for 30 minutes) and Nrf2 or actin 
secondary antibody for 1 hour. Membranes were treated with a Western Lightning plus 
enhanced chemiluminescence (ECL) reagent kit (Perkin Elmer, Coventry, UK) for film 
development.  Quantification of free Nrf2 was carried out using a GS-800 calibrated 
densitometer and the Quantity One software version 4.6.1. Data were normalised to 
actin. 
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2.2.14 Glutathione assay:Derivatisation with iodoacetamide. 
 
The samples were derivatised using iodoacetamide (IAA) to prevent formation of 
disulphide bonds, following methods described by [106] [132] . Briefly, 1 mM stock 
solution of GSH was prepared in ultrapure water and subsequently diluted with 
ultrapure water to prepare a set of calibration standards covering the range 0.5-200 µM 
(final concentrations analysed 0.05 to 20 µM). An identical procedure was used to 
prepare a matching set of calibration standards for GSSG (final concentrations analysed 
0.025 to 10 µM).  
An aliquot of 100 µL of each GSH standard or cell/RHE sample was mixed with 50 µL of 
glutathione glycine-13C2,15N (100 µM) and 100 µL of IAA (10 mM, prepared in 10 mM 
ammonium bicarbonate aqueous solution and adjusted to pH 9.5) in an amber glass vial 
and left to react for approximately 1.5 h. The structure of the derivatised GSH is 
presented in Fig 2.2. 
 
Figure 2.2: Iodoacetic acid reacts with the free thiol on GSH at pH 9.5. 
 
 An aliquot of 50 µL of sulfosalicyclic acid (10 % w/w in water) was added to facilitate 
the precipitation of proteins present in the cell lysates.  Cell samples were filtered 
through 0.2 µm filters by centrifugation (10,000 rpm, 10 minutes). 50 µL of each GSSG 
solution were added to the matching GSH standards. All standards and samples were 
then diluted to 1 mL with a solution of 0.1 % formic acid in LC-MS grade water. 
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2.2.15 Mass spectrometric analyses. 
 
2.2.15.1 GSH assay. 
 
The Acquity Ultra-High Pressure Liquid Chromatography (UPLC) system (Waters, Elstree, 
UK) was used for the LC separation of the compounds of interest. Chromatographic 
separation was achieved using an Acquity HSS T3 (150 x 2.1 mm, 1.8 µm particle size) 
column (Waters, Elstree, UK) set at 4 0°C, following recommendations for the 
chromatographic separation of GSH in biological matrices reported by [107] - using 
gradient elution with 0.1 % formic acid in water (mobile phase A) and acetonitrile 
(mobile phase B) at a flow rate of 0.2 mL/min. Initially, the mobile phase composition 
was set to 2 % B, held for 2 minutes and then increased to 95 % B over a further 7 
minutes. The composition was held for a further 3 minutes, returned to the initial 
conditions over 1 minute and held at 2 % B for a further 2 minutes. 
The Quattro Premier mass spectrometer (Waters, Elstree, UK) was used with an ESI 
(Electrospray Ionisation) source operating in positive ionisation mode. The mass 
spectrometer was operated with a capillary voltage of 3.2 kV. The temperature of the 
source was set at 130 °C and the desolvation temperature was set at 300 °C. Other 
parameters were set at values according to the manufacturer’s recommendations. 
All samples were analysed using Multiple Reaction Monitoring (MRM) for the complete 
length of the UPLC acquisition time (15 min). The MRM transition used for IAA-
derivatised glutathione glycine- 13C2,15N was m/z 369.10 > 176.80 and for IAA-
derivatised glutathione was m/z 366.02 >173.80, with the mass spectrometer operating 
with a cone energy fixed at 25 V and collision energy fixed at 20 eV for both analyses.  
The MRM transition used for GSSG was 613.10 > 355.10 with a cone energy fixed at 30 
V and collision energy fixed at 20 eV. All data processing was carried out using the 
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Quanlynx quantification software, part of the Masslynx software (version 4.1) (Waters) 
controlling both Acquity UPLC and Premier mass spectrometer. 
 
2.2.15.2 GSH incubations with model compounds. 
 
The UPLC method was identical to the one described in the GSH assay section, with the 
exception of the flow rate, which was fixed at 0.3 mL/min. The mass spectrometer 
parameters were identical to the ones described in the previous section with the 
exception that the ESI source was operating in positive mode with a Cone voltage fixed 
at 20 V.  
All samples were analysed in full scan mode over the range m/z 100-1000 for the 
complete length of the UPLC acquisition time (15 min).  
 
2.2.15.3 Dinitrophenyl-glutathione measurements. 
 
Samples were analysed in MRM for the complete length of the UPLC acquisition time 
(15 min, method described in GSH assay Section). The MRM transition used for 
dinitrophenyl-glutathione (DNP-SG) was m/z 474.1 > 242.1 with the mass spectrometer 
operating with a cone energy fixed at 10 V and collision energy fixed at 25 eV. 
 
2.2.16 Protein quantification by bicinchoninic acid assay. 
 
The protein content of each RHE sample was assessed by the bicinchoninic acid (BCA) assay 
using methodology described by [133]  with a few adaptations specific to the Micro BCA 
protein assay kit (Thermo Scientific,Rockford, USA). All RHE lysates were diluted 1/10 in 
ultrapure water before analysis, to minimise the influence of the presence of RIPA buffer. 
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Calibration standards of Bovine Serum Albumin (BSA) were prepared in ultrapure water to 
cover the range 0.5-200 µg/mL, with the addition of a standard blank (ultrapure water 
only). The absorbance was read at 562 nm using a Spectramax M3 microplate reader 
operated with Softmax Pro software. 
 
2.2.17 Statistical analysis. 
 
 MTT assay in HaCaT cells. Experiments were carried out in a single day. Eight wells 
of the 96-well plate were treated with the same concentration of test reagent (n=8).  
The mean absorbance of controls cells treated with HaCaT culture medium 
containing 0.5 % DMSO was used to define the viability in control cells and fixed at 
100%.  The viability of each well treated with test reagent was expressed as the ratio 
of absorbance in treated cells over the mean of absorbance in control cells (mean 
value) and expressed as a percentage. The percentage viability was reported as 
Mean ± Standard deviation (n=8) for each concentration tested. 
 MTT assay in RHE models. Experiments were carried out in a single day. Three 
models were cultured in medium + 10 % DMSO for the required time (n=3). Each 
concentration of test reagent was applied on RHE models in triplicate (n=3). Viability 
was calculated as described for HaCaT cells experiments. The percentage viability 
was reported as Mean ± Standard deviation (n=3) for each concentration tested. 
 Model sensitisers: Dose response in HaCaT cells. Experiments were carried out in a 
single day. Each concentration was applied to the wells in triplicate (n=3). To 
evaluate the difference in GSH levels between treated cells and solvent treated 
control cells, the Student t-test was applied between the mean at each 
concentration (n=3) and the mean at 0 µM. Significant statistical difference was 
obtained when the P value was <0.05. 
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 Model sensitisers: 24-hour time course in HaCaT cells. Experiments were carried out 
in quadruplicate (n=2 on two separate occasions) for dinitrohalobenzenes. To 
evaluate the difference in GSH levels between treated cells at a specific time point 
and control cells at the start of the experiment (t = 0), a Student t-test was carried 
out to measure difference between the mean at each time point and the mean at t= 
0. Significant statistical difference was obtained when the P value was <0.05.  
Other experiments were carried out in duplicate or triplicate in a single day. 
Statistical analysis for figure 3.12 used a Student t-test where the P value was fixed 
at 0.1. 
To evaluate the difference in GSH levels between cells treated with 10 µM of 
different dinitrohalobenzenes for 24 hours, a ANOVA test was carried out. Statistical 
difference between the three dinitrohalobenzenes DNCB, DNFB and DNBB was 
obtained for this concentration with a P value <0.05.  
 Determination of Nrf2 activation by Western Blot: HaCaT cells. Experiments were 
carried out in triplicate measurements on two separate occasions for cell treatments 
(n= 2 and n= 1). For t=0 h three control samples were pooled to generate a single t=0 
sample, with value fixed at ratio 1 (100 % baseline value) and used to calculate the 
“ratio over controls” for the other samples. Results were normalised to actin and 
presented as Mean ratio over controls ± Standard deviation. 
 RHE repeated treatment with DNCB.  Experiments were carried out in triplicate. 
Statistical difference between the mean value for GSH level in treated RHE samples 
and the mean value for GSH level in RHE samples lysed before treatment (t= 0 hour) 
was evaluated using a Student’s t-test. Statistical difference was obtained when the 
P value < 0.05. 
 Determination of Nrf2 activation by Western Blot: RHE models.  RHE models were 
treated with DNCB for the appropriate length of time (time course experiment). Lysates 
Chapter 2 
65 
 
were used to carry out Western Blot analysis showing Nrf2 release (n=3). Data was 
normalised to actin, NQO1 enzyme measured as positive control of Nrf2 activation. For 
t=0 h three control samples were pooled to generate a single t=0 sample, with value 
fixed at ratio 1 (100 % baseline value) and used to calculate the “ratio over controls” for 
the other samples. A Student t-test was carried out to measure the difference between 
each time point and t= 0 for NQO1. Statistical difference with a p value < 0.1 was 
obtained at 72 h. To evaluate the difference between the first, second and third 
exposure to DNCB on nrf2 levels, a ANOVA test was carried out and statistical difference 
was obtained with a P value < 0.05. 
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Chapter 3: Modulation of GSH oxido-reduction 
mechanism in the HaCaT cell line. 
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3.1  Overview. 
 
3.1.1 GSH in skin.  
 
The level of total glutathione in human skin (GSH and its disulfide form GSSG) has rarely 
been reported and the values available to date are variable (summarised in Table 3.1). 
Significant differences were found in one study between the epidermis and the dermis 
levels of GSH, with the epidermis containing more than five times the amount of total 
GSH present in the dermis (expressed in nmol/g of wet tissue) [134],  whilst another 
study found similar levels in both layers [135]. The location at which the sample was 
taken also appears to play a role. For example, Kaur and colleagues reported values of 
total GSH in healthy skin of patients and observed that GSH levels doubled in skin lesions 
linked to chronic contact dermatitis [136].   
Total GSH (nmol/g) Technique used Number of 
donors 
Reference 
480 (epidermis) 
85 (dermis) 
Ellman’s reagent-
GR recycling assay 
6 (healthy) Shindo et al (1994)  
250-450 
(epidermis)  
280-530 (dermis) 
Ellman’s reagent-
GR recycling assay 
7 (mean 
21y.old) 
9 (mean 
71y.old) 
Rhie et al (2001)  
195 (healthy 
whole skin) 
442 (lesional skin) 
Ellman’s reagent-
GR recycling assay 
5 (healthy 
skin) 
6 (ICD or ACD 
on hands) 
Kaur et al (2001)  
 Table 3.1:  Total GSH (reduced and oxidised) measured in human skin samples. 
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3.1.2 GSH formation in the HaCaT cell line.  
 
The synthesis of glutathione has been described in Section 1.6.2 in the Introduction: two 
enzymes, Glutamate cysteine ligase (GCL) and glutathione synthetase (GS) enable cells 
to generate de novo glutathione from its constitutive amino acids. 
The presence of GCL and GS in HaCaT cells has been demonstrated at both mRNA level 
and protein level [137, 138].  An increase of GCL at the mRNA level after treatment with 
alpha-tocopherol or arsenic has been linked to an increase in GSH level in the cells [137, 
139]. It is generally accepted that the availability of cysteine is the limiting factor in the 
formation of the de novo GSH. This is difficult to demonstrate as reducing the amount 
of cysteine available without drastically changing the cell’s culture medium is 
challenging in vitro. Hence, researchers have investigated ways to modulate GSH 
synthesis by inhibition of the GCL enzyme. L-buthionine sulfoximine (BSO, structure 
detailed in Fig 3.1) has been used as an inhibitor of GCL (Fig 3.2) in numerous studies.  
 
Figure 3.1:  L-buthionine sulfoximine 3D chemical structure. Reproduced from 
PubChem [109] where the colouring of atoms is grey: carbon, white: hydrogen, red: 
oxygen, blue: nitrogen and yellow: sulphur. 
 
 
Most protocols detailed how M levels of BSO inhibited the synthesis of GSH and 
following treatment with a specific probe such as Cadmium, enhanced the GSH 
depletion observed compared to cells that were not treated with BSO [90]. 
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Figure 3.2:  L-buthionine sulfoximine inhibits GCL and prevents the formation of de novo 
γ-glutamyl-cysteine 
BSO is a mechanism-based enzyme inhibitor that has been purposefully designed to 
inhibit the GCL enzyme by Griffith and various colleagues in the 1980s [140, 141]. BSO 
is first phosphorylated on the nitrogen atom of the sulfoximine group and, in contact 
with GCL, form a complex with ADP, which can very tightly but not covalently bind into 
the reactive site of GCL. Mechanistic investigations of this “GCL-BSO complex” has been 
carried out by Biterova et al [142] and the complex is reproduced in Fig. 3.3. This 
complex is stable for a period of time long enough that glutamate and cysteine cannot 
enter the reactive site and γ-glutamylcysteine cannot be formed for several hours, 
hence BSO is often called an irreversible inhibitor. 
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Figure 3.3: Ribbon representations of the crystal structures of ScGCL in complex with 
inhibitors. An ScGCL monomer is contained in the asymmetric unit, and the N- and C-
terminal residues are indicated. β-Strands are colored in yellow, and α-helices are 
depicted in green. A, bound GSH is shown in space filling representation with carbon 
atoms colored in gray, oxygen atoms are in red, sulfur atoms are in yellow, and nitrogen 
atoms are in blue. The glutathione-binding site overlaps the glutamate binding site 
within the active site funnel. B, ADP and the transition state analogue, phosphorylated 
BSO (BSO-P), are shown in space filling representation. Phosphorus and magnesium 
atoms are colored in orange and purple, respectively, with the remaining atoms colored 
as in A. Kindly reproduced from Betirova et al [142]. 
 
3.1.3 GSH in oxido-reduction mechanisms.  
 
GSH, being the most prominent thiol antioxidant in cells, plays a major role in the 
quenching of radicals and detoxification of ROS. The mechanism by which ROS are 
inactivated by the GSH pathway relies on GSH being oxidised to GS-. Disulphide bond is 
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then formed between the two oxidised glutathione molecules, yielding GSSG, which is 
often called oxidised glutathione.  The oxidation of GSH into its disulphide GSSG can be 
a non-enzymatic phenomenon or can be greatly enhanced by Glutathione Peroxidase 
(GPx).  Most cells require GSSG to either be quickly expelled or reduced back to two 
molecules of GSH, using Glutathione Reductase (GR).    
A common technique to prevent the recycling of GSSG back to GSH is to inhibit GR 
activity chemically. Carmustine (or BCNU, structure detailed in Fig 3.4) has long been 
used for such purposes [143, 144]. It is part of the nitrosoureas compounds, where the 
nitroso and the urea group are N-N linked and can be used as a chemotherapeutic agent.  
 
 
Figure 3.4:  carmustine 3D chemical structure. Reproduced from PubChem [109] 
where the colouring of atoms is grey: carbon, white: hydrogen, red: oxygen, blue: 
nitrogen and green: chlorine. 
 
 
This GR inhibitor is not solely designed to interact with GR and has also been shown to 
target DNA and RNA [145] and non-related enzymes in red blood cells [146], thus the 
concentrations required to demonstrate loss of GR activity are quite high. The 
mechanism by which GR is inhibited is not completely elucidated either: Shinohara et al 
originally thought that the inhibition was somehow linked to a change in redox state in 
the cells [146]. Later a mouse study where a 50 mg/kg BCNU dose was used showed 
that GR activity was depleted after only 10-30 min in organs such as liver, lungs and 
heart and was sustained for up to 48-96 h. However, a lower dose of 25 mg/kg showed 
almost no effect [147]. An explanation for this inhibition, is that GR is irreversibly 
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modified by covalent binding with BCNU as Cohen et al later demonstrated that GR 
activity in murine leukemia cells could only recover after exposure to BCNU if the ability 
to synthesise de novo GR protein was maintained. They observed that when protein 
synthesis was blocked GR activity was permanently lost [148]. Studies have shown that 
the inhibition of purified human GR had an IC50 value of approximately 55 M and GR 
activity was reduced to 10 % of its original value after 3 hours of incubation with a 200 
M of BCNU [144]. For future experiments, a concentration approximating this value 
will be used if no specific adverse effect linked to the HaCaT cell line is seen.  
Another inhibitor, developed much more recently by Guan and Seefeldt, is 2-
acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylthiocarbonylamino) 
phenylthiocarbamoylsulfanyl]propionic acid (2-AAPA, structure detailed in Fig 3.5) [129, 
149, 150].  
 
Figure 3.5:  2-AAPA 3D chemical structure (ChemBio3D Ultra version 12.0) where the 
colouring of atoms is grey: carbon, white: hydrogen, red: oxygen, blue: nitrogen and 
yellow: sulphur. 
 
It results from the reaction of one molecule of 1,4-diisothiocyanatobenzene with two 
molecules of N-acetylcysteine (NAC), both commercially available. This inhibitor is 
thought to be more specific than BCNU, but can also induce some DNA damage as well 
as inhibit GR. 2-AAPA is an irreversible inhibitor as it reacts covalently with GR at the 
GSSG binding site of the enzyme (with departure of one or both molecules of NAC in the 
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process) [149]. The 2-AAPA inhibited GR enzyme has been isolated and analysed by Q-
ToF LC-MS and the structure is presented in Fig 3.6. 
 
Figure 3.6:  Nature of covalent modification of GR monomer by 2-AAPA. Reproduced 
from Seefeldt et al [149]. 
 
2-AAPA was evaluated as an inhibitor of GR in different human cancerous cell lines, 
including skin, breast, lung and ovary and used in conjunction with X-ray radiation to 
increase the level of GSSG and oxidative stress in these cells. In this study, the 
cytotoxicity of 2-AAPA was estimated to have an IC50 value of 70 M in all cell lines. The 
recommended pre-treatment with 2-AAPA is for 2 hours [129].  
Both of these inhibitors were considered in this study when inhibition of GR was 
required to highlight the potential increase in GSSG observed by inducing oxidative 
stress on HaCaT cells using a model aldehyde with skin sensitising properties, 
phenylacetaldehyde (PA). 
 
3.1.4 Reactivity of aldehydes.  
 
Benzaldehyde (BA) and phenylacetaldehyde (PA) are fragrant aldehydes that can be 
used in products that are applied on the skin. Due to its volatility and ability to rapidly 
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oxidise to benzoic acid, BA is considered relatively safe [126]. It is classified as a non-
sensitiser in the LLNA assay [124].  However a patch test study has reported sensitisation 
to BA in patients who had already been diagnosed with fragrance allergy in 3 out of 747 
cases [125].  PA, however close in chemical structure to BA, is considered a moderate 
sensitiser in the LLNA assay [151]. Historical patch testing of PA, prepared at 0.5 % in 
alcohol, led to an allergic reaction in 3 out of 275 volunteers [152]. A case of contact 
allergy to PA was reported after an occupational accident in a fragrance factory [153]. 
The mechanism of reaction by which PA induces skin sensitization has not been 
described in detail. In chemico studies showed that reactivity of aldehydes or ketones 
with primary amines, such as the one present on Lysine residues, can happen via a Schiff 
base mechanism, yielding an imine. The reactivity of aldehydes with primary amines is 
illustrated in Fig 3.7. 
 
 
Figure 3.7:  Schiff base formation between a protein containing an available lysine 
residue and an aldehyde. 
 
PA is prone to form Schiff base with lysine containing peptides in chemico but assay 
conditions such as chemical:peptide ratio or temperature have a significant influence 
on the % peptide depletion reported in assays. While Gerberick et al reported a % 
depletion of their lysine containing peptide of 22.6 % [19], Aleksic et al obtained 
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complete depletion within 24 hours [24]. Both assays highlight the potential of PA for 
Schiff base formation. It is also worth noting that in the second assay [24], incubations 
of the lysine peptide with BA led to partial peptide depletion of 26.7 %, while 
incubations with a peptide containing a terminal NH2 group (N-term) at pH 7.4 rather 
than 10, resulted in a 82.1 % depletion of this peptide. 
 In chemico studies have also demonstrated that PA reacts as an oxidant with Cys 
peptides.  PA incubations with the cor1-C420 peptide (containing a single Cys residue) 
used in the LC-MS based peptide reactivity assay described by Natsch et al [20] showed  
>95 % peptide depletion solely due to dimerisation of the peptide. These results are 
similar to the ones obtained with a less complex peptide where only one reactive site is 
available for modification, AcFAACAA, containing a Cys residue, that was 100 % 
dimerised after reaction with PA [24]. Results concerning the oxidation of Cys residues 
by BA are more difficult to interpret. While AcFAACAA was again completely depleted 
by dimerization in the same conditions [24], cor1-C420 was not significantly depleted 
by BA (approximately 5 %) and no significant amount of dimer was observed. 
It is therefore difficult to predict which mechanism would be prevalent in skin based on 
in chemico assays alone. For instance, the variability of results observed for BA might be 
due to the assay conditions and choice of peptide or to the volatility of BA itself. How 
the volatility of BA would influence the results of assays involving ex vivo skin, or a cell 
line, in culture is unknown. The ratio of available cysteine residues in skin/keratinocytes 
proteins compared to lysine is also not completely defined, even though initial data 
suggests that lysine would be significantly more prominent than cysteine for reactivity 
with skin proteins [154]. GSH being a tri-peptide of relatively simple structure that 
contains a Cys residue, it was anticipated that it could be oxidised into its disulfide form 
GSSG by reaction with one or both of the model aldehydes BA or PA, to a comparable 
extent to the oxidation of cysteine residues on proteins. This mechanism was 
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investigated both in chemico and in the HaCaT cell line to explore the fate of GSH in 
reaction with such aldehydes in skin. 
3.2  Aims and objectives. 
 
The GSH pathway complexity has been defined [61, 66] but has not been fully 
characterised in in vitro skin cells. The overall aim of was to understand the GSH 
pathway in a skin relevant model, the HaCaT cell line, and how this pathway can be 
modulated in the context of skin defence. The first step to achieve this was to measure 
the homeostatic level of GSH in HaCaT cells and characterise the synthesis of de novo 
GSH in this cell line. This was followed by investigations of clearance potential of model 
aldehydes, considered to be oxidants with skin sensitisation relevance.  
 
3.3  Results. 
 
3.3.1 GSH quantification in the HaCaT cell line.  
 
Human epidermis is formed mainly of keratinocytes (95 %), therefore the use of 
immortalized keratinocytes such as HaCaT cells as an in vitro tool for estimation of GSH 
in healthy skin was investigated. The level of GSH measured in HaCaT cells seeded at 
4x105 cells/well after overnight incubation in 6-well plates was 4.2±1.1 µmol/L (n=10) 
and doubling to 9.8±1.3 µmol/L (n=10) at 48 h, demonstrating that GSH concentration 
is proportional to the multiplication rate of healthy cells.  
 
 
3.3.2 GSH depletion by inhibition of GSH synthesis. 
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Following application of a non-toxic concentration of BSO, the GSH level was depleted 
to less than 10 % of that of untreated controls at 24 h (Fig 3.8), demonstrating an active 
GSH cycle in HaCaT cells.  
 
Figure 3.8:   50 µM treatment with BSO for 24 h versus absence of treatment. Each 
well (400 000 cells/well) was treated with 50 µM BSO or left undisturbed for the length 
of time required. Each well was rinsed twice with PBS and the cells lysed by adding 200 
µL of sterile water and storing at -80 °C. 100 µL of lysate was derivatised with 
iodoacetamide, GSH quantified in this lysate and concentration reported in µM GSH 
(n=2). The figure shows that BSO inhibits the synthesis of GSH in HaCaT cells. The level 
of GSH slowly depleted over time, as part of normal antioxidant cellular defence. Results 
for each time point are presented as mean ± standard deviation. 
 
BSO does not deplete GSH directly. During the 24 hours of reaction it was likely that the 
cells used up their stock of GSH, which could not be replenished.  
 
3.3.3 GSH depletion by oxidation with hydrogen peroxide. 
 
3.3.3.1. Enhancing ROS levels with hydrogen peroxide treatment. 
 
Oxidation of GSH to its disulphide GSSG can be achieved by enhancing the level of ROS 
in cells. In this experiment, cells were treated with hydrogen peroxide (H2O2, HP) for 4 
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hours. The level of GSH decreased in cells treated with 1.5 mM or more, compared to 
untreated controls (Fig 3.9). 
 
Figure 3.9:  GSH level in HaCaT cells treated with hydrogen peroxide. Treatment was 
carried out in each well (400 000 cells) for 4 h (range 0-2.5 mM) after which cells were 
rinsed with PBS twice, 200 µL sterile water was added and the cells lysed by storage at 
-80 °C. Half the lysate (equivalent to 200 000 cells) was derivatised with iodoacetamide 
and the GSH content measured and reported in µM (n=3).  The Figure shows that the 
level of GSH in HaCaT cells can be depleted with an increased level of ROS. However, 
cell viability decreased simultaneously as GSH was consumed. Result for each time point 
is reported as mean ± standard deviation. 
 
The level of GSSG measured in the cells was always below the limit of detection of the 
assay (0.1 µM). Cytotoxicity of HP was investigated by MTT assay and demonstrated that 
cell viability quickly decreases for concentrations above 1 mM (data not shown). The 
low level of GSH measured in this experiment was therefore directly linked to the low 
level of viable cells in the wells. Discerning whether GSH depletion induced cell death or 
whether cell death led to the GSH being leached into the medium and discarded 
(resulting in a low GSH value) was difficult to assess. 
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3.3.3.2. GSH oxidation by hydrogen peroxide in chemico. 
 
Incubations using HP at a concentration 10 times higher than GSH, resulted in 
chromatograms that only contained a small peak of GSSG, without the presence of any 
other peaks. This was observed at both pH studied (pH 7.4 and pH 9.5). The nature of 
the experiment did not allow for quantitation of total glutathione but the GSSG peak 
observed was unlikely to account for the amount of GSH initially introduced. It is also 
possible that HP generated some ion suppression in the samples (compared to controls 
containing exclusively GSH and buffer) in the mass spectrometry experiment. 
3.3.4. GSH oxidation by aldehydes. 
 
Due to the volatility of fragrant aldehydes, all experiments involving HaCaT cells were 
limited to 2 hours maximum and were carried out as much as possible in occluded 
conditions. 
3.3.4.1. Cytotoxicity of Benzaldehyde and phenylacetaldehyde 
 
The results obtained using the MTT assay showed that BA did not induce more than 20 
% cell death for concentrations up to 100 µg/mL (Fig 3.10a). For PA, the toxicity seemed 
to reach a plateau at approximately 80 % viability for the concentration range 25-100 
µg/mL (Fig 3.10b). Overall, PA appeared to be more toxic to HaCaT cells than BA. 
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Figure 3.10:  Cytotoxicity of aldehydes for a 2-hour exposure in occluded conditions.  
MTT assay results for (a) benzaldehyde, (b) phenylacetaldehyde covering the range 0-
500 µg/mL. Each well (20 000 cells per well) was treated with the required amount of 
aldehyde, covered with a plastic adhesive cover and incubated for 2 hours. Cells were 
then rinsed and incubated with a solution of MTT (0.3 mg/mL) for 3 hours, rinsed twice 
with PBS and the formazan crystals diluted with isopropanol (n=8). The figure shows 
that cytotoxicity is observed over 100 µg/mL for benzaldehyde and over 25 µg/mL for 
phenylacetaldehyde. Results are presented as Mean viability ± Standard deviation. 
 
The results of MTT assay demonstrate that the volatility of both compounds tested is 
not a critical parameter when occluded conditions are considered (plates were sealed 
immediately after exposure to the aldehydes). For both compounds a high level of 
toxicity influencing mitochondrial activity could be observed (i.e at 500 µg/mL 
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concentration) and therefore the penetration of the aldehydes into the cells was 
significant.  
 
3.3.4.2. BA and PA reactivity with GSH in chemico 
 
The oxidation of GSH into GSSG was investigated in chemico, in occluded conditions at 
37 °C, using BA and PA at a concentration 10 times higher than GSH. BA incubations 
analysed by LC-MS only contained the two peaks related to GSSG with the retention 
times 1.67 and 2.74 minutes respectively (data not shown). PA incubations contained 
GSSG as well as minor peaks apparently unrelated to GSH (Fig 3.11). 
 
Figure 3.11:  Typical chromatogram of incubation containing GSH and PA at ratio 
1:10.  Incubations were carried out at in 50mM potassium phosphate buffer at pH 7.4 
for 24 hours. The resulting mixture was analysed by LC-MS operating in scan mode for 
15 minutes (n=3). The figure shows a) GSSG (retention time 1.67 min), b) GSSG 
(retention time 2.77 minutes) but no reduced GSH. Phenylacetaldehyde is not visible 
on the chromatogram and c) is a series of unrelated minor peaks. 
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3.3.4.3. HaCaT cells treatments with BA and PA 
  
Based on the previous in chemico experiment, the assumption was that the aldehydes 
are able to oxidise GSH into GSSG. However, it was unknown whether a depletion of 
GSH and an increase of GSSG level would be visible experimentally by mass 
spectrometry. 
The profile of GSH concentration in cells that were treated with 0.1 mg/mL BA or 0.025 
mg/mL PA is presented in Fig 3.12. The level of GSSG was below the limit of 
quantification (less than 0.1 µM) for all samples analysed. The level of GSH decreased 
slightly during the first 10 min of exposure for both BA (Fig 3.12a) and PA (Fig 3.12b). It 
is also noticeable that the effect of aldehydes on GSH appears to be short lived. GSH 
was quickly replenished, with a maximum concentration observed at 30 min for BA and 
60 min for PA.  
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Figure 3.12: GSH level in HaCaT cells treated with (a) BA and (b) PA for a maximum of 
two hours. Treatment was carried out in each well (400 000 cells) for up to 2 h (100 
µg/mL for BA and 25 µg/mL for PA). The time points “t=0” and “Medium 2 h” were 
prepared with cells that were not exposed to aldehydes. At the required time, the cells 
were rinsed with PBS twice, 200 µL sterile water was added and the cells lysed by 
storage at -80 °C. Half the lysate (equivalent to 200 000 cells) was derivatised with 
iodoacetamide and the GSH content measured and reported in µM (n=3).  The Figure 
shows that GSH concentration is stable throughout the length of the assay, except for 
the 10 min time point. Result for each time point is reported as mean ± standard 
deviation. (*) Statistical difference between GSH level in samples treated for 10 min and 
controls (0 min) Student’s t-test, p value <0.1. 
 
 
3.3.5 GSH oxidation by aldehydes, influence of Glutathione 
Reductase inhibitor pre-treatment. 
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3.3.5.1. GR inhibition with carmustine before BA and PA treatment 
 
3.3.5.1.1   Carmustine cytotoxicity 
 
The toxicity of BCNU was investigated specifically for the HaCaT cell line, using the MTT 
assay. HaCaT cells were treated with a range of BCNU concentrations (1-200 µM) for 30 
min or 1 h respectively. 
The viability of cells was not significantly affected (more than 20 % cell death compared to 
control untreated cells) for the concentrations and time points investigated even though 
variability within the plates was higher than expected (±25 %) (Fig 3.13).  
BCNU was not considered toxic to HaCaT cells at the maximum concentration of 200 M 
for an exposure time of 1 h. 
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Figure 3.13:  Cytotoxicity of carmustine after 30 min and 1-hour exposure. Results of 
MTT assay after a) 30 min exposure and b) 1 h exposure. Each well (20 000 cells per well) 
was treated with the required amount of carmustine covering the range 0-200 µM and 
incubated for up to 1 hour. Cells were then rinsed twice with PBS and incubated with a 
solution of MTT (0.3 mg/mL) for 3 hours. The cells were rinsed twice with PBS and the 
formazan crystals diluted with isopropanol (n=8). In both graphs, the toxicity of 
carmustine does not follow a decreasing trend as the concentration applied increases. 
Maximum concentration (200 M) can therefore be applied to HaCaT cells. Results are 
presented as Mean viability ± Standard deviation. 
 
3.3.5.1.2   Effect of carmustine treatment on GSH level in HaCaT cells 
 
The influence of BCNU, in the absence of any other treatment, on GSH levels was also 
investigated. Each concentration was investigated in triplicate analysis and GSH level 
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expressed as a percentage of GSH left compared to untreated cells (concentration 
carmustine 0 M). Results are summarised in Table 3.2. 
Concentration 
carmustine (µM) 
Average GSH 
(µM) 
Standard 
Deviation 
(µM) 
GSH remaining (% of 0µM) 
0 1.926 0.163 100 
10 1.881 0.238 97.7 
50 1.543 0.144 80.1 
100 1.999 0.463 104 
200 1.988 0.643 103 
0 1.847 0.391 100 
10 1.61 0.29 87.2 
50 2.316 0.859 125 
100 1.664 0.504 90.1 
200 2.139 0.221 116 
Statistical analysis: Equivalence test, TOST (two-one-sided-test): Aim, show that results at 
30 min and 1 hour are equivalent there is no trend. 
Mean 30 min data 1.867 Test P- value 
Defined boundary 20% Mean Upper 0.0276 
Lower/upper boundary ± 0.373 Lower 0.0075 
Test result Equivalent Overall 0.0276 
 
Table 3.2:  Effect of carmustine on GSH level in HaCaT cells. Each well (400 000 cells per 
well) was treated with the required amount of carmustine covering the range 0-200 µM 
and incubated for orange) 30 min and pink) 1 hour. Cells were then rinsed twice with 
PBS, 200 µL of sterile water added and the cells frozen to -80 °C. Half the generated 
lysate (200 000 cells) was derivatised with iodoacetamide and the GSH content 
measured. Results were expressed in µM (n=3). In both cases, carmustine does not 
influence significantly on GSH levels (TOST test, P value <0.05). Maximum concentration 
(200 M) can therefore be applied to HaCaT cells for 1 hour. Results are presented as 
Mean ± Standard deviation. 
As with the MTT assay, the GSH level was similar in all samples and was comparable to 
untreated cells. It was estimated that 200 M of BCNU applied on HaCaT cells for 1 hour 
would not induce a depletion (or overproduction) of GSH. 
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3.3.5.1.3   BA and PA treatment after pre-treatment with 200 M carmustine 
 
Cells were treated with 200 M of BCNU for 1 hour, after which the cells were washed 
with PBS and treated with the two aldehydes in occluded conditions (BA 0.1 mg/mL and 
PA 0.025 mg/mL). The variation of GSH level was plotted versus the time of application. 
Results are summarised in Fig 3.14. 
 
Figure 3.14:  Effect of aldehydes on GSH level in HaCaT cells incubated in occluded 
conditions. Each well (400 000 cells per well) was treated with 200 µM of carmustine 
and incubated for 1 hour. Cells were then rinsed twice with PBS, treated with red: 0.1 
mg/mL of benzaldehyde or blue: 0.025 mg/mL of phenylacetaldehyde, covered with a 
plastic adhesive cover and incubated at 37 °C for the required amount of time. Cells 
were rinsed, lysed and derivatised with iodoacetamide as described in previous figures. 
Results were expressed in µM (n=3) and presented as Mean ± Standard deviation. The 
figure shows that for both aldehydes, variability within the plates was high (±20 %) but 
GSH concentration did not follow a trend. A Student t-test was carried out to measure 
difference between the mean at each time point and the mean at t = 0 and showed no 
statistical difference (with a P value<0.05). 
 
It appeared that the concentration of GSH did not significantly decrease as a function of 
time. Moreover, there was no increase in GSSG level in the samples during LC-MS 
analysis (no values were significantly over the limit of quantification of 0.1 µM). As it 
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was unclear why the increase of GSSG seen in chemico could not be reproduced in vitro 
another GR inhibitor, 2-AAPA was selected to repeat the experiment. 
 
3.2.5.2. GR inhibition with 2-AAPA before BA and PA treatment 
 
Cells were treated for 2 hours with a 50 µM solution of 2-AAPA before exposure to the 
aldehydes under experimental procedure identical to the one previously described. The 
results are available in Fig 3.15. 
For BA, no significant depletion of GSH level was observed (Fig 3.15a). The last two time 
points suggest an overproduction of GSH. For PA, a depletion of approximately 20 % was 
observable up to 1 hour (Fig 3.15b) but the same phenomenon of GSH repletion was 
observed for the later time points (90 and 120 min). 
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Figure 3.15:  GSH levels in HaCaT cells treated with BA or PA with or without pre-
treatment with 2-AAPA. Red: Half the wells (400 000 cells per well) was treated with 50 
µM of 2-AAPA and incubated for 2 hours. Blue: Cells were incubated without treatment 
for 2 hours. Cells were then rinsed twice with PBS, treated with a) 0.1 mg/mL of 
benzaldehyde or b) 0.025 mg/mL of phenylacetaldehyde, covered with a plastic 
adhesive cover and incubated at 37 °C for the required amount of time. Cells were 
rinsed, lysed and derivatised with iodoacetamide as described in previous figures. 
Results were expressed in µM (n=3) and presented as Mean ± Standard deviation. The 
figure shows that for both aldehydes, variability within the plates was high (±20 %) but 
GSH concentration did not follow a trend. A Student t-test was carried out to measure 
difference between the mean at each time point and the mean at t = 0 and showed no 
statistical difference (with a P value<0.05). 
 
3.3.5.2.1   Influence of 2-AAPA on GSH overproduction 
 
The influence of 2-AAPA in the GSH cycle is suspected to be an inhibition of the GR 
enzyme in an “oxido-reduction” context. However, it was unknown whether this 
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particular compound could influence the synthesis of de novo GSH in cells. To verify 
whether 2-AAPA was at the origin of the GSH overproduction, HaCaT cells were cultured 
without any treatment for 2 hours. One set of cells were treated with 2-AAPA for 2 
hours. 
 Untreated time matched controls had a limited GSH production compared to t=0; at 2 
hours an increase from 5.4±0.8 µM to 6.3±1.2 µM (16 % increase) was observed (Fig 
3.16). In contrast, 2-AAPA treated cells showed an overproduction of GSH of almost 40 
% in the same timeframe.  This might explain why the level of GSH did not seem to 
reduce as much as expected in the experiments involving exposure to aldehydes, 
especially PA, which seemed to induce the highest level of toxicity to cells in the MTT 
assay.  
 
Figure 3.16: GSH levels in HaCaT cells treated/not treated with 2-AAPA for 2 hours. 
Purple: Half the wells (400 000 cells per well) was treated with 50 µM of 2-AAPA and 
incubated for 2 hours. Red: Cells were incubated without treatment for 2 hours. Cells 
were rinsed, lysed and derivatised with iodoacetamide as described in previous figures. 
Results were expressed in µM (n=3) and presented as Mean ± Standard deviation. The 
figure shows that 2-AAPA induces the production of GSH in HaCaT cells. 
(*) Statistical difference between cells treated with 2-AAPA for 2 hours and initials 
controls (t=0 min), Student’s t-test, p value <0.05. 
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3.3.5.2.2   10 min treatment with BA and PA 
 
For all samples analysed up to this point the level of GSSG was below the limit of 
quantification (less than 0.1 µM). It was expected that the earliest time point (10 min) 
where GSH seemed to have been depleted (Fig 3.15) would show an increase in GSSG 
level above the limit of quantification. 
The BA and PA treatments were limited to 10 minutes and the concentration in 
aldehydes was increased to see whether the depletion in GSH was dose dependent (this 
increase in concentration was carried out without taking into account the increased 
toxicity probably involved) and whether high concentrations could help the potential 
formation of GSSG above limit of quantification. 
The results obtained are illustrated in Fig 3.17. The concentration of benzaldehyde 
applied on the cells was increased up to 5 times (Fig 3.17a), which appeared to favour 
the detoxification of the aldehydes by increasing the level of GSH produced. Indeed, 
after 10 min exposure to 0.1 mg/mL of BA the level of GSH measured was on average 
30 % lower than in control cells, while for a 0.5 mg/mL solution it was only 9 % lower. 
The same phenomenon was observed for PA (Fig 3.17b) where a 0.025 mg/ml solution 
applied for 10 min resulted in a GSH level approximately 40 % lower than in control cells 
but a 0.2 mg/mL solution led to a decrease of only 19 % in GSH. In this particular 
experiment, the pre-treatment with 2-AAPA did not seem to influence significantly the 
level of GSH measured at various concentrations of aldehydes applied. Both 
experimental dose-response curves followed the same trend. 
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Figure 3.17: Effect of pre-incubation with 2-AAPA on HaCaT cells treated for 10 
minutes with aldehydes. Each well (400 000 cells per well) was treated with 50 µM of 
2-AAPA and incubated for 2 hours. Cells were then rinsed twice with PBS, treated with 
a) benzaldehyde or b) phenylacetaldehyde, covered with a plastic adhesive cover and 
incubated at 37 °C for 10 minutes. Cells were rinsed, lysed and derivatised with 
iodoacetamide as described in previous figures. Results were expressed in µM (n=3) and 
presented as Mean ± Standard deviation. The figure shows that for both aldehydes, GSH 
does not deplete as a function of the dose applied. A Student t-test was carried out to 
measure difference between the mean at each time point and the mean at t = 0 and 
showed no statistical difference (with a P value<0.05). 
 
GSH level in HaCaT cells treated with (a) BA and (b) PA for 10 min. Blue columns are the 
results for cells treated with aldehydes only. Red columns show the influence of a pre-
treatment of HaCaT cells with 50 µM of 2-AAPA for 2 hours, previous to the exposure to 
aldehydes. 
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3.4  Discussion. 
 
The characterisation of the GSH pathway in the HaCaT cell line focussed specifically on 
the following points: 1) the synthesis of de novo GSH, with or without the inhibition of 
GCL by BSO was quantified, 2) the formation of GSSG due to oxidative stress was 
investigated using HP, BA and PA, 3) the inhibition of GR activity was carried out using 
two different probes, carmustine and 2-AAPA, 4) an estimation of PA and BA 
detoxification by the GSH pathway in the HaCaT cell line was given. 
The level of GSH in HaCaTs, as measured in our assay, was in the low µM range for a 100 
000-cell lysate. The level of GSH depletion observed in the HaCaT cell line due to the 
inhibition of GCL by BSO was in accordance with results reported in the literature for a 
similar experiment using Hepa-1c1c7 cells [155]. In our assay, after 24 hours of 
incubation a dose as low as 50 M BSO reduced the GSH pool to less than 10 %. GSH 
turnover in skin cells has not been published for comparison, but the half-life of GSH in 
liver is approximated at 3-4 hours [156]. It is generally accepted that GSH production in 
the liver covers for most of the GSH needs throughout the body [123]. Therefore, a 
turnover of GSH stock taking 6-8 hours is likely to be one of the fastest times observed 
under normal, non-stressed conditions in human organs. Here, HaCaT cells consumed 
the vast majority of the GSH pool under normal conditions in 24 hours. Even though 
human skin is not solely constituted of keratinocytes (the stratum corneum being 
constituted of cells non-enzymatically active and the dermis being constituted of 
fibroblasts, which were not studied here) it is possible to estimate GSH turnover after 
24 hours, without disagreeing with the fact that skin requirements in GSH are 
realistically lower than liver. 
The ratio GSH:GSSG is an indicator of cellular health. At homeostasis and in healthy 
conditions, this ratio is estimated to be at least 100:1 [157], and as a result GSSG is rarely 
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measured in biological samples using standard assays. In the HaCaT cell line, GSH, in its 
reduced form, could be measured in the 5-10 M range while GSSG was systematically 
below the limit of quantification (0.1 M), which looked in accordance with the healthy 
GSH:GSSG ratio expected.  
Generating oxidative stress leads to an imbalance of the GSH:GSSG ratio in cells. This is 
usually achieved by treatment with HP. HP is a potent oxidant that induced complete 
oxidation of GSH in chemico at pH 7.4 and pH 9.5 in our experiments. This was in 
accordance with previous observations made by Finley et al [158], who studied the 
kinetics of oxidation of GSH in chemico at different pHs. However, 0.5-2.5 mM HP 
treated HaCaT cells demonstrated a dose response trend in GSH depletion for 
concentrations above 1mM but not the formation of GSSG in the cells. This could be due 
to two main factors: 1) the GSH is not used for the formation of oxidised GSH (GSSG) 
but used to quench other ROS and form separate entities or 2) GSSG potentially formed 
by oxidation is rapidly reduced back to GSH (reaction catalised by Glutathione 
reductase).  
HP toxicity, as measured by MTT assay, was significantly increased at concentrations 
above 1 mM (data not shown), which corroborates with findings in other studies in 
which HP induced significant toxicity for a concentration range 50-500 M after 2 hours 
exposure [159] and a 1 mM dose decreased cell viability by 60 % within 4 hours [160].  
This tends to justify the GSH depletion observed experimentally by cell death rather 
than oxidation of GSH into GSSG, in this particular set of experiments.   
To investigate the detoxification of compounds with skin sensitisation relevance, model 
aldehydes (BA and PA) were incubated in chemico with GSH. Both compounds 
demonstrated oxidising properties that enabled the complete oxidation of GSH into 
GSSG, while no secondary products (i.e GSH-conjugates) could be identified. This was in 
accordance with previous observations made with Cys containing peptides [20, 24]. 
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Cytoxicity of BA in the HaCaT cell line (occluded conditions) was considered satisfactory 
(<20 % cell death) for a concentration up to 0.1 mg/mL, while for PA, which was more 
toxic, the maximum concentration applied before significant cell death occurred was 
0.025 mg/mL. It was expected that these concentrations would be high enough 
compared to the intracellular GSH concentration to induce GSH depletion by 
dimerisation. However, in our set of experiments the formation of GSSG could not be 
measured. Increasing these concentrations to toxic levels (Figure 3.14) and reducing the 
experimental period to 10 minutes (time at which the GSH levels seemed the lowest in 
Figure 3.9) did not increase the formation of GSSG. It was therefore considered that, if 
the detoxification mechanism of aldehydes was the same in chemico and in vitro, the 
speed at which GR reduced GSSG back to GSH was higher than the time required to 
prepare the samples (i.e < 10 min + sample freezing time). These experiments were 
therefore repeated with the introduction of an inhibition step using BCNU. 
The oxidation of GSH into GSSG after exposure to aldehydes was investigated.  While 
BCNU was not significantly toxic nor induced a depletion or overproduction of GSH 
when applied at 200 µM for an hour, the experiment set up did not demonstrate an 
increase in GSSG level due to oxidation by aldehydes. The level of GSH was also constant 
during the two hours of exposure to each of the aldehydes and were not significantly 
different from control cells at t=0 h. 
Changing BCNU for 2-AAPA, a more specific inhibitor of GR, did not increase the 
formation of GSSG in HaCaTs. 2-AAPA was applied at a concentration of 50 µM for 2 
hours prior to any aldehyde treatment. However, the level of GSSG did not increase 
above the limit of quantification. More surprisingly 2-AAPA appeared to induce the 
production of fresh GSH (up to 40 % compared to untreated controls). A 10 min dose 
response to aldehydes showed that GSH was not depleting but increasing slightly with 
the dose, whether or not the cells were pre-treated with 2-AAPA.The only rationale to 
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explain why the level of GSH increased proportionally to the concentration of aldehydes 
applied is to consider that the synthesis of GSH in HaCaT cells can be quicker than 10 
minutes. 
The lack of GSSG might be due to 1) BCNU and 2-AAPA not being able to inhibit GR in 
the HaCaT cell line to a suitable level, using this particular protocol (medium, 
temperature, time) or 2) aldehydes did not oxidise GSH in HaCaT cells but were mainly 
consumed elsewhere.  
Considering the relative volatility of BA and PA, an important amount might be present 
in the headspace above the cell medium in the occluded wells. This would explain the 
availability of aldehydes to react with GSH in solution (in chemico experiment, where 
samples are sealed in Eppendorf tubes and maintained under low agitation) is 
significantly different than the one observed in a biological sample (HaCaT cells covered 
with a plastic or aluminium seal but left resting in an incubator without agitation). 
The proportion of aldehydes that penetrated the cells might have reacted using a 
combination of mechanisms: A few cases of skin allergy involving contact with PA have 
been reported, therefore the aldehyde must be involved in covalent binding with skin 
proteins. The main mechanism involved is a Schiff base formation with residues 
containing a primary amine, such as lysine residues. The mechanism reported with thiols 
in chemico is an oxidation yielding a sulfur dimer. This reaction appears relatively minor 
in proportion compared to the Schiff base reaction, as dimerisation of GSH was not 
observed in our experiments even though detoxification by oxido-reduction mechanism 
is usually fast. This type of chemistry with thiols is not favoured by the local environment 
in skin compared to Schiff reaction with amines. Oxidation of thiols, once it had 
occurred, even to a relatively small extent might have triggered cellular defence systems 
such as the production of GSH, as was observed in the 10 minutes experiment, in which 
GSH levels increased for a short period.  
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3.5. Conclusion  
 
After initial investigations on the basal level of GSH present in these cells (in the 5-10 
M range using our assay) it was demonstrated that, under homeostatic conditions, the 
natural consumption of the GSH pool took 24 hours, between two and six times slower 
than estimated in the liver by Reed et al [161], who reported a half-life value of cellular 
GSH in the range 2-6 h based on previous work published by Ookhtens et al [162] and 
Lauterburg et al [163]. HaCaT cells are equipped with the required level of working 
enzymes to synthesise de novo GSH, i.e GCL and GS, and when the cells were left in 
culture medium for 24 hours, the level of GSH usually doubled in the culturing well. 
This cell line appeared relatively resilient to oxidative stress as exposure to oxidants such 
as HP, and to a lesser extent BA and PA, usually did not deplete the pool of GSH or 
increased significantly the level of GSSG before high level of cytotoxicity was observed. 
This suggested that the recycling enzyme Glutathione Reductase was very efficient in 
this cell line. 
In terms of detoxification of xenobiotics, oxido-reduction mechanisms are fast and 
reliable in the HaCaT cell line. In our experiments, the defence mechanism involving GSH 
was in direct competition with reactivity with proteins in terms of kinetics. In the case 
of the two aldehydes studied, reaction with GSH did not seem to be a major reaction, 
even though mechanistically, the reaction was possible and easily observed in chemico. 
Covalent binding with proteins via a Schiff base mechanism with primary amines 
seemed to be preferred in the conditions of the assay. The protein content of HaCaT cell 
lysates has not been fully characterised yet but the ratio of cysteine/lysine is suspected 
to be in favour of lysine residues. This is based on findings relating to proteome analysis 
of human skin for which over 600 proteins were characterised, where lysine 
represented 5.7 % and cysteine 0.9 %  of all residues, nucleophilic or not [154]. 
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 To conclude, in the study of the detoxification of skin sensitisers by GSH, the use of the 
HaCaT cell line is justified as the main enzymes involved in the GSH pathway are present.  
However, focus should be placed on detoxification by a conjugation mechanism, in 
which the main enzymes used are Glutathione-S-Transferases (GSTs). This mechanism 
will be at the centre of the investigations carried out within the next chapter of this 
thesis. 
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Chapter 4: GSH conjugation as clearance mechanism of 
dinitrohalobenzenes in the HaCaT cell line. 
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4.1  Overview. 
 
4.1.1 GSTs in the HaCaT cell line and other skin models. 
 
The previous chapter highlighted the presence of detoxification enzymes included in the 
GSH pathway that are linked to countering oxidative stress such as Glutathione 
Reductase [164]. Evidence of detoxifying enzymes operating by formation of 
glutathione conjugates (GSTs) has also been found in the HaCaT cell line by identifying 
a few peptides characteristic of each enzymes using high resolution mass spectrometry 
[165]. Van Eijl et al demonstrated that HacaT cells contained GSTs from the pi and 
omega isoforms and compared the results to whole human skin samples, which were 
found to cover a wider range of isoforms as they also contained the alpha and mu 
isoforms. Primary keratinocytes, which would be less complex than fresh ex vivo skin 
but more specific than an immortalised cell line, might or might not contain GSTs mu 
and alpha at a protein level, as gene expression for GST A4, GST M2 and GST pi have 
been reported but activity measurements have only been highlighting the activity due 
to GST pi [166]. Such differences at the protein expression level might not be 
detrimental to the use of the HaCaT cell line in our studies of detoxification of sensitisers 
by conjugation mechanisms. 
4.1.2 GSH reactivity with DNCB. 
 
GST activity in cells is usually measured by consumption of the substrate DNCB. DNCB is 
considered a broad-spectrum substrate as it is not confined to a specific isoform of GST 
and the conjugate dinitrophenyl-glutathione (DNP-SG) can be formed in all cases.  To 
measure the GSH conjugate formed, DNP-SG, several methods have been developed, 
including spectrophotometric ones. It is now very common to measure the increased in 
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absorbance at 340 nm using kits commercially available. The conjugation reaction 
between GSH and DNCB is illustrated in Fig 4.1. 
 
Figure 4.1:  Formation of dinitrophenyl-glutathione (DNP-SG) 
The mechanism by which the thiol contained in GSH reacts with the electrophilic DNCB 
is an aromatic nucleophilic substitution (SNAr), which results with the substitution of Cl 
for the GSH moiety and the release of hydrochloric acid (HCl). The GSH conjugation of 
DNCB can happen spontaneously in chemico at pH 8 and has been used extensively to 
prepare this conjugate using a general method such as the one described in Vince et al 
[127]. The ability of GSH to conjugate an extensive range of electrophiles, not limited to 
the ones reacting by SNAr, without the necessity for enzymes has been used to develop 
in chemico assays in the past [167]. Therefore, it cannot be ruled out that a mixture of 
enzymatic and non-enzymatic reactions between DNCB and GSH might happen in cells 
to some extent.  However, experimentally, the second order rate constant for the 
spontaneous reaction between GSH and DNCB has been reported at 4.2±0.2 x102 µM-
1.min-1 but the introduction of GST enzymes (purified and in isolation) made the 
conjugation reaction much faster, with a kinetics rate kcat/Km reported ranging from 
93±19 to 716±234 x102 µM-1.min-1 [168, 169]. It is expected that overall, spontaneous 
reaction should not be the main driver for GSH depletion in the HaCaT cell line or any 
other cell line demonstrating the presence of GSTs. 
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As a result, DNCB was used as a non specific probe for the overall determination of GST 
activity, regardless of isoform, in skin related cell lines. GST activity in the HaCaT cell line 
was measured at approximately 150 nmol/min/mg soluble protein and was found to be 
38 % lower than the activity measured in normal keratinocytes (NHEK)[79]. More 
recently, a similar study measured GST activity in the 50 nmol/min/mg soluble protein 
range, these results being comparable to activity measured in the other immortalised 
keratinocyte cell line used in the study (NCTC) and primary keratinocytes (NHEK)[53]. 
The general consensus for this is that GST activity in human skin and related cultured 
models should be in the low nmol/min/mg soluble protein range [53]. Jewell et al also 
measured the formation of DNP-SG in human ex vivo skin during skin penetration 
measurements of DNCB [170], demonstrating that GST activity in skin could be 
maintained for a number of hours after the skin was excised and GSTs should therefore, 
be fully operational in living keratinocyte based cells such as the HaCaT cell line. 
 
4.1.3 2,4-dinitrohalobenzenes as model skin sensitisers. 
 
DNCB and DNFB have both been used as model sensitisers to reveal hypersensitivity in 
patients by patch testing since the early 70s as patients are unlikely to be in contact with 
these chemicals outside the clinic. Reports of healthy volunteers tested with DNFB [171] 
or DNCB [111] are available. However, rare cases of Occupational Contact Dermatitis, 
linked to the use of DNFB [172] or DNBB [173] [174] by chemistry students can still 
occur. It has been noted that induction of a certain level of sensitisation to DNCB can 
also have a beneficial effect in the treatment of recalcitrant warts. Historical treatment 
with DNCB 0.05 % to 1 % in acetone, applied daily to twice daily, removed warts within 
2-42 weeks (average of 15.2 weeks) [175]. Side effects were also described and 
moderate signs of sensitisation such as localised erythema and oedema were expected 
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but sometimes observed at an unacceptable level, which required extra treatment and 
removal from the panel. This highlighted the fact that this treatment should be reserved 
only for extreme medical cases, for which other treatments have failed. A more recent 
review of the use of DNCB for medical treatment is available [112] but the general 
consensus is that its use should be extremely well controlled. 
All of these observed immunological responses are a direct consequence of the 
dinitrohalobenzenes ability to haptenate proteins, phenomenon that is now clearly 
defined based on all the evidence accumulated throughout the years. DNCB, DNFB and 
DNBB are all very potent skin sensitisers that have been classified as “extreme” in terms 
of potency (% EC3 values less than 0.1, this value being the estimated concentration of 
a chemical required to produce a 3-fold stimulation of draining lymph node cell 
proliferation compared with concurrent controls, expressed as a %) in the Local Lymph 
Node Assay (LLNA) [176] and are now commonly referred to as “extreme sensitisers”. 
As a result, most new in vitro methods which aim to detect potential skin sensitisers use 
dinitrohalobenzenes (first DNCB then extending to DNFB when the number of chemicals 
tested is increased, whereas DNBB is not often used) as part of their chemical evaluation 
set (Direct Peptide Reactivity Assay [19], Myeloid U937 Skin Sensitisation Test, now U-
Sens [177], Human Cell Line Activation Test, h-CLAT [178], KeratinoSens [179]). Our 
choice to investigate these three dinitrohalobenzenes in GSH investigations is linked to 
both the skin sensitisation evidence (suitable for investigations in the HaCaT cell line) 
and the fact that the reactivity with GSH is similar to the reactivity with skin proteins 
containing a cysteine residue. 
 
4.1.4 Inducing GSTs activity and enzymes linked to the 
production of GSH: the Nrf2 pathway. 
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Nrf2 (Nuclear factor erythroid 2-related factor 2) is a stress signalling protein. While cells 
are maintained in homeostatic conditions, Nrf2 is sequestered by Kelch-like ECH-
associated protein 1 (Keap1) in the cytosol and therefore tagged for regular degradation 
by ubiquitination. Modification of Keap1 however, enables the release of Nrf2 in the 
cytosol and its migration to the nucleus where it is recruiting ARE (Antioxidant Response 
Element) sequences of genes coding for protective enzymes, including Phase II 
metabolism enzymes [180].  
Some, if not most skin sensitisers are electrophilic compounds capable of direct Nrf2 
activation by covalent modification of the cysteine residues present. The protein 
sequencing of Keap1 has demonstrated that Keap1 contains a total of 4.3 % cysteine 
residues (27 cysteine residues present) but not all of them are targets for these 
electrophiles and it has been suggested that Cys151, 273 and 288 might play a more 
important role [180]. This particular feature of sensitisers (i.e their ability to covalently 
bind to protein) usually helps to differentiate them from skin irritants. The HaCaT cell 
line, treated with eight sensitisers and six irritants, was used to demonstrate that in a 
gene expression study looking at upregulation of Nrf2 dependent genes such as HMOX1, 
upregulation only happens with sensitisers [181]. 
The Nrf2-keap1 sensor is now well characterised and has been used for the 
development of a luciferase assay for assessment of skin sensitisation potential. Initially, 
a modified female breast cancer cell line transfected with eight copies of the ARE 
sequence coding for a luciferase reporter gene (AREc32 cells) was used and results were 
compared to the activation of Nrf2 in an unmodified hepatic cell line (Hepa1C1C7) [182]. 
This was then exploited further in the development of the KeratinoSens assay®, in which 
a custom made cell line of keratinocytes transfected with the ARE sequence of the 
human gene AKR1C2 (aldoketoreductase) linked to a luciferase gene (Luc2) is used 
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[183]. The OECD carried out a review of this test [184], which is now included in their 
Test Guideline 442d. 
These luciferase based assays have proven useful for the detection of skin sensitisers 
(as opposed to non-sensitisers) but they are not usually used for assessing the effect of 
these sensitisers on skin cells. Nrf2 activation has been shown to induce detoxification 
enzymes, including Phase II metabolism enzymes such as GSTs [174]. GSTs requiring GSH 
as co-factor to form conjugates with the sensitisers (after which GSH cannot be recycled 
and the conjugates are excreted), it is essential to the cell’s health that a fresh supply of 
GSH is available. Hence Nrf2 activation has also been linked to the upregulation of 
enzymes required for the synthesis of de novo GSH such as GCL [185]. 
Using the HaCaT cell line, without further genetic modifications should enable detecting 
of Nrf2 activation by treatment with model sensitisers in our set of experiments and link 
it to the synthesis of GSH to help cellular defence. 
 
4.2  Aims and Objectives. 
 
The following experiments aimed to demonstrate that GST activity in the HaCaT cell line 
was sufficient to deplete stocks of GSH present in the cells using the 
dinitrohalobenzenes selected (demonstration of GST activity in HaCaTs). However, this 
could be achieved using a freshly prepared HaCaT cell lysate. The aim here was to select 
a concentration in dinitrohalobenzenes that would be as close as possible to the point 
at which HaCaT cells were able to clear the dose they were exposed to and induce a 
repletion of GSH by de novo synthesis of GSH stock without irreparably compromising 
the cells’ health. The selection of such a dose of dinitrohalobenzene involved a 
combination of toxicity consideration (cytotoxicity measured here by MTT assay after 
24 hours of treatment) and observation of a significant GSH depletion followed by an 
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increase by liquid chromatography-mass spectrometry (dose response measurements 
after 1 hour and 24 hours exposure). Activation of the Nrf2 pathway, here release of 
NRf2 into the cytosol, was also used as an indirect measure of the ability of HaCaT cells 
to synthesise de novo GSH after induction of GCL and ability to clear the dose after 
induction Phase II metabolism GSTs. Full 24 hour time course experiments at the fixed 
dose for the three dinitrohalobenzenes enabled us to highlight some differences in the 
ability of HaCaT cells to synthesize GSH after exposure to the three compounds. The 
experimental data were then fitted to simple mathematical model, which could be used 
in the future as a benchmark for estimating the influence of concentration of 
electrophile on the GSH synthesis pathway in skin within 24 hours, for chemicals of the 
same reactive domain (SNAr reaction).  
 
4.3  Results. 
 
4.3.1 Cytotoxicity of 2,4-dinitrohalobenzenes in HaCaT cells. 
  
Cytotoxicity of 2,4-dinitrohalobenzenes was measured at 24 h to coincide with the 
maximum time of exposure in the GSH assay. The range of concentrations applied varied 
between 0 and 10 µg/mL. Concentrations resulting in 80 % or over of viable cells, 
compared to untreated cells kept in culture medium containing 0.5 % DMSO, were 
considered non-toxic. For the three 2,4-dinitrohalobenzenes the non-toxic 
concentrations were determined to be below 2000 ng/mL (10µM) (Fig. 4.2).  
The toxicity of DNCB and DNBB appeared to follow a similar trend as a function of 
concentrations, with a viability of 20 % or less at 5000 ng/mL, in contrast to DNFB for 
which percentage viability was still 40 % at the same concentration. These data suggest 
that HaCaT cells are less affected by exposure to DNFB compared with DNCB and DNBB, 
with the general order of toxicity being DNFB < DNCB = DNBB at 5000 ng/mL (Fig 4.2). 
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Figure 4.2:  Cytotoxicity of dinitrohalobenzenes in HaCaT cells after 24 hours. The 
toxicity of DNCB, DNFB and DNBB was determined using the MTT assay after 24 hours 
of exposure. Each well (20 000 cells/well) was treated with the appropriate 
concentration of either DNCB, DNBB or DNFB. The concentration applied was 
considered non-toxic when the cell viability is at least 80 % compared to control cells 
kept in culture medium containing 0.5 % DMSO for a similar length of time. Each 
concentration was tested in 8 wells (n=8) and the result was presented as Mean viability 
± Standard deviation.  The figure shows that all concentrations lower or equal to 2000 
ng/mL (10 µM) for DNCB, DNBB and DNFB were non-toxic.  
 
4.3.2 GSH depletion after exposure to 2,4-dinitrohalobenzenes is 
dose dependent. 
 
Significant depletion of GSH was observed with all three 2,4-dinitrohalobenzenes at 
concentrations over 5 µM (approximately 1 µg/mL) after a 1 hour incubation. The 
depletion was dose dependent and no observable differences were noted between the 
compounds at this time point (Fig 4.3 a). However, at 24 hours significant differences 
were observed between the chemicals as well as in relative GSH levels between treated 
and control cells (Fig 4.3 b). At a concentration of 10 µM a marked difference in GSH 
levels was observed between the chemicals. DNBB-treated cells had less than 50 % GSH 
compared to concomitantly-run control, whereas DNFB- and DNCB-treated cells were 
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comparable to controls. At 10 µM the relative GSH levels were significantly different to 
control (Fig 4.3) with less than 20 % cell death (Fig 4.2, 10 µM= approx. 2 µg/mL) so this 
concentration was chosen for all three compounds for the time-course study.  
 
Figure 4.3:  GSH levels in HaCaT cells treated with dinitrohalobenzenes. HaCaT cells 
(400 000 cells/well) were treated with 0-30 µM dinitrohalobenzenes for a) 1 hour and 
b) 24 hours. The cells were then rinsed twice with PBS and 200 µL water were added to 
the well. The cells were lysed at -80 °C and half the lysate (equivalent to 200 000 cells) 
was derivatised with iodoacetamide for GSH quantification. GSH levels were expressed 
in µM and reported as Mean ± Standard deviation (n= 4). (Δ) Statistical difference 
between GSH level in treated samples and concomitantly run controls (0 µM) Student’s 
t-test, p value <0.05. (□) StaƟsƟcal diﬀerence between GSH level in samples treated with 
10 µM DNCB, 10 µM DNFB or 10 µM DNBB, ANOVA, p value <0.05. 
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4.3.3 GSH depletion and repletion after exposure to a single 10 
µM dose of 2,4-dinitrohalobenzenes. 
 
Depletion of GSH in HaCaT cells was observed for the first two hours of monitoring 
following treatment with 10 µM of DNCB, DNFB or DNBB. The GSH level was 
approximately halved at the two hour time point and this depletion trend was similar 
for all compounds (Fig 4.4).  
 
 
 
Figure 4.4:  GSH level in HaCaT cells treated with 10 µM of 2,4-dinitrohalobenzenes 
over a 24-hour time course period. Each well (400 000 cells/well) was treated with the 
10 µM of either DNCB, DNBB or DNFB and incubated for the required amount of time. 
The cells were then rinsed with PBS, lysed and derivatised with iodoacetamide as 
described in previous figures. GSH levels were measured in half the lysate (equivalent 
to 200 000 cells, and the concentration expressed in µM and presented as Mean viability 
± Standard deviation (n=4).  The figure shows that the rate of repletion of GSH is 
chemical dependent, with DNCB and DNFB allowing for the quickest recovery while the 
DNBB only allows partial GSH replenishment. Insert: Comparison between t=0 h and 24 
h in control cells. Statistical analysis of the results is covered in Section 4.4 Modelling 
approaches. 
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At 4 hours of exposure, it is evident that the HaCaT cells have reached a maximum 
depletion of GSH. In response, the cellular defence system has triggered a production 
of GSH to replace the missing antioxidant, regardless of which dinitrohalobenzene was 
used.  The later time points (6, 7 and 24 hours) highlighted considerable differences 
between the three structurally similar 2,4-dinitrohalobenzenes. While both DNCB- and 
DNFB-treatment allowed for a replenishment of GSH to a level equivalent to untreated 
cells (Fig 4.4 insert), with DNBB-treatment the measured GSH level was 5.0±0.6 µmol/L, 
approximately half the level observed at 24 hours for untreated cells.   
 
4.3.4 Exposure to 2,4-dinitrohalobenzenes activates the Nrf2 
pathway in HaCaT cells. 
 
HaCaT cells were exposed to identical concentrations of DNCB, DNFB and DNBB (0-10 
µM) for 2 hours.   Western blots of the cell lysates showed that all three compounds 
activated the Nrf2 pathway (Table 4.1, Fig 4.5). 
 
Figure 4.5: Representative example of Western Blot analysis. HaCaT cells (100 000 
cells/well) were treated with 0-10 µM dinitrohalobenzenes for two hours, rinsed twice 
with culture medium and lysed with 80 µL of RIPA buffer enriched with 0.2 % protease 
inhibitor per well. Control experiments were carried out with 0.5 % DMSO in culture 
medium. 10 µg protein for DNCB and DNFB samples, 8 µg for DNBB (adjusted for protein 
concentration) were denatured at 85 °C for 10 minutes, loaded on gels and separated 
by electrophoresis at 90 V for 10 minutes followed by 170 V for 1 hour. The content of 
each gel was then transferred to a nitrocellulose blotting membrane (230 mA for 65 
minutes), which was stained with Ponceau S and blocked with non-fat dry milk solution 
(10 % in Tris-Buffered Saline) overnight. Membranes were treated with rabbit anti-Nrf2 
primary antibody for 3 hours (or mouse anti-actin primary antibody for 30 minutes) and 
DNCB  DNFB DNBB 
0      1     5      7    10     1    5      7     10  0    1      5    7    10  
Nrf2 
Actin 
Conc. (  
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Nrf2 secondary antibody for 1 hour. Membranes were treated with a Western Lightning 
plus enhanced chemiluminescence (ECL) reagent kit (Perkin Elmer, Coventry, UK) for 
film development.  Quantification of free Nrf2 was carried out using a GS-800 calibrated 
densitometer and the Quantity One software version 4.6.1. Data were normalised to 
actin (n=3). Results are presented in Table 4.1. 
 
 
 
 
 
 
 
 
 Ratio:  Nrf2 in sample/ Nrf2 in solvent control (0µM) 
 
Concentration of 
dinitrohalobenzene 
(µM) 
DNCB DNFB DNBB 
0 1 1 1 
1 1.6 ± 0.7 1.2 ± 0.2 1.3 ± 0.4 
5 2.4 ± 0.9 1.7 ± 1.1 1.9 ± 0.5 
7 2.0 ± 0.7 1.6 ± 0.8 2.0 ± 1.0 
10 2.1 ± 1.0 1.4 ± 1.5 1.5 ± 0.7 
 
Table 4.1: Representative Activation of the Nrf2 pathway after exposure to 2,4-
dinitrohalobenzenes relative to solvent control. The results are presented as Mean ± 
Standard Deviation (n= 3). 
 
All compounds showed activation of Nrf2 at a range of concentrations (5-10 µM), which 
is consistent with the results observed in the GSH assay, in which the application of 5-
10 µM of DNCB and DNFB (Fig 4.3) induced a significant repletion of GSH (up to control 
levels) in 24 h.  However, at 10 µM the Nrf2 activation is evident with DNBB (Fig 4.5) but 
the repletion of GSH is significantly lower than for DNCB and DNFB (Fig 4.3 b). 
 
4.4 Modelling approaches. 
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4.4.1 Overview of techniques available to model GSH in a skin 
sensitisation context. 
 
Reed et al have developed a very complex mathematical model, which included the 
whole of the GSH pathway in liver, i.e synthesis, breakdown, oxidative stress defence 
mechanism (GPx and GR) and export to the blood stream, as part of their attempt to 
represent metabolism in liver. With this model they tried to show how oxidative stress 
influenced this metabolic pathway in Down syndrome patients [161]. The same research 
group then improved their model by including GST as a detoxifying pathway as well as 
the metabolism of 5-oxoproline and ophthalmic acid [186] two biomarkers previously 
linked to the GSH pathway, the former being a precursor of L-glutamate [59] and the 
latter a biomarker of hepatic GSH consumption due to oxidative stress [187].  
 So far, a fully operational mathematical model does not exist for GSH metabolism in 
skin and it is unrealistic to try and reproduce a model with such a level of details as the 
one developed by Reed et al [161]. If a GSH based model for detoxification is to be useful 
in terms of skin sensitisation predictions, it should be incorporated into a broader model 
covering all of the sensitiser’s bioavailability in the skin after topical application.  
Predictive chemistry software packages (alerting the user of skin sensitisation potential 
by highlighting the electrophilic and pro-electrophilic moieties of a molecule) are 
already available but are so far incomplete and under constant improvements. The 
TIssue MEtabolism Simulator platform used for predicting Skin Sensitisation (TIMES-SS) 
is a software developed to give alerts for the potential for skin sensitisation and the 
potential for metabolism, which is based on chemical structure [188, 189]. Lhasa Limited 
also offers such a software, with the Derek Nexus skin sensitisation model giving a 
predicted EC3 value for the compound entered and the Meteor Nexus software making 
Phase I and Phase II metabolites prediction of the compound of interest, based on rules 
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derived from available literature data and experimental data given by collaborative 
partners [190, 191]. 
Using the HaCaT cell line, our experiments put the dinitrohalobenzenes in direct contact 
with viable cells, which gives a good overall overview of their bioavailability in skin as 
several mechanisms are in competition: the chemicals can simultaneously react with 
membranes, intracellular proteins, free amino-acids or small-sized peptides such as GSH 
(in this case covering the potential for metabolism). In our set of experiments, we 
observed both a depletion and a repletion of GSH levels over a 24 h time course. We 
decided to focus our simplified model around these two phenomena. 
 
4.4.2 Model. 
 
Whilst it is most likely that depletion of GSH and the synthesis of de novo GSH occur 
concomitantly, the method used to interpret our dataset separates depletion of GSH 
due to dinitrohalobenzene exposure and the replenishment subsequently observed, 
while fitting a linear equation through each event (Figure 4.6). This was achieved using 
the non-linear mixed (NLMIXED) procedure in the SAS software version 9.3 (SAS 
Institute, Marlow, UK). The depletion was modelled by the equation 
GSH = a + b * Time1/3 
 where a is the GSH value at the start of the experiment (in µM) and b is the rate of 
depletion (in µM/min1/3).  The tipping point at which depletion changes to 
replenishment was denoted tp (in min1/3). The replenishment of GSH was thus modelled 
by the equation 
GSH = a + b * tp  + c (Time1/3 - tp) 
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where a and b are unchanged compared to the depletion equation and c is the rate of 
repletion (in µM/ min1/3). 
 
Figure 4.6: Schematic of the variation of GSH in HaCaT cells after a single treatment. 
HaCaT cells were treated with 10 µM of dinitrohalobenzene. Time course results were 
represented as two events following a linear curve (depletion from a to tp and 
replenishment starting from tp). Model was fitted using the SAS institute NLMIXED 
procedure. 
 
4.4.3 Model results. 
 
Initially, all data points were taken into account (regardless of which dinitrohalobenzene 
experiment they related to) and the model was run to estimate an average value for a, 
b, c and tp (Figure 4.7, Table 4.2) across the three compounds. The fitting of the models 
for each dinitrohalobenzene could then be investigated following two hypotheses.  
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Figure 4.7: Model fitting a value for tp and c when averaging all data points available. 
Exepriments were carried out in triplicate measurements for each compound and each 
time point (n=9), irrespective of dinitrohalobenzene. 
 
Parameter estimates Fit statistics 
Parameter Estimate Standard error AIC 
tp 4.351 0.345 
464.2 
a 3.313 0.427 
b -0.409 0.157 
c 1.099 0.097 
 
Table 4.2: Estimated parameters and fit statistics values for a model fitting one value 
for tp and one value for c, where all data points were considered. This gives an average 
value which is used as starting point for comparison to cases where dinitrohalobenzenes 
are taken individually and the rate-limiting steps considered. 
 
In the first hypothesis, the depletion of GSH was the significant factor and the fitting 
therefore consisted of individual tp values for each chemical, while the repletion rate c 
Chapter 4 
116 
 
was fixed regardless of chemical applied (Figure 4.8). The tp values estimated in this 
manner for DNCB (3.78) and DNFB (3.55) were similar but considerably different from 
that for DNBB (5.41) (Table 4.3).  
Parameter estimates Fit statistics 
Parameter  Estimate Standard error AIC 
tp_DNBB 5.418 0.356 
421.6 
tp_DNCB 3.776 0.270 
tp_DNFB 3.555 0.269 
a 3.423 0.342 
b -0.488 0.125 
c 1.113 0.074 
 
Table 4.3: Estimated parameters and fit statistics values for a model fitting one value 
for c and individual values for tp. This is used for modelling the depletion of GSH due 
to treatment with dinitrohalobenzenes. 
 
The Akaike information criterion (AIC) is used to assess candidate models for a specific 
set of data. AIC rewards goodness of fit (as assessed by the likelihood function) and 
penalises the number of estimated parameters in each model, hence discouraging an 
overfit of the data. The preferred model is the one with the minimum AIC value [192]. 
The AIC value obtained for fitting this model was lower than in the model in which all 
chemicals were averaged, demonstrating an improvement in the fitting and thus the 
difference between DNBB and the other two dinitrohalobenzenes. 
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 Figure 4.8: Model fitting a value for tp for each dinitrohalobenzene, while the value of 
c is fixed and the same for the three compounds. This is used for modelling the depletion 
of GSH due to treatment with dinitrohalobenzenes. 
 
 In the second hypothesis, the repletion rate was the significant factor, therefore the 
depletion of GSH was fixed (the tipping point was set as the same value regardless of 
compound) and the fitting consisted of three individual c values, representing the 
replenishment rates observed for each dinitrohalobenzene (Figure 4.9).   
 
Figure 4.9: Model fitting a value for c for each dinitrohalobenzene, while the value of 
tp is fixed and the same for the three compounds. This is used for modelling the 
repletion of GSH, after HaCaT cells have cleared the dose of dinitrohalobenzenes. 
Chapter 4 
118 
 
 
Again the two c values estimated for DNCB (1.40) and DNFB (1.35) were similar while 
the value obtained for DNBB (0.53) was considerably different.  The fitting for this 
hypothesis (AIC value 399.2, Table 4.4) was improved when compared to the first 
hypothesis (AIC value 421.6, Table 4.3) suggesting that the significant difference 
between the dinitrohalobenzenes (Figure 4.9) stemmed from GSH repletion rate. 
Parameter estimates Fit statistics 
   Parameter Estimate Standard error AIC 
tp 4.32 0.24 
399.2 
a 3.325 0.318 
b -0.417 0.115 
c_DNBB 0.529 0.084 
c_DNCB 1.405 0.103 
c_DNFB 1.349 0.097 
 
Table 4.4: Estimated parameters and fit statistics values for a model fitting one value 
for tp and individual values for c. This is used for modelling the replenishment of GSH 
after the cells have cleared the dinitrohalobenzenes applied. 
 
4.5 Discussion. 
 
Here we considered both GSH conjugation from the level of reduced GSH remaining in 
cells after exposure to dinitrohalobenzenes and modifications of Keap1 by the increased 
amount of free Nrf2 protein in cell lysates. 
Of the chemicals studied, DNCB appeared to be the most potent Nrf2 activator and 
DNFB the weakest, but the three dinitrohalobenzenes examined all induced Nrf2 at 
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lower concentrations than those required to induce detectable GSH depletion (1-5 µM). 
Modification of Keap1 cysteine residues has been detailed for DNCB in [193] but the 
same level of information is not available for the DNFB and DNBB. However, since these 
dinitrohalobenzenes are close structural relatives and the translocation of Nrf2 was 
observed for all three, it is likely that modification of cysteine residues has happened 
with DNFB and DNBB as has been reported for DNCB.  The induction of antioxidant 
response element (ARE)-dependent genes regulates the synthesis of enzymes such as 
glutamyl-cysteine ligase (GCL), which is necessary for the generation of de novo GSH in 
cells, but also GSTs that will help the conjugation of this newly synthesised GSH to 
electrophiles. Our results suggest both the activation of Nrf2 and depletion of GSH in 
the cytosol are observed simultaneously. The translocation of Nrf2 was observed at 2 h 
time point, concomitant with the most pronounced GSH depletion (2-4 h based on time 
course experiment).  The differentiation between our three dinitrohalobenzenes during 
the repletion of the GSH pool is most likely linked to the toxicity of the halogens 
themselves once released into the cells [194-196]. 
 The order of cytotoxicity of the compounds (as measured by MTT assay) was difficult 
to determine for concentrations less than 2 µg/mL= 10 µM, although DNFB seemed the 
least toxic at a concentration of 5 µg/mL. The MTT assay is based on measurements of 
mitochondrial activity which can be influenced by the availability of antioxidants. 
However, most of the widely used assays present differences of their own and the 
cytotoxicty level at 24 h can vary from assay to assay [197]. Therefore observation of 
biological effects linked to exposure at the organ level (viable skin) or in vivo when 
possible, provides more valuable information than cytotoxicyty in one cell type alone. 
All three compounds are extremely potent sensitisers in the local lymph node assay 
(LLNA), with very similar LLNA EC3 expressed as a % (DNFB 0.0323 < DNCB 0.0765 < 
DNBB 0.0849)[176]. Similar LLNA EC3 values were reported by in Natsch et al [198] with 
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slightly different halogen order. Human data is rather scarce as occupational exposure 
to either dinitrohalobenzene is very occasional but data on sensitisation was obtained 
in controlled conditions by patch testing healthy volunteers with DNFB [171] or DNCB 
[111]. In the DNFB study 15 out of 16 people tested demonstrated some level of 
sensitisation after initial exposure to a 2 % solution of DNFB in acetone (2000 µg dose) 
followed 7 days later by a re-exposure to a quarter of the original dose.  The DNCB study 
showed that for an initial exposure to 500 µg of DNCB all patients were sensitised (re-
exposure 4 weeks later with DNCB doses to up to 12.5 µg). Data for patch testing using 
DNBB was not available but it would also be expected to generate high level of 
sensitisation in volunteers. Based on this, it would be difficult to differentiate between 
the three compounds as they have almost identical biological effects.  
The order of reactivity for dinitrohalobenzenes with a peptide containing a cysteine 
residue (Ac-RFAACAA) is DNFB>>DNCB comparable to DNBB [198] and follows the 
electronegativity order of the halogens in Pauling’s electronegativity table (F 3.98 > Cl 
3.16 > Br 2.96). The expectation is therefore that DNFB>DNCB>DNBB in terms of pure 
reactivity towards nucleophiles. This is observed when glutathione is used as the model 
thiol nucleophile in an in chemico assay at physiological pH, where the RC50 values 
(concentration in mM for which half of GSH used in the assay is consumed) reported 
follow this rule (DNFB (0.07) << DNBB (1.00) comparable to DNCB (1.60)) [115]. 
Megherbi et al. have shown that dinitrohalobenzenes appear to haptenate cell proteins 
to different extents irrespective of their order of reactivity [199]. However it is difficult 
to draw direct conclusions about the relative order of reactivity of the 
dinitrohalobenzenes using a complex protein mixture and an antibody detection 
system, as compared to a simpler in chemico reactivity assay.  
The GSH depletion data described here do not challenge the expected order of 
reactivity, as all three dinitrohalobenzenes were found to deplete available GSH over a 
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short period of time (2-4 hours) to a similar extent. However, the fact that DNBB and 
DNCB appeared more toxic than DNFB at 24 h at a concentration of 5 µg/mL highlights 
the need to investigate the potential of the biological system to recover from exposure 
to external chemicals to obtain a better understanding of the effect of topical 
application on humans. 
 
4.6 Conclusion. 
 
The data showed that the HaCaT cell line was a suitable model to represent the 
clearance of dinitrohalobenzenes by the GSH pathway in human skin. HaCaT cells 
possessed the required enzymes to form dinitrophenyl-glutathione conjugates (GSTs) 
and synthesise de novo GSH (GCL, GS). The Nrf2 signalling pathway was activated after 
exposure for each compound, enhancing the Phase II enzymes linked to the GSH 
pathway involved in this defence mechanism. The critical piece of information obtained 
from this piece of work is that for a non-toxic level of exposure, cell recovery (here GSH 
repletion) might be a differentiating factor for compounds which all react with GSH by 
the same mechanism.  This might be important to assess new chemicals. Overall, when 
studying the MIE of skin sensitisation, i.e protein haptenation, it might be possible, in 
theory, to cumulate the kinetics rates at which a molecule conjugates to small peptides 
in chemico [20, 24] (even though this is not systematically measured, to assess the 
potential for protein binding) and GSH conjugation rate in chemico [167] (to assess the 
skin protective mechanism) to get an estimation of this molecule haptenation potential 
in an in silico model. However, the data is not really representative of skin in vivo and 
would only be used for risk measurements. We have shown in our simplistic 
mathematical model that all three dinitrohalobenzenes react with GSH at approximately 
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the same rate in HaCaT cells (Figure 4.9) but the repletion step, which is rarely studied 
was a differentiating factor. Efforts should be made in the future to integrate the 
potential for skin “recovery from exposure” in in silico predictions. 
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5.1 Overview. 
 
5.1.1 Using the HaCaT cell line GSH assay for comparing 
chemicals. 
 
As previously discussed in Chapter 4, 24 hour experiments enabled a comparison of the 
effect of model skin sensitisers of similar structure, i.e dinitrohalobenzenes, on the GSH 
pathway in the HaCaT cell line. Repletion rate, rather than the kinetics of reactivity 
during the depletion process, proved to be a differentiating factor. It was also 
demonstrated that some of the differences could be due to variations in toxicity in the 
chemicals themselves (for example, Br (DNBB) was slightly more toxic than F (DNFB)). 
To exploit this theory further, this chapter aimed to reproduce 24 hour experiments 
using two different model sensitisers, which react with thiols via a different mechanism 
to that explored so far with DNCB (SNAr). The two chemicals were also selected with a 
difference in potency in the LLNA, one being an extreme sensitiser 
(diphenylcyclopropenone, DPCP), comparable to DNCB, and the other being less potent 
(diethyl maleate, DEM) and classified as a moderate sensitiser. 
 
5.1.2 Diphenylcyclopropenone (DPCP) and diethyl maleate 
(DEM) as model skin sensitisers.  
 
Based on a recommendation made by the Scientific Committee on Cosmetics Products 
and Non-food Products Intended for Consumers (SCCNFP) which was presented in 2000, 
DEM should not be used in any fragrance mixture used in cosmetics [200]. As a result, 
the general population should not be exposed to DEM on a normal basis. However, 
some leathers and textiles are treated with dimethyl fumarate (DMF), which is 
structurally quite similar to DEM (Fig 5.1) as these are cis/trans isomers and DMF related 
skin allergy has been reported recently [121]. Patch testing studies for people who had 
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suffered contact allergy to sofas and furniture that had been treated with dimethyl 
fumarate (DMF), included control chemicals such as diethyl fumarate (DEF, 1 carbon 
longer in the chain) and diethyl maleate (DEM, cis isomer of DEF) [121]. Results showed 
that people sensitised to DEF could also have an allergic reaction to DEM. The rationale 
for explaining this cross sensitisation between fumarates and maleates is that the 
antigens formed by reaction with proteins would have the same structure and chiral 
centres for both compounds [201]. The structure itself is discussed further below, in 
Section 5.1.3. 
 
 Figure 5.1: Diethyl maleate (DEM) is structurally related to dimethyl maleate (DMM), 
dimethyl fumarate (DMF) and diethyl fumarate (DEF). 
 
DPCP is not used in personal care products or other commercial products available to 
the public and is solely considered as a drug. It is a very potent skin sensitiser, classed 
as extreme in the LLNA [202], which when topically applied enables the induction of an 
immune response [203]. The immunotherapy technique with DPCP is used in the 
treatment of alopecia areata  and occasionally as an alternative to DNCB in the 
treatment of persistent warts [112]. Therefore, as is the case for DEM, the general 
population, with the exception of some patients suffering from the two conditions 
described above, is not exposed to DPCP but occupational allergic reaction in laboratory 
or clinical staff is always a possibility [204]. 
 
5.1.3 Model skin sensitiser reactivity with proteins.  
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As DEM is classified as a moderate skin sensitiser in the LLNA [202] it is often used as a 
benchmark chemical in in vitro assays aiming at evaluating skin sensitisation potential. 
In chemico reactivity assays using small peptides have used DEM as a probe and showed 
that it extensively reacted with cysteine residues in these assays [19, 20]. More 
specifically for our study, the strong electrophilicity of DEM has made it an attractive 
compound to deplete GSH stock in biological tissues [123] and this methodology has 
been used for a long time. Recently DEM has been used in the in vitro test SenCeeTox® 
assay for skin, for a new applicability to medical devices. In this assay, DEM was found 
to deplete 73 % of GSH present in saline buffer and 69 % in sesame oil [205], meaning 
that GSH could potentially detoxify DEM in organs presenting localised variations in 
hydrophobicity, such as the various layers of human skin. The mechanism by which the 
conjugation between GSH and DEM happens is a Michael addition and is illustrated in 
Fig. 5.2. The formation of the DEM conjugates with GSH has been monitored by NMR 
and structures have been confirmed [206]. Under non-specific conditions of pH (i.e pH 
7.4 in phosphate buffer and in most cases of cell culture medium or tissue extracts) 
diastereoisomers are formed in equal proportions. For the purpose of this work, we will 
only represent one isomer and call it “GSH+DEM” adduct. 
 
 
 
Figure 5.2: Reaction between DEM and GSH occurs via a Michael addition mechanism, 
yielding a “DEM+GSH” conjugate of molecular weight 479 g/mol. 
 
Chapter 5 
127 
 
The molecule DPCP itself was only synthesised for the first time in 1959. However, the 
mechanism by which it reacts with nucleophiles has been investigated reasonably early 
by Eicher and Weber in the mid-1970s, before it started to be used by dermatologists 
to treat skin conditions. Eicher and Weber reported that DPCP could react with 
hydroxide or alkoxide ions, primary and secondary amines, hydrazines, carboxylates and 
amides, by reaction on the carbonyl group followed by opening of the ring [207]. They 
did not comment on reactivity with thiols but the more recent in chemico peptide 
reactivity studies have shown that DPCP could extensively deplete cysteine-containing 
peptides [19, 20]. In the reactivity assay using the peptide Cor1C-420 (sequence Ac-
NKKCDLF) more information is given about adduct formation as LC-MS analysis was 
carried out: three adducts with DPCP were observed, two being direct adducts of the 
same mass (peptide+ DPCP) and one being described as a di-adduct (peptide + 2DPCP) 
[20]. Extrapolating from all this information, reactivity with GSH could lead to the 
following conjugates (Fig 5.3). 
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Figure 5.3: Reaction between DPCP and GSH lead to the opening of DPCP’s ring. 
Depending on the nucleophile attacking the carbonyl group (thiol or amine) two 
structures (a and b) can be hypothesised for a “DPCP+GSH” conjugate of molecular 
weight 513 g/mol, even though option a) should be prevalent. 
 
5.2 Aims and Objectives. 
 
The following experiments aimed to illustrate how compounds of various skin 
sensitisation potency influenced the GSH clearance pathway in the HaCaT cell line. First, 
the comparison focussed on two extreme sensitisers, DNCB and DPCP and how their 
different chemistries played a role on their metabolic clearance. Secondly, results 
observed for an extreme sensitiser were assessed against a moderate sensitiser, here 
DNCB and DEM. These chemicals have all been reported to be thiol reactive, with 
various level of details given concerning the structure of adducts formed. In a first 
instance, the formation of GSH conjugates was verified in chemico, with a very brief 
mention to the formation of DNP-SG by GSH conjugation of DNCB, which was implicit 
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throughout the previous chapter. Cytotoxicity of each new compound was assessed by 
MTT assay on the HaCaT cell line. As described previously, toxicity was only considered 
acceptable when cell viability was at least 80% of untreated control cells, over a 24 hour 
period. In order to select an optimum concentration, for which a 24 h time course 
experiment could be carried out using our GSH assay, GSH depletion was also assessed 
after 1 h exposure (to highlight any significant depletion). 
The objective of these comparisons was to demonstrate that chemical reactivity with 
GSH in chemico was not a sufficient factor to assess behaviour on the GSH pathway in 
human skin after exposure. Bioavailability and toxicity in a living in vitro system, here 
HaCaT cells, led to different outcomes, even though the detoxification pathways 
involved were predicted to be the same (thiol clearance), based on in chemico studies. 
 
5.3 Results. 
 
5.3.1 In chemico incubations of model skin sensitisers.  
 
5.3.1.1. Incubations at pH 7.4 for 24 h at 37 °C, with ratio GSH: chemical 
fixed at 1:10 
 
DNCB was incubated as a control experiment only, as the formation of dinitrophenyl-
glutathione (DNP-SG) was relatively easy to carry out [127] and formed the basis of GST 
activity spectrometric measurements in most commercial kits sold.  A typical 
chromatogram is presented in Fig 5.4. The major peak (RT = 5.65 min) was the expected 
DNP-SG adduct with m/z 474 (Fig 5.5). There were three minor peaks on the 
chromatogram (RT =1.54 min, 7.17 min and 8.15 min), all with low m/z, unlikely to be 
related to the reaction between GSH and DNCB (Fig 5.4).  
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Figure 5.4: Typical chromatogram obtained for DNCB incubation with GSH at pH 7.4 
for 24 h.  Blue highlight: the DNP-SG conjugate formed during the incubation and was 
observed at a retention time (RT) of 5.65 minutes (details of extracted mass m/z 474 is 
available in Figure 5.5). Other peaks at RT = a) 1.54 min, b) 7.17 min and c) 8.15 min, all 
with low m/z, were unrelated to DNCB or GSH. Incubations were carried out in plastic 
Eppendorf tubes in triplicate (n=3). 
 
 
Figure 5.5:  Representative extracted mass for peak observed at RT 5.65 minutes. 
Mass spectrum of DNP-SG conjugate [M+H]+ ion at m/z 474 (extracted from 
chromatogram presented in Fig 5.4 in the blue highlight). 
 
A typical chromatogram of DEM incubations is presented in Fig. 5.6. It contained signals 
corresponding with oxidation of unreacted GSH (retention time 1.67 and 2.74 min), 
unreacted DEM (retention time 7.34 min) and a “DEM+GSH” conjugate (retention time 
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5.43 min) with m/z 480 (Fig. 5.7).  This conjugate was structurally the same as the 
conjugate formed by Kubal et al [206]. Minor peaks at retention time 5.30 min, 5.96 
min, 7.86 min and 8.05 min could not easily be linked to the structure of either GSH or 
DEM. Peaks at retention time 1.13 min and 13.54 min were linked to the mobile phase 
or buffer used for the incubations.  
 
Figure 5.6: Typical chromatogram obtained for DEM incubation with GSH at pH 7.4 for 
24 h. Blue highlight: the “GSH + DEM” conjugate formed during the incubation and was 
observed at a retention time (RT) of 5.43 minutes (details of extracted mass m/z 480 is 
available in Figure 5.7). Peaks at RT = a) 1.67 min and b) 2.74 min were due to unreacted 
GSH. Peak at RT = c) 7.34 min was unreacted DEM.  Other peaks at RT = d) 5.30 min, e) 
5.96 min, f) 7.86 min and g) 8.05 min could not easily be linked to the structure of either 
GSH or DEM. Peaks at retention time h) 1.13 min and i) 13.54 min were linked to the 
mobile phase. Incubations were carried out in plastic Eppendorf tubes in triplicate (n=3). 
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Figure 5.7: Representative extracted mass for peak observed at RT 5.43 minutes. Mass 
spectrum of “DEM + GSH” conjugate with [M+H]+ ion at m/z 480 (extracted from 
chromatogram presented in Fig 5.6 at retention time 5.43 min). 
The chromatograms obtained for incubations containing DPCP were more complex and 
some peaks were not assigned (Fig 5.8). Small peaks of GSSG (retention time 1.67 and 
2.74 min) as well as unreacted DPCP (retention time 7.83 min) were observed. The peak 
with a retention time of 6.56 min and the peak immediately following (retention time 
6.77 min) have a mass m/z 514, likely to be the conjugate “DPCP+ GSH” (Fig 5.9). The 
two peaks with a retention time 8.55 and 8.6 min have a mass m/z 720, which is likely 
to be the adduct of structure “2 DPCP + GSH” (Fig 5.10). 
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Figure 5.8: Typical chromatogram obtained for DPCP incubation with GSH at pH 7.4 
for 24 h. Blue highlight: the “GSH + DPCP” conjugate formed during the incubation and 
was observed at a retention time (RT) of 6.77 minutes (details of extracted mass m/z 
514 is available in Figure 5.9) and “GSH+ 2 DPCP” at retention times 8.55 and 8.69 min 
(details of extracted mass m/z 720 is available in Figure 5.10). Peaks at RT = a) 1.67 min 
and b) 2.74 min were due to unreacted GSH. Peak at RT = c) 7.83 min was unreacted 
DPCP.  Other peaks at RT = d) 5.91 min, e) 6.13 min, f) 8.30 min and g) 8.69 min could 
not easily be linked to the structure of either GSH or DPCP. Peaks at retention time h) 
1.13 min and i) 13.54 min were linked to the mobile phase. Incubations were carried out 
in plastic Eppendorf tubes in triplicate (n=3). 
 
 
Figure 5.9: Representative extracted mass for peak observed at RT 6.56 minutes. Mass 
spectrum of “DPCP + GSH” conjugate with [M+H]+ ion at m/z 514 (extracted from 
chromatogram presented in Fig 5.8 at retention time 6.56 min). 
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Figure 5.10: Representative extracted mass for peak observed at RT 8.55 minutes. 
Mass spectrum of “2 DPCP + GSH” conjugate with [M+H]+ ion at m/z 720 (extracted from 
chromatogram presented in Fig 5.8 at retention time 8.55 min). 
 
5.3.1.2. Incubations at pH 9.5 for 24 h at 37 °C, with ratio GSH: chemical 
fixed at 1:10 
 
To attempt to increase the reactivity between the chemicals and the thiol present on 
GSH, the pH was increased above the pKa of GSH, reported to be between 9.2 and 9.4 
[130, 131]. A typical chromatogram for Incubations with DEM is presented in Fig 5.11. 
As observed at pH 7.4 a “DEM+GSH” adduct was observed at retention time 5.43 min. 
Contrary to expectations the reaction between DEM and GSH was still not complete and 
some GSH was oxidized to GSSG instead (retention time 1.68 min).  
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Figure 5.11: Typical chromatogram obtained for DEM incubation with GSH at pH 9.5 
for 24 h. Blue highlight: the “GSH + hydrolysed DEM” conjugate formed during the 
incubation and was observed at a retention time (RT) of 4.6-4.77 minutes (split peak 
details of extracted mass m/z 452 is available in Figure 5.12) and “GSH+ 2 DEM” at 
retention times 6.37 and 6.52 min (details of extracted mass m/z 652 is available in 
Figure 5.13). Peak at RT = a) 1.67 min was unreacted GSH. Peak at RT = b) 7.34 min was 
unreacted DEM.  Peaks at RT = c) 5.15-5. 32 min (split peak) could not be assigned to 
DEM or GSH. Peak at RT = d) 5.43 min (similar to one observed in figure 5.6) was “GSH 
+ DEM” conjugate. Incubations were carried out in plastic Eppendorf tubes in triplicate 
(n=3). 
 
New products were formed at pH 9.5 compared to pH 7.4. A major peak was broadly 
defined at retention time 4.6-4.7 min with a consistent m/z 452 throughout the width 
of the peak. The extracted spectrum is presented in Fig 5.12. It seems that increasing 
the pH to 9.5 enabled the hydrolysis of one of the ethyl moiety in DEM. The resulting 
hydrolysed compound then reacts with GSH in the same way that DEM would and both 
conjugates are observed. Two minor peaks at retention time 6.37 and 6.52 min have an 
extracted mass m/z 652, which is consistent with the addition of two DEM molecules to 
a molecule of GSH (Fig 5.13). Two major peaks at retention times 5.15 and 5.32 min 
could not be easily assigned a structure. 
Chapter 5 
136 
 
 
Figure 5.12:  Representative extracted mass for peak observed at RT 4.7 minutes. Mass 
spectrum of “hydrolysed DEM + GSH” conjugate with [M+H]+ ion at m/z 452 (extracted 
from chromatogram presented in Fig 5.11 at retention time 4.7 min). 
 
 
 Figure 5.13:  Representative extracted mass for peak observed at RT 6.52 minutes. 
Mass spectrum of “2 DEM + GSH” conjugate with [M+H]+ ion at m/z 652 (extracted from 
chromatogram presented in Fig 5.11 at retention time 6.52 min). 
An apparent increase in complexity was also observed in chromatograms issued from 
DPCP incubations (Fig.5.14). Two peaks with a retention time of 5.92 and 6.14 minutes 
with a m/z 819 showing an apparent fragmentation pattern of 206-203-203-206 could 
be related to tetramerisation of DPCP (data not shown). The peak with a retention time 
of 6.5 minutes with a m/z 514 is consistent with a “DPCP+GSH” conjugate and the two 
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minor peaks at retention time 8.55 and 8.69 minutes with m/z 720 are consistent with 
a “2DPCP+ GSH“ conjugate. Both conjugates were previously observed in incubations 
carried out at pH 7.4 at the same retention times.  
 
Figure 5.14: Typical chromatogram obtained for DPCP incubation with GSH at pH 9.5 
for 24 h. the peak at RT = a) 6.5 min was the “GSH = DPCP” conjugate (m/z 514), the 
peak at RT = b) 7.86 min was unreacted DPCP and the peak at RT = c) 8.55 min was the 
“GSH + 2DPCP” adduct (m/z 720), all similar to ones observed in figure 5.8. Incubations 
were carried out in plastic Eppendorf tubes in triplicate (n=3). The level of complexity of 
the chromatogram increased but there wasn’t any new GSH adducts detected 
compared to pH 7.4 incubations. The intensity of the peaks linked to GSH conjugates did 
not increase significantly compare to pH 7.4 incubations. 
 
5.3.2 Cytotoxicity assay (MTT assay).  
 
Cytotoxicity measurement for DNCB has been carried out in the HaCaT cell line as part 
of the previous chapter (Chapter 4, Section 4.2.1), in which the maximum concentration 
that did not induce more than 20 % loss of viability was 10 µM. Similarly, DPCP showed 
a high level of toxicity to HaCaT cells exposed for 24 h (Fig 5.15). The maximum 
concentration that did not induce significant toxicity was 2.4 µM, which was rounded 
down to 2 µM for future experiments for practical reasons. 
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Figure 5.15:  Cytotoxicity of diphenylcyclopropenone in HaCaT cells after 24 hours. The 
toxicity of DPCP was determined using the MTT assay after 24 hours of exposure. Each 
well (20 000 cells/well) was treated with the appropriate concentration of DPCP. The 
concentration applied was considered non-toxic when the cell viability is at least 80 % 
compared to control cells kept in culture medium containing 0.5 % DMSO for a similar 
length of time. Each concentration was tested in 8 wells (n=8) and the result was 
presented as Mean viability ± Standard deviation.  The figure shows that all 
concentrations lower or equal to 2 µM were non-toxic. 
 
DEM did not exhibit significant toxicity to HaCaT cells when applied at concentrations of 
up to approximately 90 µM in the MTT assay (Fig 5.16). Above this threshold, the 
viability of cells decreases slowly with increasing concentration with approximately 20 
% of cells still viable when DEM was present at a concentration of approximately 580 
µM. 
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Figure 5.16: Cytotoxicity of diethylmaleate in HaCaT cells after 24 hours. The toxicity 
of DEM was determined using the MTT assay after 24 hours of exposure. Each well (20 
000 cells/well) was treated with the appropriate concentration of DEM. The 
concentration applied was considered non-toxic when the cell viability is at least 80 % 
compared to control cells kept in culture medium containing 0.5 % DMSO for a similar 
length of time. Each concentration was tested in 8 wells (n=8) and the result was 
presented as Mean viability ± Standard deviation.  The figure shows that all 
concentrations lower or equal to 580 µM were non-toxic. 
 
5.3.3 GSH cycling in the HaCaT cell line. 
 
5.3.3.1. DEM and DPCP show different GSH dose responses from DNCB 
after 1 hour and 24 hour exposure. 
 
The following results are expressed as a percentage of GSH remaining in viable cells after 
exposure, the amount of GSH in untreated cells remaining in HaCaT cell culture medium 
for the length of time of the experiment being used as the reference for 100 % GSH 
(untreated controls, shown as 0 µM concentration in figures). 
The results for DNCB were presented in Section 4.2.2, Chapter 4 (Fig 4.3) and are not 
repeated here. Dose responses showed that the optimum concentration for which 
DNCB depleted GSH at 1 hour and replenished at 24 hours was 10 M.  These results 
will be discussed further to compare them with DEM and DPCP. 
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In experiments where the exposure time was 1 h, the level of GSH was not significantly 
lower in treated compared to untreated cells, regardless of the concentration of DEM 
(approximately 75 % of GSH present for a concentration of 150 µM), even though DEM 
has been shown to covalently bind to GSH in chemico. When the exposure time was 
increased to 24 hour, DEM did not deplete GSH but a clear upregulation of the synthesis 
of GSH was observed for all concentrations applied up to 150 µM. The highest level 
being observed for a 50 µM concentration where the level of glutathione was double 
that of untreated cells. Considering the results obtained in the MTT assay for DEM, it 
was expected that at high concentrations (100-150 µM) the level of GSH would be 
approximately 60 % of basal untreated cells to match cell viability but this did not seem 
to be the case (Fig 5.17).  
 
 
Figure 5.17:  GSH levels in HaCaT cells treated with various concentrations of DEM for 
1 hour or 24 hours. Each well (400 000 cells/well) was treated with DEM and incubated 
for blue: 1 hour and red: 24 hours. The cells were then rinsed with PBS, lysed and 
derivatised with iodoacetamide as described in previous figures. GSH levels were 
measured in half the lysate (equivalent to 200 000 cells, and the concentration 
expressed in µM.  GSH levels were reported as percentage of untreated cells controls 
matching the exposure time and presented as Mean % of GSH in untreated cells ± 
Standard deviation (n=2).  The figure shows that GSH level after 1 hour of exposure was 
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within ± 20 % of GSH level in untreated control cells but GSH levels at 24 hours were 
higher than in control cells. 
 
A potential explanation for this result is that some cell death is likely occurring during 
the experiment but the remaining cells produce a very high GSH upregulation (probably 
up to 200 % of basal level as was the case for a 50 µM dose) resulting in the total amount 
of reduced GSH available higher than the level observed in untreated cells.  
DPCP showed very different results (Fig 5.18). The concentration range investigated (0-
30 µM) was closer to the one used for DNCB, as both chemicals are extreme sensitisers. 
A 24 hour exposure period to DPCP could not deplete GSH levels at a concentration that 
was not toxic for the cells. GSH upregulation was observed for a concentration of 1 µM. 
A complete depletion of GSH was observed at approximately 10 µM and over, however 
this concentration would normally result in 100 % reduction in cell viability over a 24 h 
period. For an incubation time of 1 hour only, the level of GSH was not significantly 
depleted in treated cells up to 20 µM. The most significant depletion was observed at 
the top concentration of 30 µM, where approximately 70 % of the GSH level of the cells 
remained. From this, it can be observed that DPCP is more toxic than DNCB but the 
speed of reaction with GSH in in vivo conditions is slower.  
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Figure 5.18:  GSH levels in HaCaT cells treated with various concentrations of DPCP for 
1 hour or 24 hours. Each well (400 000 cells/well) was treated with DPCP and incubated 
for blue: 1 hour and red: 24 hours. The cells were then rinsed with PBS, lysed and 
derivatised with iodoacetamide as described in previous figures. GSH levels were 
measured in half the lysate (equivalent to 200 000 cells, and the concentration 
expressed in µM.  GSH levels were reported as percentage of untreated cells controls 
matching the exposure time and presented as Mean % of GSH in untreated cells ± 
Standard deviation (n=2).  The figure shows that GSH level after 1 hour of exposure was 
within ± 20 % of GSH level in untreated control cells but GSH levels at 24 hours were 
higher than in control cells (1 µM dose) or depleted (10-30 µM). 
 
5.3.3.2. GSH 24 hour time course in HaCaTs after treatment with DEM or 
DPCP showed a different pattern than the one seen with DNCB. 
 
 
The results for DNCB were presented in Section 4.2.3, Chapter 4 and Fig 4.4. The time 
course experiment at a 10 µM showed a depletion of GSH up to 2 hours followed by a 
period of repletion of GSH stock (Fig 5.19, extracted from Fig 4.4).  These results will be 
discussed further to compare them with DEM and DPCP. 
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Figure 5.19:  Main: GSH levels in HaCaT cells treated with 10 µM DNCB for 24 hours. 
GSH levels are expressed in µM. Insert: Comparison between controls cells at t= 0 hour 
and t= 24 hours, representing the GSH increase due to cell division in the well during 
the length of the experiment (n= 4). This figure is extracted from the results presented 
in Fig. 4.4 (Chapter 4). 
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HaCaT cells were treated with the DEM concentration leading to the maximum 
upregulation of GSH over 24 h observed in Section 5.3.3.1 (50 µM). This concentration 
was not toxic over the 24 hour period in the MTT assay. The aim was to observe some 
depletion of GSH (at early time points up to 1 hour) followed by a sharp repletion above 
control levels.  A significant depletion of GSH levels was not observed in the early time 
points and GSH levels were fluctuating between 75-125 % of their basal value (t= 0 hour) 
for up to 4 hours (Fig 5.20). An exponential increase in GSH concentration in the cells 
was visible between 4-6 hours and 24 hours to reach approximately 450 % of their basal 
value (t= 0 hour) or double the level observed in cells that were left untreated for 24 
hours (basal value t= 24 hours, Fig 5.20 insert) due to natural cell division in the well, 
which was similar to the result observed for DNCB in Fig 5.19.  
HaCaT cells were treated with the DPCP concentration which was not toxic over the 24 
hour period in the MTT assay, here 2 µM (Fig 5.15). This was expected to lead to a 
potential upregulation of GSH over 24 hours, as seen with a 1 µM dose (Fig 5.18). The 
GSH levels did not decrease with time at the early time points and fluctuated between 
90-130 % of the basal value at t= 0 hour for the first two hours of experiment. Between 
4 hours and 24 hours the levels observed were higher, 130-160 % and were generally in 
line with the value observed in the control cells at 24 hours (173 %). This indicated that 
a 2 µM dose of DPCP had no significant influence on the GSH cycling pathway in the 
HaCaT cell line (Fig 5.20). 
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Figure 5.20:  GSH levels in HaCaT cells treated with DEM or DPCP. Main: GSH levels in 
HaCaT cells treated with 50 µM DEM or 2 µM DPCP for 24 hours. Insert: Comparison 
between controls cells at t=0 hour and t=24 hours, representing the GSH increase due 
to cell division in the well during the length of the experiment. Each well (400 000 
cells/well) was treated with DEM or DPCP for the required amount of time. The cells 
were then rinsed with PBS, lysed and derivatised with iodoacetamide as described in 
previous figures. GSH levels were measured in half the lysate (equivalent to 200 000 
cells, and the concentration expressed in µM.  GSH levels were reported as percentage 
of untreated cells controls matching the exposure time and presented as Mean % of 
GSH in untreated cells ± Standard deviation (n=2).   
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5.4 Discussion. 
 
Cytotoxicity considerations formed the basis of the assumption that GSH would be able 
to detoxify any dose that would not induce more than 20 % cell death in the MTT assay. 
This was the case for DNCB and other dinitrohalobenzenes studied previously, where a 
visible depletion of GSH levels was observed as well as a repletion period after the dose 
was cleared (by a combination of GSH conjugation and protein haptenation). 
Historically, DEM has been used as a mean to deplete thiols in organs, including GSH, 
after treatment with high doses (low mmol/kg range) administered on animals by 
injection [208]. Hence, when pre-treatment of cultured cells by DEM was used as a mean 
to reduce GSH before evaluation of other parameters, high doses (hundreds of M to 
low mM) tended to be used as well [209]. In our experiments the moderate sensitiser 
DEM induced significant cytotoxicity when the concentration was increased above 90 
µM. Comparing this result with the extreme sensitiser DNCB, it seemed reasonably 
intuitive that the less potent sensitiser could be applied at a higher dose before 
detrimental effect was observed.  
However, levels of GSH did not deplete significantly after 1 hour in a dose response 
manner, as was seen for DNCB, and the maximum dose investigated (150 µM) only 
depleted GSH stock by 25 %. West et al tried to rationalise the observed toxicities of 
DEM and related molecules (containing an α,β-unsaturated carbonyl group) and 
reached the conclusion that concentrations inducing toxicity correlated directly with 
concentrations inducing DNA damage and apoptosis. As in our GSH assay, while DEM 
IC50 in their cytotoxicity assay was approximately 130 µM, DNA fragmentation was the 
most visible at the high concentration range of 200-400 µM [210]. This hinted at the fact 
that a concentration inducing mild cytotoxicity (80 % cell viability) was artificially 
“masking” the effect of DEM conjugation with GSH. Potentially, the kinetics of reaction 
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(GSH conjugation) might have been initially relatively slow compare to the kinetics of 
synthesis of GSH and visible depletion could only be detected in our assay if DEM 
concentration was high and toxic (generating other detrimental impact on cell health, 
including a slowdown of GSH synthesis).  
To investigate this further, we chose DPCP as an extreme sensitiser (same potency for 
skin sensitisation as DNCB) that also contained an α,β-unsaturated carbonyl group 
(same as DEM). Cytotoxicity to the HaCaT cell line at 24 hours was much closer to the 
results observed for DNCB and mild cytotoxicity (80 % viability) was obtained in the 
concentration range 2-3 M. In chemico kinetics reported for nitrobenzenethiol also 
supported the assumption that DPCP (k =  3x10-6 s-1, first order kinetics) and DNCB (k= 
2.1x 10-5 s-1, first order kinetics) should react with GSH at comparable speed [211]. 
Recently, DNCB and DPCP treatments were carried out on both HaCaT cells and freshly 
excised human skin to show that a specific set of genes was over expressed in the same 
way in both cells and skin [212]. More importantly for us, this study showed that DNCB 
and DPCP were broadly influencing the same genes. However, when HaCaT cells were 
dosed with concentrations of DPCP varying between 0-30 M for 1 hour, there was no 
significant trend in GSH depletion and levels varied between 100-75 % GSH remaining 
at the end of the experiment (Fig 5.18), which was significantly different from the results 
previously obtained for DNCB. This suggests that either GSH was not the main thiol 
reacting with DPCP (protein haptenation was somehow favoured) and/or that DPCP 
might be a poor substrate of GSTs. It is also likely that DPCP had not physically reached 
the intracellular pool of GSH after 1 hour of exposure. This second option can be 
considered a serious possibility as it has been reported that DPCP (4-38 M 
concentration range) reacted with the thiols present in the membranes at the surface 
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of THP-1 cells, while no effect on the intracellular GSH/GSSG ratio  was seen for short 
periods of exposure (here 2 hours) [213]. 
Furthermore, incubations of 10 M DPCP in skin S9 freshly prepared from frozen ex vivo 
skin carried out by Unilever SEAC collaborators at the University of Bradford (Prof P. 
Loadman’s research group, personal communication) led to similar conclusions. After 1 
hour, DPCP in skin S9 (with addition of an extra 10 M GSH to the mixture or not), 
generated three new peaks in the UV trace recorded during analysis, none of which 
corresponding to a DPCP adduct with GSH (Fig 5.21). Control incubations carried out in 
PBS showed that GSH conjugation to DPCP was not visible after 1 hour of incubation, 
similar to the results we obtained in chemico, where the DPCP conjugates (single or 
double) were present but not visible as the main peaks in a chromatogram acquired 
after 24 hours incubation (Fig 5.8 and 5.14). 
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Figure 5.21:  UV analysis of DPCP incubations in skin S9 or PBS, with or without the 
addition of extra 10 M of GSH. Left: UV trace at t=0 min and Right: UV trace at t=60 
min containing a) DPCP peak at RT = 14.8 min) and b) three new peaks generated in the 
UV trace issued from S9 incubations with RT included in the 15-18 min range. After 1 
hour of incubation (n =1) DPCP was not fully depleted and the new peaks (b) could not 
be related to DPCP+GSH conjugates. Reproduced from Unilever internal report for work 
carried out in partnership with the University of Bradford. 
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The formation of “DEM + GSH” conjugate ([M+H]+ ion at m/z 480) was obtained in the 
same experimental conditions (Fig 5.22). This conjugate was also formed in S9, with or 
without extra GSH added, though GSH availability in the S9 was a limiting factor. The 
reaction stopped after 30 min when GSH had run out in the extract but carried out 
linearly when GSH was available, demonstrating that GST activity was not compromised 
in the S9 after 30 min. Results also showed that DEM was reacting slower with GSH than 
DNCB, which consumed the extra 10 M added within a few minutes (data not shown).  
 
Figure 5.22:  DEM incubations in skin S9 with or without the addition of extra 10 M 
of GSH. Triplicate incubations of 10 µM DEM were carried out in freshly prepared skin 
S9 or in phosphate buffer saline (n= 3). DEM conjugate was formed in skin S9 as long as 
GSH was available in the mixture (green vs red curves). Control incubations in PBS show 
that reactivity is significantly slower when GSTs are not present. Reproduced from 
Unilever internal report for work carried out in partnership with the University of 
Bradford. 
 
The GSH repletion in the HaCaT cell line after 24 hours provided more information to 
differentiate between the selected model sensitisers. While DNCB induced an 
upregulation of GSH production in the range of 20-40 % at the maximum non-toxic dose 
of 10 µM (Chapter 4, Fig 4.4) it was less visible for lower concentrations. This could be 
rationalised by the fact that the cells produced more GSH as the external damage caused 
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by DNCB was higher and seemed to correlate well with Nrf2 activation results also 
presented in Chapter 4. Using the same assay, DPCP treatment did not induce significant 
variation in GSH concentration after 24 hours compared to untreated cells, except when 
toxicity was high (GSH depletion was then due solely to cell death in the well). DEM 
however, induced an upregulation of GSH over the full range of concentrations applied 
(10-150 µM). At a non-toxic dose of 50 µM, GSH levels after 24 hours had doubled 
compared to untreated controls.  We have previously linked the upregulation of GSH to 
an activation of the Nrf2 pathway in the HaCaT cell line after treatment with 
dinitrohalobenzenes, including DNCB. Natsch and collaborators have tested DNCB, 
DPCP and DEM in the Nrf2-induced luciferase assay KeratinoSens® and reported an EC3 
value for each (concentration in M for which an induction of Nrf2 3-fold above the 
value observed in untreated cells is obtained) [202]. Both DNCB and DPCP were able to 
induce Nrf2 at relatively low concentrations with EC3 values of 3.89 M for DNCB and 
1.84 M for DPCP, while DEM EC3 value was significantly higher (82.85 M). These 
values are consistent with the concentrations used in our GSH assay. As all chemicals 
induced a 3-fold increase of Nrf2 in the luciferase assay, this does provide an obvious 
explanation as to why 2-4 M DPCP did not generate an upregulation of GSH in our 
experiments (one would suspect that Nrf2 activation would lead to an increase in the 
ARE-related gene coding for GCL and subsequently an increase in GSH in the cells) or 
why the upregulation was not of the same magnitude for all three chemicals (none for 
DPCP, 20-40 % for DNCB and 200 % for DEM). Thus, to estimate the ability of skin to 
clear a xenobiotic dose using the GSH pathway it is crucial to measure GSH at both an 
early time point (0-2 hours, for obvious depletion measurements) and after clearance 
of dose (24 hours, after which time GSH levels should have recovered) and supplement 
this information with results from an assay measuring Nrf2 activation if the GSH results 
are difficult to interpret. This is a more complete assessment of the biological impact of 
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skin sensitisers than the workflow developed by Naven et al, who combined an in 
chemico assay using GSH, BSA and human liver microsomes with a luciferase based 
assay to measure Nrf2 activation  but only use this set of results to provide a general 
assessment of thiol reactivity [214]. 
5.5 Conclusion. 
 
To understand the biological effect of skin sensitisers on the GSH pathway and 
potentially incorporate it into a mathematical model for skin sensitisation predictions, 
we have shown that it is important to consider:  
1) The ability of the sensitiser to react with GSH specifically as well as other thiols. 
 We have demonstrated that DNCB, DPCP and DEM were able to bind covalently to 
GSH, either by SNAr for DNCB or Michael addition for DPCP or DEM. Others have 
also reported reactivity with small thiol-containing peptides for all three compounds 
elsewhere. Activation of the Nrf2 pathway, as shown in the KeratinoSens assay, also 
indirectly hinted at reactivity with the cysteine residues in Keap1. 
 
2) The bioavailability of each sensitiser in skin, i.e whether the chemical is likely to be 
in contact with intracellular GSH? If this is the case, would the presence of GSTs 
catalyse the reaction?  
Though we have demonstrated reactivity in chemico, demonstrating GSH 
conjugation in the HaCaT cell line or skin S9 proved a challenge for DPCP. For this 
particular compound, reactivity with external thiols (membranes) was potentially 
favoured. Even when the compound was in contact with GSH, as was the case for 
DEM, GSTs did not seem to catalyse the reaction to the extent that they did for 
DNCB. GSH depletion was not obvious in our assay and it was suspected that the 
kinetics of GSH synthesis (GCL and GS enzymatic activities) were of the same order 
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of magnitude as the kinetics of GSH conjugation. Hence the concentration in GSH in 
the cells appeared stable for the first 6 hours of exposure. 
 
3) The magnitude of GSH repletion.  
An important information gained from this piece of work was that the GSH repletion 
observed was different for each of the compounds. All of them were Nrf2 inducers 
in the KeratinoSens assay, generating a three-fold increase in the luciferase readout. 
The order of affinity for this assay was DPCP>DNCB>DEM (DPCP concentration 
required to generate the readout was smaller than DNCB concentration, which was 
lower than DEM). However, the GSH levels at 24 hours in our assay, expressed as 
percentage of untreated cells, was in reversed order to that and followed the trend 
DPCP<DNCB<DEM (DPCP did not generate any increase, DNCB 20-40 % and DEM 
200 %). It is worth noting that some sensitisers can also act as oxidant and therefore 
alter the ratio GSH:GSSG in cells. As we have shown in Chapter 3 of this thesis, 
accurately measuring the change in GSH:GSSG ratio in HaCaT cells for the moderate 
skin sensitiser phenylacetaldehyde  (applied at concentrations for which the cells 
are still able to recover) proved very challenging. However, phenylacetaldehyde is 
suspected to generate an imbalance in GSH:GSSG ratio and has been shown to 
induce Nrf2 in the KeratinoSens assay [202]. Therefore, a sensitiser’s oxidative 
potential should be considered as well as the ability to conjugate GSH. Nrf2 
activation information needs to be complemented by information on GSH repletion 
for all sensitisers, regardless of mechanism of action, to be meaningful in terms of 
skin defence capacity.  
 
The simplistic model developed using the HaCaT cell line gives an idea of the complexity 
involved in understanding the effect of a chemical on human skin. Qualifying the 
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defence mechanisms, here the GSH pathway, alongside the sensitisation potential (of 
which thiol reactivity offers one possibility of haptenation to proteins) seemed to be 
chemical specific. Grouping chemical by skin sensitisation potency (DNCB and DPCP) or 
by chemical reactivity (DPCP and DEM) proved difficult. The next question is now to 
understand the effect of multiple exposures to the same dose of a specific sensitiser on 
skin and whether any differences in GSH repletion, an indirect measure of skin defence 
potential, would be seen. 
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Chapter 6: Effect of multiple dosing of DNCB on the 
Reconstructed Human Epidermis model. 
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6.1 Overview. 
 
6.1.1 3D skin models: current uses.  
 
One of the principal roles of skin is to protect against external factors (such as 
temperature variations, chemicals and moderate mechanical pressures). Consequently, 
it is able to process a wide variety of chemicals to which individuals are exposed as part 
of everyday lives. Assessing the effect of these chemicals on skin, whether associated 
with intended use (i.e., topically applied at recommended concentration for the 
recommended amount of time) or misuse from high exposure through single or 
repeated use, presents a challenge. Skin in vitro models that emulate metabolic 
mechanisms in skin, and which can be used to characterise the clearance of topical 
medicines or environmental chemicals still require refinement. Here we have used a 
recently developed Reconstructed Human Epidermis (RHE) skin model to study the 
metabolic clearance of DNCB by GSH. 
Immortalised cell lines such as HaCaT or primary cells such as normal human epidermal 
keratinocytes (NHEK) have been used in co-culture with other cell types [34, 215] in an 
attempt to reproduce some of the biological responses observed in skin in vivo. A 
disadvantage of these cell systems is that they grow as monolayers, which may lead to 
differences in compound distribution and metabolic competence when compared with 
intact skin. As a result, to mimic skin in an in vitro environment, models have been 
developed over the past 20 years to reproduce a 3D structure. The least complex models 
simply comprise keratinocytes grown at the air interface of an inert insert while more 
complex ones include a collagen bedding, in which cultured fibroblasts are located [3].  
These are cultured until they develop several layers of specialised keratinocytes and 
corneocytes and form a structure resembling a stratum corneum. Recent studies have 
demonstrated that the stratum corneum of in vitro cultured models differs from native 
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skin in terms of lipid composition and lipid spatial organisation [216], however they still 
present a clear improvement on 2D cell cultures. Examples where reconstructed skin 
models have been used for skin penetration studies have been reported [217, 218]. 
Though these models have probably been selected due to their availability, previous 
studies by Garcia et al, in which the penetration rate for caffeine was measured [219] 
and Schafer-Korting et al, in which a wider selection of chemicals were used for 
validation purposes [220] showed that the stratum corneum of these reconstructed 
models is not as effective as the stratum corneum of ex vivo skin. Currently, 
reconstructed 3D skin models are not recommended for skin penetration studies. 
However, the models have been validated and found suitable for assessment of skin 
corrosion and skin irritation potential [221-224]. Recent studies have also tried to link 
cell viability and cytokine secretion in these models to the sensitizing potential of 
chemicals [225, 226]. These skin equivalents can however be used more broadly to 
understand human skin biology and skin sensitization on a molecular level [227-229]. 
 
6.1.2 Measuring GST activity in 3D skin models. 
  
The relatively few metabolism studies conducted using 3D skin models have only 
evaluated Phase I and Phase II enzyme expression and activity [48, 49, 53]. In the 
reported protocols, the test compound is usually applied as a single dose topically or by 
dissolving the test compound in the culture medium [49, 230] and the rate of metabolite 
formation is monitored. Other techniques use skin fractions freshly prepared from the 
models to carry out metabolism studies. For example, cytosolic fractions of 3D skin 
models have been prepared to measure glutathione-S-transferase (GST) activity by 
monitoring the formation of dinitrophenyl-glutathione (DNP-SG) conjugates following 
exposure to 2,4-dinitrochlorobenzene (DNCB)[231, 232].  
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GSH is a key molecule in the skin defense system as it has antioxidant properties and it 
can conjugate electrophilic xenobiotics. Understanding the extent to which GSH can 
detoxify compounds in healthy in vivo skin is vital, however existing tools do not allow 
non-invasive investigations in humans. Consequently, this process is poorly understood. 
This problem is only partially addressed by measuring GST activity in fresh ex vivo skin 
or 3D skin models fractions, since non-enzyme mediated GSH conjugation is a well 
characterised phenomenon.  
 
6.1.3 Repeated dosing in vitro.  
 
Assuming that either 3D skin models or cultured ex vivo skin can be maintained in a 
healthy state close to the one observed in vivo, current publications do not report the 
influence of repeated dosing on their defense mechanisms, or what is it expected to be 
in human skin. Most of the research in the field is focusing on chemical/drug 
permeability for one application in vitro with extrapolation being made for multiple 
exposures in silico. Mathematical modelling of the repeated application of a fixed 
concentration of drug on skin has been attempted by Kubota et al [233]. The first set of 
parameters that they used to test their model was representing a treatment comprising 
13 daily applications of 1 h followed by a 23 h recovery period. The amount of drug in 
the skin (noted As in the published work) was plotted and showed a characteristic ‘saw 
tooth’ pattern, with a maximum and minimum value that did not vary after the first 
treatment (Fig 6.1). 
Chapter 6 
159 
 
 
Figure 6.1:  Profile of internal drug concentration in skin treated daily with a fixed 
concentration of drug for a) 1 h, b) 3 h, c) 12 h and d) 24 h. The internal concentration 
increased as the application time increased. Figure reproduced from [233]. 
 
To refine mathematical models such as the one described above, researchers are now 
developing strategies using cell systems and/or tissue models for repeated dosing and 
attempts at quantitative in vitro-in vivo (QIVIVE) extrapolation [234] but these have 
mostly been focussing on liver, kidney or brain so far. Another in vitro model trying to 
mimic the fate of a drug entering the body via topical application on skin is the “human 
on a chip” model (i.e ex vivo skin in one compartment, liver equivalent in the other) 
developed by Maschmeyer et al [235]. Information on the homeostatic state of these 
new in vitro models and most 3D skin models is missing and the disturbance of the 
models defence mechanisms (in our case the GSH pathway) has not been reported yet.  
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6.2 Aims and Objectives. 
 
6.2.1 Aims.  
 
GSH metabolism being a vital component of human skin defence system, we initially 
studied modulations of the GSH pathway in one of the most simplistic model to 
represent human skin, i.e the HaCaT cell line (Chapters 3-5). In this chapter, the concept 
of GSH pathway as a defence mechanism was investigated further, using a skin model 
of increased complexity, the RHE model. The main objective was to use this model, 
physiologically closer to human skin, to attempt a 7 day long experiment thought to 
mimic the daily use of a personal care product or even a topically applied drug: the 
model would be submitted to one daily treatment with a model skin sensitiser, rinsed 
with PBS and left to recover from exposure until the next treatment the following day.   
First, we aimed at characterising the basal level of GSH in the RHE model for a 7 day 
period. This could be used as an estimation of what the basal level of GSH in healthy 
skin in a resting state would be (i.e without exposure to external xenobiotics and 
without the potential oxidative stress induced by handling a biopsy sample before being 
able to measure GSH).  We then extended our experiments to single and multiple 
exposures to the model skin sensitiser DNCB, to increase our understanding of the GSH 
depletion/repletion cycle following repeat exposures in vitro. We investigated whether 
there was a cumulative effect of DNCB treatments, which could either decrease or 
increase the overall availability of reduced GSH to clear the subsequent doses applied 
(i.e. Is there an induction of GST activity after several exposures? Is GSH production 
increased in the RHE? Or, on the contrary, does the defence system get overwhelmed 
with time and the clearance capacity gets affected?). Finally, we questioned whether 
the dynamics of danger signalling which influence the GSH pathway at a cellular level, 
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in this case the activation of the Nrf2 pathway, were anticipating the future variations 
of GSH level after a series of doses were applied to this in vitro model. 
6.2.2 Experimental design.  
 
The RHE model is commercially available and supplied with a 48 h maintenance 
medium. Additional growth medium can be purchased for culturing the models for 
longer periods. The composition of these media was not disclosed by the supplier and 
little detail was provided about the conditions under which the models should be 
cultured, with the exception of a recommended daily change of medium. The first set 
of experiments carried out aimed at selecting the most appropriate medium to maintain 
the level of GSH in the model over a 7 day period. Moreover, the basal level of GSH in 
the RHE model is not reported in the literature or by the supplier, so this was also 
assessed as soon as the models were received from the supplier. 
Once optimal culture conditions were obtained, we investigated the clearance of DNCB 
over a 24 hour period to match/compare them with the previous findings from our 
studies in the HaCaT cell line. This was followed by further investigations to increase the 
number of topical applications of DNCB in the RHE skin model. RHE models were 
topically exposed to a non-toxic dose of DNCB and clearance was measured. Moreover, 
we quantified GSH replenishment in the topically-treated RHE models as a measure of 
recovery from chemical stress and evaluated the effect of multiple non-toxic and toxic 
daily doses of DNCB on GSH depletion/repletion. Finally, activation of the Nrf2 pathway, 
which up-regulates the synthesis of glutamyl-cysteine ligase (GCL) and GST, was 
measured after each DNCB treatment. 
 
6.3 Results. 
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6.3.1 Basal level of GSH in RHE model.  
 
 
RHE samples are structurally close to skin explants as they contain differentiated layers 
of viable keratinocytes as well as terminally differentiated top layers, forming an in vitro 
equivalent of stratum corneum. Basal GSH levels were evaluated on receipt of the 
samples. The mean value was 4.26 0.99 g/mg soluble protein (14±3 nmol/mg soluble 
protein) (protein content in RHE expressed against BSA standards in the BCA assay) for 
six samples delivered on four different days. The GSSG levels were below the limit of 
detection. These results were comparable to the results obtained in the HaCaT cell line 
(7 nmol/mg soluble protein GSH) measured in the previous chapters and not dissimilar 
to the GSH levels in skin explants reported by others, which were in the 85-480 nmol/g 
wet tissue range (see details in  Chapter 3, Section 3.1.1).  
The models were maintained in culture in different types of medium: the RHE 
maintenance medium (recommended by the supplier for model maintenance for up to 48 
h), the HaCaT cell culture medium, for which the recipe has been optimised in house for 
the culture of HaCaT cells and the RHE growth medium (recommended by the supplier for 
model culture over several days).  
To evaluate the suitability of the RHE maintenance medium, time points investigated were 
t= 0 h, when the models are just received from the supplier,  t=3 h, which is a realistic 
representation of the time required to prepare solutions to treat the models, t=24 h, which 
is  a usual  time at which a read-out of experiment is carried out (i.e.  end of 24 h MTT assay) 
and t= 48 h, which is the maximum time for which the models can be maintained in the 
RHE maintenance medium (recommendation from the supplier). The results are presented 
in Table 6.1. 
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Time point (hour) 
GSH level, Normalised 
data (in µg/mg soluble 
protein) 
Standard deviation (in 
µg/mg soluble protein) 
0 4.71 0.57 
3 5.83 1.57 
24 3.41 0.69 
48 4.73 Not Applicable (*) 
 
Table 6.1: GSH level in RHE models cultured for 0, 3, 24 and 48 h in SkinEthic RHE 
maintenance medium without medium change. Two separate models were used for 
each time point (n= 2). Soluble protein concentration was measured by BCA assay to 
normalise the GSH concentration measured. (*) GSH level was below the limit of 
quantification of the assay for one of the two models, GSH level is reported for a single 
model for this particular time point. 
It appeared that the level of GSH in the models decreased erratically over time and was 
lower at 24 h than at t=0. After 48 h of culture one of the models had a GSH level below 
the limit of quantification of the method, 0.05 µM, while the other had GSH maintained 
at the same level as t=0. Therefore, it was concluded that while the maintenance 
medium is provided for experiments carried out less than 48 h after reception from 
supplier, its use in experiments involving the maintenance or regeneration of GSH was 
not appropriate. 
A similar experiment was carried out in HaCaT cell culture medium and in RHE growth 
medium for a period of 7 days (single replicate). The medium was refreshed daily in all 6-
well plates containing RHE models. The results are presented in Table 6.2. Both media 
allowed for the culture of RHE models for several days, with the exception that the RHE 
model cultured in HaCaT medium for 7 days had a lower level of GSH. The stability of 
the GSH level was better achieved with the RHE growth medium, which was 
subsequently used for RHE models culture experiments. 
In contrast to the HaCaT cell line, for which the level of GSH doubles over a 24 h period, 
in line with cell proliferation in the well [236], GSH levels are stable for several days in 
RHE. 
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Time point in 
hours (day) 
Sample ID GSH (in µg/mg  soluble protein) 
0 (1) HaCaT medium 9.35 
24 (2) HaCaT medium 6.34 
48 (3) HaCaT medium 7.55 
72 (4) HaCaT medium 7.84 
96 (5) HaCaT medium 9.00 
144 (7) HaCaT medium 3.06 
0 (1) RHE growth medium 5.63 
24 (2) RHE growth medium 5.40 
48 (3) RHE growth medium 5.04 
72 (4) RHE growth medium 6.39 
96 (5) RHE growth medium 7.68 
144 (7) RHE growth medium 6.15 
 
Table 6.2: GSH level in RHE models cultured for 7 days in RHE growth medium or HaCaT 
cell culture medium. RHE models were cultured in medium for the required length of 
time, washed with PBS and lysed in 2 mL RIPA buffer. GSH quantification was carried 
out after derivatisation with iodoacetamide. Protein quantification was carried out by 
BCA assay and the GSH concentration expressed in µg/mg soluble protein for each 
model (n=1). Based on these results, RHE model were subsequently cultured in RHE 
growth medium to maintain GSH levels at a relatively constant concentration for several 
days. 
 
6.3.2 Cytotoxicity assay (MTT) after exposure to a single dose of 
DNCB.  
 
Cytotoxicity of DNCB was assessed by MTT assay at 24 hours to evaluate the likelihood 
that the washing step of the RHE samples after 2 hours of exposure with replacement 
of the medium would not remove the DNCB introduced (worst case scenario).  Doses 
ranging 0.05-0.1 mM were non-toxic but doses ranging 0.5-1 mM showed cytotoxicity, 
highlighting the importance of this washing step with PBS after 2 hours accompanied by 
a complete replacement of the medium (Fig 6.2).  
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Figure 6.2:  24 hour cytotoxicity in RHE samples treated with a single dose of DNCB. 
The RHE samples were treated with 50 µL of DNCB solutions ranging 0-10 mM prepared 
in RHE growth medium containing 10 % DMSO. DNCB toxicity was determined using the 
MTT assay after 24 hours of exposure. The concentration applied was considered non-
toxic when the model viability is at least 80 % compared to control RHE model kept in 
culture medium containing 10 % DMSO for a similar length of time. Each concentration 
was tested in duplicate (n=2) and the result was presented as Mean viability ± Standard 
deviation.   
 
6.3.3. GSH depletion/repletion cycle after exposure to a single 
dose of DNCB. 
 
To evaluate the effect of the DNCB treatment on GSH levels, the DNCB concentration 
was fixed at 1 mM (20 µg/cm2) and 0.1 mM (2 µg/cm2). The samples were treated, 
washed with PBS after 2 hours and left to recover in fresh RHE growth medium for 22 
hours. At both DNCB concentrations GSH was depleted during the 2 h exposure period. 
Treatment of RHE models with 1 mM DNCB was associated with greater than 90 % 
depletion of intracellular GSH. In contrast, treatment with the lower DNCB 
concentration (0.1 mM) depleted GSH levels by approximately 30 % (Fig 6.3). GSH 
replenishment started as soon as soluble DNCB was removed through washing. 
Repletion of GSH levels was observed after 24 h with both treatment regimens.  
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Figure 6.3:  24 hour GSH cycle in RHE samples treated with a single dose of DNCB. The 
RHE samples were treated with 50 µL of DNCB solutions prepared in RHE growth 
medium containing 1 % DMSO, washed with PBS after 2 hours and left to recover in 
fresh RHE growth medium for the remaining time of the experiment. RHE models were 
lysed in 2mL RIPA buffer. 100 µL of lysate was derivatised for GSH quantification and the 
results obtained expressed in % of  0 h controls(n=3). (*) Statistical difference between 
GSH level in treated RHE samples and RHE samples lysed before treatment (t= 0 hour) 
Student’s t-test, p value <0.05. 
However, the outcome of the repletion process was dose-dependent: 0.1 mM DNCB 
induced a slight up-regulation of GSH in the samples, similar to previous observations in 
the HaCaT cell line [236], whereas GSH levels were not completely replenished for 1 mM 
DNCB  treatment (GSH concentrations at 24 hours statistically different from initial 
levels, Student’s t-test, p value <0.05). 
6.3.4. GSH depletion/repletion cycle after three repeated 
treatments with DNCB. 
 
Based on the partial GSH repletion observed with 1 mM DNCB (Fig 6.3), multiple 
exposure experiments were designed using 0.1 mM (2 µg/cm2) and an intermediate 
dose of 0.5 mM (10 µg/cm2). The RHE samples were treated daily with a single 
concentration of DNCB (0.1 mM or 0.5 mM), washed with PBS after 2 hours and left to 
recover in fresh RHE growth medium for 22 hours. For each exposure to DNCB the GSH 
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pool was partially but significantly depleted after 2 h (Student’s t-test, p value <0.05) 
(Fig 6.4). During the recovery period, GSH was replenished to levels that were similar to 
the initial levels at t= 0 hour (t= 24, 48 and 72 hours), without upregulation, for both 
doses investigated (Fig 6.4). The repletion of GSH after the third 0.5 mM DNCB 
treatment (t=72 hours) was not statistically different from the levels observed at t=0 
hour (Student ‘s t-test).   
 
Figure 6.4:  72 hour GSH cycle in RHE samples treated daily with DNCB. The RHE models 
were treated with 50 µL of DNCB solutions prepared in RHE growth medium containing 
1 % DMSO, washed with PBS after 2 hours and left to recover in RHE growth medium 
for 22 hours. The process was repeated three times over a 72 hour period. RHE models 
were lysed in 2mL RIPA buffer. 100 µL lysate was derivatised with iodoacetamide for 
GSH quantification. Protein quantification was carried out and GSH results were 
expressed in µg/mL soluble protein (n=3). (*) Statistical difference between GSH level in 
treated RHE samples and RHE samples lysed before treatment (t= 0, 24 and 48 hours) 
Student’s t-test, p value <0.05. 
 
6.3.5. DNP-SG clearance is enhanced after repeated treatments 
with DNCB. 
 
The difference in the levels of GSH repletion observed in single and repeat dose 
experiments was investigated further by measuring the levels of DNCB glutathione 
conjugation (DNP-SG). DNP-SG was quantified in all the samples collected during the 72 
hour experiments. The level of DNP-SG found in the PBS wash collected was negligible 
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compared to levels observed in the RHE lysates and RHE growth medium. In each 
experiment, the total amount of DNP-SG formed after each DNCB exposure increased. 
For 1 mM DNCB, the total DNP-SG at t= 2 hours was 1.7±0.3 µM and increased to 3.1±0.5 
µM at t= 50 hours. The same trend was observed for the 0.5 mM dose, DNP-SG 
increasing from 6.7±0.5 µM at t=2 hours to 11.3±1.1 µM at t= 50 hours (Fig 6.5). The 
distribution of DNP-SG differed considerably between 0.1 and 0.5 mM doses. For 0.1 
mM DNCB, the level of DNP-SG in the RHE lysate was very low at each exposure (t= 2, 
26 and 50 hours) (Fig 6.5 a), whereas for 0.5 mM DNCB, the amount of DNP-SG in the 
RHE lysate increased at each exposure (Fig 6.5 b). As well as an increase in cumulated 
DNP-SG at the end of the exposure periods, an increase in DNP-SG in the RHE growth 
medium was also observed during the recovery period after each exposure for the 
higher dose (0.5 mM) (Fig 6.5 b).  
To determine whether there is a time-dependent increase in DNP-SG synthesis, a mean 
comparison test was performed using Tukey’s Honest Significance Test. This method 
made an adjustment in rejection criteria to account for multiple tests being carried out 
on the same data. In this case with three tests, without any adjustment, there is a 14.3 
% chance of at least one significant result under the null hypothesis. Using the Tukey 
method adjusts this value to 5 %, thus making it harder for a single test to yield a 
significant result but allowing the chance of a false positive over all the tests to remain 
at 5 %. Results are reported in Table 6.3. 
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Figure 6.5:  DNP-SG conjugate formation and excretion in the RHE model. The DNCB 
doses applied at t= 0, 24 and 48 hours were a) 0.1 mM and b) 0.5 mM. Medium and PBS 
wash were diluted 4:1 with acetonitrile before analysis and results expressed in µM.  
RHE models were lysed in 2mL of RIPA buffer and the lysate diluted 4:1 with acetonitrile 
for analysis. Cumulative data presented for each time point includes PBS washes, RHE 
growth medium and RHE lysates (n=3). After each DNCB treatment (t= 2, 26 and 50 
hours), the total amount of DNP-SG in the RHE samples increases. At high dose (0.5 mM) 
the amount of DNP-SG in the medium at the end of the 22 hour recovery period 
increases at each exposure. 
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Table 6.3: DNP-SG conjugate formation increases after each exposure to DNCB. The 
DNP-SG levels (µM) in RHE growth medium, PBS wash and RHE lysate were summed for 
each time point, in triplicate measurements, and the mean calculated. Means were 
compared using the Tukey’s Honest Significance Test.*** Significant difference between 
the two time points investigated, confidence interval at 5 %. 
  
For both concentrations investigated (0.1 mM and 0.5 mM), repeated exposure 
generated an increase in clearance that quickly reached a plateau. The second exposure 
to DNCB led to the generation of significantly more DNP-SG conjugate than the first 
exposure even though the dose was applied for the same time. However, the third 
exposure did not generate an increase compared to the second exposure, suggesting 
that the clearance capacity of the RHE model has reached its upper limit. 
 DNP-SG concentration (µM) presented as Mean±Standard 
Deviation 
Time (hours) DNCB applied: 0.1 (mM) DNCB applied: 0.5 (mM) 
2 1.7117±0.3185 6.6610±0.5054 
26 2.7260±0.1265 9.8450±0.6429 
50 3.1353±0.4815 11.2807±1.1055 
DNCB Applied  
(mM) 
Time 
Comparison 
Difference 
Between 
Means 
Simultaneous 95 %  
Confidence Limits 
  
0.1 50 - 26 0.4093 -0.4455 1.2641   
0.1 50 - 2 1.4237 0.5689 2.2785 *** 
0.1 26 - 2 1.0143 0.1595 1.8691 *** 
0.5 50 - 26 1.4357 -0.5532 3.4245   
0.5 50 - 2 4.6197 2.6308 6.6085 *** 
0.5 26 - 2 3.1840 1.1951 5.1729 *** 
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6.3.6. Nrf2 activation after repeated treatments with DNCB. 
 
Since Nrf2 is known to regulate the expression of both Glutamyl Cysteine Ligase (GCL), 
the rate limiting enzyme in GSH synthesis, as well as GST, which mediates conjugation 
with GSH, a plausible explanation for the increase in DNP-SG is that Nrf2 is induced 
following repeated exposure to DNCB. Therefore, Nrf2 levels and NQO1 levels in cytosol 
following DNCB treatment was measured by Western blotting and compared with a 
potent Nrf2 established inducer [237], CDDO-Me, as a positive control (Fig 6.6 a). The 
data show a 4-7 fold increase in Nrf2 compared with the basal level (t = 0 h) during each 
exposure period (t = 2, 26 and 50 h, a replicate at t=2 h is a clear outlier, possibly due to 
sample preparation error and has been removed).  
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Figure 6.6: Daily DNCB dosing releases Nrf2 exclusively during exposure time. a) 
Typical Western Blot showing Nrf2 release during exposure to DNCB (n=3). Data 
normalised to actin, NQO1 enzyme measured as positive control of Nrf2 activation, 
positive control CDDO-Me (n=1). For t=0 h three control samples were pooled to 
generate a single t=0 sample, with value fixed at ratio 1 (100 % baseline value) and used 
to calculate the “ratio over controls” for the other samples. b)  Data illustration for Nrf2 
and NQO1 as a function of time. DNCB induced an increase in Nrf2 level of 4-7 fold at t= 
2, 26 and 50 h during exposure and decreases back to 1-3 fold, NQO1 activation 
statistically significant at t=7 2h (student t-test, p<0.1) c) The release of Nrf2 was 
increased after each exposure to DNCB. The mean Nrf2 values of time points 2 h, 26 h 
and 50 h were statistically different (ANOVA, p<0.05). 
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During the 22h recovery period the Nrf2 decreased to within 1-3 fold of the t=0 h value. 
NQO1 levels were not statistically different from initial levels until the third exposure to 
DNCB (Student t-test, p<0.01) (Fig 6.6 b) possibly due to the selection of time points, 
which were optimised for GSH depletion measurements.  
These data confirmed the observations made in the GSH experiment. Nrf2 was released 
the most at the time points where GSH levels were depleted the most, suggesting that 
the Nrf2 pathway was quickly activated to signal the need for an increased GSH 
production to compensate for the rapid consumption of cellular GSH by DNCB 
conjugation. This correlates well with findings made by Copple et al., who demonstrated 
an increase in nucleic Nrf2 in mouse hepatocytes treated with 100 µM DNCB for 1 hour 
[193]. There was also a linear increase in Nrf2 release after each DNCB exposure (Fig 6.6 
c), which corroborates the increase in DNP-SG being formed after each exposure (Fig 
6.5). 
 
6.3.7. Limitations of clearance capacity and dose considerations 
in repeated dosing experiments. 
 
To test the limitations of the experimental design, single replicates of RHE samples were 
treated daily with a 1 mM dose of DNCB for one week. In the single exposure 
experiment, a 1 mM DNCB concentration allowed for a partial replenishment of GSH 
level at the end of the 22 hour recovery period (Fig 6.2). However, repeat 1 mM daily 
dosing with DNCB resulted in complete loss of all GSH related metabolic activity for 
some samples at different time points  (RHE5 (lysed before the third DNCB treatment), 
RHE7 (lysed before the fourth DNCB treatment), RHE10 (lysed after the fifth DNCB 
treatment) and RHE13 (lysed before the seventh DNCB treatment) (Fig 6.7)). Overall, 
the metabolic capacity of all samples investigated appeared to decrease after only two 
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cycles of exposures. Additionally, the DNP-SG level in the RHE lysates lowered steadily 
after each subsequent DNCB treatment.  
To pinpoint at which time point/number of DNCB exposures the RHE samples lose their 
metabolic activity, we measured the level of DNP-SG in PBS wash carried out before and 
after each treatment for all the samples (as opposed to restricting measurements to the 
samples that are lysed at a specific time point).  With the aid of this data, it is evident 
that RHE7 lost its metabolic activity at 48 hours (after the third DNCB treatment), RHE10 
at 74 hours (after the fourth DNCB treatment) and RHE13 at 122 hours (after the sixth 
treatment) (Fig 6.8). 
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Figure 6.7: DNP-SG and GSH level in RHE samples treated daily with 1 mM DNCB for a 
week long period. The DNCB treatment occurred at t=0, 24, 48, 72, 96, 120 and 144 
hours (n= 1). DNP-SG was quantified in lysate diluted 4:1 with acetonitrile. Protein 
quantification was carried out by BCA assay and results expressed in µg/mg soluble 
protein. The amount of DNP-SG increased in the RHE lysates between the first (RHE 2) 
and second treatment (RHE 4) but decreased steadily after all subsequent treatments, 
demonstrating a decrease in metabolic activity of the RHE models. The level of GSH was 
replenished after the first treatment but this was not sustained in subsequent 
treatments (RHE 5, RHE 7, RHE 13).  
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Figure 6.8: DNP-SG in PBS wash when RHE samples were treated daily with 1mM DNCB 
for a week long period. DNP-SG levels were measured by LC/MSMS in PBS wash (diluted 
4:1 with acetonitrile) collected at each time point (n=1). The level of DNP-SG present in 
the washes decreased after each treatment, demonstrating an overall decrease in 
metabolic activity in the models as more treatments were applied. Specifically, RHE 7, 
RHE 10 and RHE 13 lost all metabolic activity at t= 50, 74 and 120 hours respectively. 
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6.4 Discussion. 
 
Most topically applied products are designed to be used on a regular basis or at least 
for a few cycles of application before the desired effects are obtained. Whilst repeat 
product application is considered at the clinical trial stage, repeat dosing studies are not 
frequently performed during early in vitro investigations. Considering skin allergy, it is a 
well-known phenomenon that repeated low dosing in vivo may lead to the same 
adverse outcome as a single high dose. For example,  in a  clinical study comparing single 
and multiple exposures to a model skin sensitiser, exposing volunteers to a single dose 
of 60 µg/cm2 DNCB or three times with a once weekly 10 µg/cm2  dose led to a 
comparable number of sensitised volunteers after re-exposure four weeks later [238]. 
Therefore, appropriate precautions need to be taken to estimate a safe dose of any 
chemical for a specific intended use. Simulating in silico the fate of a chemical entering 
the skin while estimating the amount of modification of proteins in a dynamic model 
representative of skin for use in risk assessments is now being attempted [239, 240] 
which may present a unique opportunity to integrate the effects of repeat dosing. 
Similarly, considering in vitro skin metabolism, studies identifying metabolites and 
measuring enzymatic activity are mostly limited to a single exposure which do not lend 
themselves readily to extrapolation to in vivo exposure and realistic assessment of 
human skin metabolism.   
In this study, we demonstrated that repeat topical dosing of a 3D skin model was not 
only feasible (at least over the 72 h period we investigated) but could deliver crucial 
information on the limitations of enzymatic induction in a model relatively close to skin. 
Based on the assumption that metabolism studies carried out at “low” doses might be 
more representative of the in vivo situation we investigated the hypothesis that the GSH 
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pathway could be maintained or even enhanced after multiple exposures to a model 
skin sensitiser. In our experiments, DNCB reproducibly depleted GSH during the two 
hours of exposure, three consecutive times. This correlated well with findings from 
Maneski et al [54], who demonstrated that a low dose of 10 µM DNCB was mostly 
cleared during the first hour of exposure in ex vivo skin. Additionally, our work 
demonstrated the limited capacity of the RHE model to synthesise de novo GSH.  
The level of GSH in human skin has been estimated to be between low to mid hundreds 
of nmol/g of wet tissue [135, 136]. Although expected to be comparable to human skin, 
the GSH levels in 3D skin models are not extensively reported in literature. We have 
measured an average GSH level of 14 nmol/mg soluble protein in RHE models [236].  As 
far as we are aware, no literature reports of GSH levels exist for repeat exposure 
scenarios in RHE models. Surprisingly, the induction of GSH biosynthesis did not lead to 
an increase in free cytosolic GSH in our experiment. GSH levels seemed to replete to an 
optimum level in the range 5-9 µg/mg soluble protein, while all the overproduced GSH 
was immediately used to conjugate DNCB. This might have been due to a concomitant 
up-regulation of GST activity caused by Nrf2 activation. 
These observations are in line with previously reported GSH-related metabolic events. 
In the experiments carried out in Chapter 4 (See Section 4.3.3 and 4.3.4), a single non-
toxic exposure to DNCB induced an upregulation of GSH production in the HaCaT cell 
line within 24 hours and activated the Nrf2 pathway. Similarly, GSH related enzymes (i.e 
GCL and GST) were upregulated in keratinocytes following single dosing with non-toxic 
levels of inorganic arsenic and the free GSH concentration in the cells was also higher 
than in control cells [139]. Moreover, when multiple dosing regimens were used in a 
clinical trial (albeit not skin related), repeated daily dosing with  125 mg oltipraz showed 
a 2.6-fold increase in GST activity in volunteers compared to a weekly 500 mg dose 
which showed no increase in GST activity [241]. These data indicate that repeat low, 
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non-toxic doses have a higher impact on the GSH levels and general responsiveness of 
the GSH defence mechanism than single higher doses.  
The complexity of the Nrf2 pathway and its role in cell protection have been recently 
reviewed [180]. In our experiments, the Nrf2 cytosolic accumulation observed when 
RHE models were lysed immediately after exposure is likely to be the result of release 
from the Nrf2-keap 1 complex after the cysteine residues of Keap-1 were modified 
covalently by DNCB [193]. Nrf2 activation, which has also been observed using other 
chemical probes such as resveratrol [242] and sulforaphane [243], plays a role in skin 
protection as demonstrated in studies with various types of isolated cell lines including 
keratinocytes, melanocytes and fibroblasts [244]. However, demonstration of its 
protective role in in vitro skin models such as 3D skin models is still a subject of debate. 
For example, a single 16 hour treatment of resveratrol, has been shown to activate the 
Nrf2 pathway in NHEK cells and reconstructed skin (multi-layered model grown in-house 
with keratinocytes on a bed of cultured fibroblasts in collagen), resulting in an up-
regulation of GSH biosynthesis [245]. When considering multiple exposure regimens, 
daily exposure to sulforaphane for 4 hours has been shown to activate the Nrf2 pathway 
in human skin fibroblasts and actively contributes to cellular protection by reducing 
ionising radiation-induced DNA damage. The effect of Nrf2 activation on cellular 
protection was more pronounced after four daily exposures than after a single exposure 
at the same dose [246]. Our study is consistent with this finding; the level of DNCB 
conjugate formed was directly related to activation of the Nrf2 pathway. 
6.5 Conclusion. 
 
3D skin models such as the RHE model can be cultured for several days and offer a good 
in vitro alternative for studying repeated dosing. We focussed our study on the GSH 
pathway as a defence mechanism in skin and demonstrated that low non-toxic exposure 
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to DNCB was able to induce GSH biosynthesis to detoxify the applied chemical.  Multiple 
exposures led to an increase in efficiency of the clearance process (more DNP-SG was 
produced) between the first and second exposure and for the duration of investigation 
this phenomenon was sustained. The increase in GSH biosynthesis was linked to the 
activation of Nrf2. The activation of Nrf2 occurred within the two hours of exposure and 
coincided with the time at which the GSH level was the lowest, demonstrating that the 
signalling process was rapid. Moreover, after each exposure to DNCB, the amount of 
Nrf2 increased, mirroring the increased formation of GSH conjugate. This confirms that 
repeat low dosing of electrophiles promotes up-regulation of the defence mechanisms 
linked to the GSH pathway in skin to protect against exogenous compounds. 
Current in silico skin metabolism models are based on structural alerts linked to the 
parent compound, qualitatively estimating the structure and properties of potential 
metabolites. As such, they lack the combination of metabolic data with estimation of 
skin bioavailability [247] and do not yet provide information on the effect of the 
metabolites on skin biology and homeostasis or dose relationship. The data obtained 
from studies dealing with natural defence mechanisms and their inherent capacity to 
deal with exposure to chemicals should provide building blocks on how organ (in this 
case skin) defence systems modify the parent chemical as well as its metabolites on a 
qualitative as well as quantitative level. The combination of these two approaches may 
result in a less conservative prediction of chemical safety providing insight not only into 
the type and nature of generated metabolites, but also how effectively an organ system 
may be able to remove them.  We hypothesise that integrating the dynamics of 
detoxification in viable skin to current in silico models [239, 240] designed to inform skin 
sensitisation potential will be vital for effective extrapolation to in vivo exposure 
scenarios for risk assessments. 
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Chapter 7: General Discussion. 
 
Skin allergy / Type IV hypersensitivity is an important issue to consider when designing 
a product that either requires topical application (cosmetics, personal care products, 
certain drugs…) or can come into contact with the skin during use (paints, pesticides...). 
As animal-based tests such as the Guinea Pig Maximisation Test or the Local Lymph 
Node Assay (mouse) have now been completely phased out for personal care products 
aimed at being commercialised in Europe [248], skin sensitisation potential of new 
ingredients will be assessed using a battery of in vitro tests. OECD test guidelines are 
currently in place for the Direct Peptide Reactivity Assay (DPRA, TG 442C) and the ARE-
Nrf2 Luciferase Test Method, KeratinoSens® (TG 442D), which are based on the well 
understood mechanistic aspects of type IV hypersensitivity.  Based on further 
mechanistic understanding, cell-based in vitro tests for skin sensitisation such as the U-
Sens® assay (previously known as the Myeloid U937 skin sensitisation test (MUSST)) 
[249] and the human Cell Line Activation Test (h-CLAT) using THP-1 cells [250] , have 
been developed partially using chemicals for which historical patch-testing data was 
available (for example PPD [251, 252], DNCB [111] or common fragrances [253, 254] ), 
i.e. these specific chemicals have generated a visible rash in individuals exposed to 
them. Using isolated immunological cells from these patients/blood donors also helped 
the understanding of antigen processing, presentation and generation of an immune 
response which have now all been summarised into an Adverse Outcome Pathway 
framework [13]. 
Current knowledge of antigen formation (i.e haptenation of skin proteins) is mostly 
based on models developed in chemico, in which a potential sensitiser is put in contact, 
in solution, with either a selection of small peptides [19, 20, 24], a single model protein 
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such as HSA [22, 72, 255] or a mixture of proteins [256].  However, these models might 
not easily correlate to in vivo situations and are mostly used to generate chemical alerts 
of the potential to cause sensitisation. In the specific case of drugs, researchers form 
the antigens in chemico then use these pre-formed antigens as standards to measure 
actual presence in T-cells isolated from patients previously treated with the drug using 
mass spectrometry [257] . This approach is therefore limited to the potential diagnosis 
of patients who have already developed hypersensitivity to a skin sensitiser during use. 
A similar protocol has been followed for the model sensitiser DNCB using a combination 
of two model peptides, Human serum albumin and cells isolated from the blood of 
healthy donors [258] but this type of study remains relatively rare. 
Little is known of the reactive competition between sensitisers and proteins (leading to 
antigen formation) and sensitisers and small nucleophilic molecules (generating non-
antigenic species that can be easily removed) in skin.  We chose to study GSH to 
represent the small nucleophilic molecules group as it is the most prominent small thiol 
containing peptide intracellularly as well as the biomarker of choice for oxidative stress. 
Surprisingly, the oxido-reduction part of the GSH pathway is well defined in liver [60, 61, 
141] but relatively poorly understood in human skin. The ratio GSH:GSSG,  indicative of 
cellular health, should be approximately 100:1  for most cell types at homeostasis [157]. 
Disturbance of this balance during sensitisation was a subject of several studies. High 
concentration of ROS has been linked to the synthesis and release of cytokines by 
keratinocytes and dendritic cells [85]. More recently, Corsini et al have reviewed the 
involvement of oxidative stress in the activation of skin cells by sensitisers [259]. It is 
therefore plausible that the level of GSH in cells could be directly linked to the initial 
mechanisms of skin sensitisation, GSH being a very efficient quencher of ROS. Few 
studies seemed to have focussed on this hypothesis so far. It has been shown that when 
the amount of intracellular GSH was reduced by reaction with sensitisers in monocyte-
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derived dendritic cells, changing the GSH:GSSG ratio, the phosphorylation of p38 MAPK 
and downstream activation of the dendritic cells occurred [260].  
We initially characterised the GSH:GSSG ratio in keratinocytes using the HaCaT cell line 
as a model. In our experiments, GSH was measured in the 5-10 µM range while GSSG 
was systematically below the limit of quantification (0.1 µM). The protective potential 
of GSH against common skin sensitisers might preferentially come from the ability of its 
reactive thiol to conjugate electrophiles. When particularly potent sensitisers such as 
dinitrohalobenzenes were used, activation of the GSH pathway occurred concomitantly 
to activation of the Nrf2 pathway. We showed that a 10 µM dose of either DNFB, DNCB 
or DNBB depleted significantly the GSH pool approximately two to four hours after 
exposure. The three dinitrohalobenzenes also induced Nrf2 at low concentrations (1-5 
µM) within 2 hours.  This information is crucial in the determination of sensitising 
potential for assays such as the non-enzymatic thiol depletion assay developed by 
Schultz et al [167] and the KeratinoSens assay [179] in which the ability to induce Nrf2 
is directly correlated to skin sensitising potential. Currently, a combination of the two 
assays, GSH depletion and Nrf2 activation, is available in the SensCee tox assay [261, 
262]. Naven et al also combined an in chemico assay using GSH, BSA and human liver 
microsomes with a luciferase based assay to measure Nrf2 activation to provide a 
general assessment of thiol reactivity [214]. However, our investigations went further 
than evaluating the potential for chemical reactivity (i.e. measuring the electrophilicity 
of these chemicals). After 24 hours of exposure, we noted that HaCaT cells dosed with 
DNCB and DNFB contained higher level of GSH than untreated control cells. The 
different repletion pattern of GSH in cells treated with DNBB was most likely linked to 
the toxicity of the halogen itself rather than the reaction mechanism [194-196]. Thus, 
the upregulation of GSH in cells previously exposed to skin sensitisers constitute an 
integral part of the cell defence mechanism system regulated by the Nrf2 pathway in 
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skin. We suggest that to determine the amplitude of the adverse effect of a potential 
sensitiser at non-toxic levels, defence mechanisms including the GSH pathway, should 
be investigated in vitro over a period of time covering both the clearance of the dose 
and the time for the cells to recover from the change (return to homeostasis level).  
Creating an imbalance in the GSH:GSSG ratio using the oxidative potential of the model 
aldehydes benzaldehyde and phenylacetaldehyde proved difficult.  The mechanism 
reported for the reaction of aldehydes with thiols in chemico is an oxidation yielding a 
sulfur dimer. We showed that both BA and PA oxidised the totality of GSH available into 
GSSG in chemico but GSH levels were not significantly changed in HaCaT cells exposed 
for up to 2 hours. Even a strong oxidant such as hydrogen peroxide did not increase 
GSSG levels in the cells before high level of cytotoxicity was observed, suggesting that 
Glutathione Reductase activity is high in this cell line. In skin, the reactivity of aldehydes 
is thought to be mainly driven by the formation of a Schiff base with the primary amine 
contained in the lysine residues of proteins. This has been investigated for a series of 
benzaldehyde derivatives [263].  The protective potential of GSH to clear these 
aldehydes by an oxido-reduction mechanism appears relatively minor in proportion 
compared to the Schiff base reaction. This questioned whether most sensitisers are 
detoxified by GSH via a conjugation mechanism. 
For a non-toxic level of exposure, cell recovery (here GSH repletion) might be a 
differentiating factor for compounds which all react with GSH by the same mechanism. 
We attempted a comparison of chemicals by sensitising potential, using DNCB and DPCP 
as extreme sensitisers and DEM as a moderate sensitiser. The mechanism by which 
these chemicals react with GSH was very different: SNAr for DNCB or Michael addition 
for DPCP and DEM. GSH conjugates were observed in chemico for the three compounds, 
as was reported elsewhere using other model thiols [19, 20, 24]., The assumption that 
all of them could deplete GSH when applied at the highest non-toxic dose on HaCaT cells 
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was solely based on these initial in chemico results. We used relatively high doses of 
DEM and DPCP compared to the available 5-10 µM reduced GSH measured in untreated 
cells. Surprisingly, these did not induce a visible depletion of GSH in our assay and 
differences could only be observed after the recovery period (24 hour time point). 
 In chemico, DPCP and DNCB have first order kinetics rates of similar order of magnitude 
[211], although the reaction mechanism with thiols is different (SNAr versus Michael 
addition). The bioavailability of each compound in cells played a crucial role in the 
results obtained. To observe any kind of GSH depletion highly toxic levels of DPCP were 
required, hence overlapping GSH depletion linked to potential conjugation with 
depletion induced by loss of viability. As GSH stock was not reduced, no upregulation of 
GSH level was observed after 24 hours. From experimental observations, GSH 
conjugation was not a principal pathway for DPCP clearance and it is thought that the 
antigens leading to sensitisation to DPCP were probably formed extracellularly [213]. 
Though both DNCB and DPCP are classified as extreme sensitisers in assays such as the 
LLNA, their behaviour in skin seem quite different. The comparison between DNCB and 
DEM was based on the ability of each chemical to react with GSH intracellularly. While 
DNCB was depleting GSH within the first 4 hours of exposure, no depletion was visible 
for DEM although the concentration applied on cells was 5 times higher. This suggested 
that the reaction kinetics were faster for the more potent sensitiser. The formation of 
conjugates has been shown to be catalysed by GSTs in both cases [113, 264] but we also 
indirectly observed the influence of these sensitisers on other enzymes of the GSH 
pathway. After 24 hours, DEM had induced an over-production of GSH in the cells of 
approximately 200 % in our assay, far more than the upregulation of GSH observed for 
DNCB. Both compounds have been shown to be Nrf2 inducers in the KeratinoSens assay, 
generating a three-fold increase in the luciferase readout at a concentration of 3.89 µM 
for DNCB and 82.85 µM for DEM [202]. The activation of Nrf2 is the signalling pathway 
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linked to the downstream upregulation of enzyme production involved in GSH synthesis 
(here, GCL and GS) and in our assay, this mechanism of defence must have been 
triggered for both chemicals to a similar extent. The difference in GSH concentration at 
24 hours might be an indirect consequence of the fact that DEM was detoxified easily 
and the surplus of GSH was accumulating in the cell, while all excess GSH was rapidly 
consumed to clear DNCB. 
Nrf2 activation and GSH clearance showed that the HaCaT cell line was a suitable in vitro 
model to assess skin sensitisers as these immortalised keratinocytes exhibited activity 
for all the enzymes of the GSH pathway. However, it is suspected that the metabolic 
capacity of this cell line might be over-expressed compared to in vivo skin. GST activity 
towards DNCB has been reported at 50 nmol/min/mg soluble protein in HaCaT cells, 
while it was only 20 nmol/min/mg soluble protein in human whole skin (cytosolic 
fraction)[53]. Hence, a complex model more closely related to human skin than a 2D cell 
culture was required. In the same publication, GST activity in a reconstructed epidermis 
model was measured at approximately 2nmol/min/mg soluble protein, though this low 
value was difficult to explain [53]. When other 3D models such as the Episkin® and RHE® 
skin models from Episkin™ were used, GST activity was still approximately double that 
of normal human skin [49].  As well as being reasonably representative in terms of 
enzymatic activity, these models seemed more appropriate for complex experiments 
requiring longer time frames than what could be achieved using a cell culture. Though 
characterisation studies carried out on these models highlighted some structural 
differences with in vivo skin, notably in terms of presence of lipids in certain layers, these 
models have shown viability for several weeks, some suggesting that apoptosis would 
not occur before 6-7 weeks [3, 265]. 
The understanding of the bioavailability of skin sensitisers in vitro can only be useful if 
it is comparable to realistic consumer use scenarios or can be extrapolated as closely as 
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possible to these situations, i.e. multiple exposures to the same sensitiser, at the same 
concentration, at regular time intervals.  In vitro models enabling repeated dosing for 
assessing the toxicity of pharmaceutical treatments on the liver, kidneys and brain are 
currently under development [234]. Equivalent applications are not this advanced for 
skin models yet. We have used the RHE from Episkin™ as a 3D skin model and showed 
that the GSH pathway could be induced after three cycles of exposure to DNCB for a 
limited period of time (here 2 hours). The Nrf2 pathway, a critical danger signalling 
pathway for cell protection [180] was also activated after each exposure and the level 
of Nrf2 released increased each time to meet demand [266].  This provided missing 
information on the limitations of metabolic clearance in a model relatively close to skin. 
Maneski et al [54] demonstrated that a low dose of 10 µM DNCB was mostly cleared 
during the first hour of exposure in ex vivo skin. We showed that this process could be 
replicated three times on the RHE models. This provided a first step towards a routine 
use of the RHE for assessment of repeated dosing with potential sensitisers. However, 
an extension to 1 week of treatment damaged the RHEs irreparably. This might have 
been due to the concentration selected for this set of experiments, which will need to 
be tailored on a case by case basis if repeated dosing is to be achieved without 
overwhelming the defence mechanisms of the models. As far as we are aware, the 
influence of repeated dosing with a sensitiser on the GSH levels in skin has not been 
studied previously. In our experiments, the level of DNP-SG formed increased after each 
exposure, showing that enhanced danger signalling by Nrf2 led to an increased 
production of GSH, which was immediately consumed to detoxify DNCB.  Similarly, it 
has been shown that daily exposure to sulforaphane for 4 hours activated the Nrf2 
pathway in human skin fibroblasts [246]. The effect on cellular protection was more 
pronounced after four daily exposures than after a single exposure at the same dose. 
Our study indirectly showed that after three exposures at non-toxic concentrations, the 
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level of DNCB available intracellularly to modify proteins, i.e. form potential antigenic 
species, decreased as the formation of non-antigenic metabolite (DNP-SG) increased. 
Although the amount of modified proteins required to generate an allergic reaction to 
a specific chemical is not known, it seems important to attempt to determine the 
threshold at which regular exposure to low levels of this chemical might not lead to any 
visible effect in the general population. 
Simulating in silico the fate of a chemical entering the skin while estimating the amount 
of modification of proteins in a dynamic model representative of skin for use in risk 
assessments is now being attempted [239, 240, 267]. We have shown that the 
behaviour of GSH in cells exposed to a non-toxic dose of chemical could be easily 
modelled as two successive linear events: 1) clearance of the dose by GSH depletion and 
2) GSH repletion (to basal level or above) for a single application. The ‘tipping’ point 
between the two events was similar for chemicals that are closely related, such as the 
dinitrohalobenzenes tested, while the repletion was the differentiating factor. However, 
for chemicals for which depletion of GSH was barely visible due to the kinetics of 
reaction being slower (as might be the case for DEM) this tipping point would need to 
be modelled at a much later (and probably only theoretical) time point. The basal level 
of GSH in skin appeared to be constant in between exposures to non-toxic level of 
sensitisers, as was seen after three cycles of treatment with DNCB. GSH was measured 
between 5-9 µg/mg soluble protein, which might represent the homeostatic level for 
the RHE model. Whether or not this value would be the same in in vivo skin is uncertain 
but it can be used as an initial estimation in a model of human skin. The aim of this 
research was not to submit a whole panel of chemicals to our GSH assay to inform a 
mathematical model but to enunciate the basics by which such information might be 
integrated into a more complex model, covering the whole process of skin sensitisation. 
Using such a model might lead to a less conservative prediction of chemical safety 
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providing insight not only into the type of stable metabolites formed (here GSH 
conjugates), but also how effectively an organ system may be able to remove them. This 
would help to refine the extrapolation to in vivo exposure scenarios for risk assessments 
when clinical data is scarce.  
The skin models we used were exclusively keratinocyte-based (HaCaT cell line or RHE 
model) but the level of complexity of in vitro models being developed keeps increasing.  
Models comprising keratinocytes and fibroblasts are now fairly easily produced for 
commercial purposes [37, 38] and techniques used to maintain viability and presence 
of major biomarkers in ex vivo skin models are improving [268]. Some newly developed  
models such as the “skin-on-a chip” also include an extra layer of endothelial cells [269]. 
It is therefore essential to determine the level of similarity with skin in vivo required 
from these models before using biological information obtained from them, such as the 
efficiency of the GSH pathway. We believe that the simple models that we have chosen 
enable the generation of larger data sets than would be possible using more 
sophisticated skin equivalents. The knowledge collected as part of these investigations 
on the GSH system and metabolism in biologically active in vitro models has a wider 
applicability than type IV hypersensitivity alone as the methodology developed can 
easily be transferred to different cell types relating to other organs. The mechanistic 
approach used to investigate chemical clearance by the GSH pathway could also inform 
on the amplitude of occurrence of other biological phenomena where electrophilic 
chemistry is involved. 
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